<units>
<unit type="BATCH">
<unit-info>
<unit-content>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="bk"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>systemic cancer effects</author-keyword>
<author-keyword>cachexia</author-keyword>
<author-keyword>cancer metabolism</author-keyword>
<author-keyword>muscle wasting</author-keyword>
<author-keyword>tumour microenvironment</author-keyword>
<author-keyword>cancer metastasis</author-keyword>
<author-keyword>signaling in cachexia</author-keyword>
<author-keyword>chemotherapy</author-keyword>
<author-keyword>cancer-induced muscle wasting</author-keyword>
<author-keyword>skeletal muscle</author-keyword>
<author-keyword>cachexia treatment</author-keyword>
<author-keyword>cytokines</author-keyword>
<author-keyword>interleukin-6 IL-6</author-keyword>
<author-keyword>cachexia prevention</author-keyword>
<author-keyword>bone 
</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">The Systemic Effects of Advanced Cancer: a Textbook on Cancer-Associated Cachexia</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>Swarnali</ce:given-name>
</author>
<affiliation>
<organization>Institute for Cancer Genetics</organization>
<organization>Department of Pathology and Cell Biology</organization>
<organization>Columbia University</organization>
<city>New York</city>
<state>NY</state>
<country iso-code="USA"/>
<ce:source-text>Institute for Cancer Genetics and Department of Pathology and Cell Biology, Columbia University, New York, NY, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>Swarnali</ce:given-name>
</person>
<affiliation>
<organization>Columbia University Irving Medical Center</organization>
<city>New York</city>
<state>NY</state>
<country iso-code="USA"/>
<ce:source-text>Swarnali Acharyya is a cancer biologist who performed her postdoctoral training at the Memorial Sloan Kettering Cancer Center and joined Columbia University as an Assistant Professor in 2014. Her laboratory investigates how metastatic tumors induce systemic changes in distant organs, such as skeletal muscle, and how these changes cause a debilitating syndrome in advanced cancer patients known as cachexia.</ce:source-text>
</affiliation>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>This textbook discusses the systemic consequences of cancer, covering a range of topics from tumor-promoting systemic effects to the development of cachexia, as summarized in the introductory chapter 1. Part I of this textbook focuses on tumor-promoting systemic effects and begins with a chapter on how tumor-derived extracellular vesicles and particles lay the foundation for future metastases (Chapter 2). Chapter 3 discusses how metastatic cells that have colonized the bone impact the local bone microenvironment, neighboring muscles, and host physiology. Chapter 4 summarizes the available strategies for targeting metastatic cancer and emphasizes the need to incorporate a systemic view of the disease. Following this overview of the systemic effects of cancer progression, Part II of the textbook discusses cancer-induced cachexia, a debilitating systemic effect of advanced cancer. Chapters 5-7 examine the key signaling pathways (interleukin-6/GP130, NF-kB, and muscle proteolysis) that drive the development of cancer cachexia. Chapters 8 and 9 in Part III of this textbook explore how toxicities from anti-cancer therapy are associated with the onset of cachexia in cancer patients, and provide insight into potential approaches to simultaneously target both cancer and cachexia. Chapters 10 and 11 (Part IV) conclude this textbook by outlining promising approaches for the diagnosis and treatment of cachexia as well as strategies to prevent the development of cachexia through exercise. An understanding of the systemic effects of cancer is essential for the design of effective anti-cancer and anti-cachexia treatment strategies. As such, this textbook provides key information for both students and scientists engaged in cancer research and oncology.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: a Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: a Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>203</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>09</month>
<day>21</day>
</publicationdate>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_1</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>Metastasis</author-keyword>
<author-keyword>Cachexia</author-keyword>
<author-keyword>Pre-metastatic conditioning</author-keyword>
<author-keyword>Progression</author-keyword>
<author-keyword>Systemic</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">A Systemic View of Metastatic Disease: Inter-Organ Crosstalk and Therapeutic Implications</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>Swarnali</ce:given-name>
<ce:e-address>sa3141@cumc.columbia.edu</ce:e-address>
</author>
<affiliation>
<organization>Institute for Cancer Genetics</organization>
<organization>Department of Pathology and Cell Biology</organization>
<organization>Columbia University</organization>
<city>New York</city>
<state>NY</state>
<country iso-code="USA"/>
<ce:source-text>Institute for Cancer Genetics and Department of Pathology and Cell Biology, Columbia University, New York, NY, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
<ce:given-name>Swarnali</ce:given-name>
</person>
<affiliation>
<organization>Institute for Cancer Genetics</organization>
<organization>Department of Pathology and Cell Biology</organization>
<organization>Columbia University</organization>
<city>New York</city>
<state>NY</state>
<country iso-code="USA"/>
<ce:source-text>Institute for Cancer Genetics and Department of Pathology and Cell Biology, Columbia University, New York, NY, USA</ce:source-text>
</affiliation>
<ce:e-address>sa3141@cumc.columbia.edu</ce:e-address>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>As cancer progresses, the communication and crosstalk between cancer cells and the tumor microenvironment become a key determinant of successful cancer cell growth and survival. These interactions arise through either local contact-mediated signaling or the systemic release of soluble factors, extracellular vesicles and particles (EVP) by tumor cells. Systemic effects that are initiated early during cancer progression, when cancer cell growth is still confined to the primary tumor, establish the pre-metastatic niche (PMN). PMN formation lays the groundwork for cancer-cell colonization of distant organs by altering the extracellular matrix, immune-cell composition, and vascular permeability of distant organs. Tumors also independently reprogram host physiology and metabolism, which often results in a debilitating skeletal-muscle-wasting syndrome known as cachexia. Indeed, over 80% of advanced cancer patients develop cachexia and consequently suffer from reduced tolerance to anti-neoplastic therapies and premature death. This introductory chapter summarizes the various systemic effects of cancer that are detrimental to the host. The design of treatments that can prevent and/or reverse these systemic changes is ultimately expected to improve the quality of life and survival of cancer patients.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: a Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: a Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>6</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>09</month>
<day>21</day>
</publicationdate>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="9">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging biological principles of metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Lambert</ce:surname>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Pattabiraman</ce:surname>
</author>
<author seq="3">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
</ref-authors>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>670</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.cell.2016.11.037</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging biological principles of metastasis. Cell. 168(4), 670–691 (2017). https://doi.org/10.1016/j.cell.2016.11.037</ref-fulltext>
<ce:source-text>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging biological principles of metastasis. Cell. 168(4), 670–691 (2017). https://doi.org/10.1016/j.cell.2016.11.037</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Surviving at a distance: Organ-specific metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>76</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.trecan.2015.07.009</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1(1), 76–91 (2015). https://doi.org/10.1016/j.trecan.2015.07.009</ref-fulltext>
<ce:source-text>Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1(1), 76–91 (2015). https://doi.org/10.1016/j.trecan.2015.07.009</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Accessories to the crime: Functions of cells recruited to the tumor microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
</author>
<author seq="2">
<ce:initials>L.M.</ce:initials>
<ce:surname>Coussens</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>309</first-page>
<last-page>322</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1016/j.ccr.2012.02.022</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Hanahan, D., Coussens, L.M.: Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 21(3), 309–322 (2012). https://doi.org/10.1016/j.ccr.2012.02.022</ref-fulltext>
<ce:source-text>Hanahan, D., Coussens, L.M.: Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell. 21(3), 309–322 (2012). https://doi.org/10.1016/j.ccr.2012.02.022</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular vesicle- and particle-mediated communication shapes innate and adaptive immune responses</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.A.</ce:initials>
<ce:surname>Pelissier Vatter</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Cioffi</ce:surname>
</author>
<author seq="3">
<ce:initials>S.J.</ce:initials>
<ce:surname>Hanna</ce:surname>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Castarede</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Caielli</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Pascual</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Exp. Med</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<volume-issue-number>
<vol-first>218</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1084/jem.20202579</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Pelissier Vatter, F.A., Cioffi, M., Hanna, S.J., Castarede, I., Caielli, S., Pascual, V., et al.: Extracellular vesicle- and particle-mediated communication shapes innate and adaptive immune responses. J. Exp. Med. 218(8) (2021). https://doi.org/10.1084/jem.20202579</ref-fulltext>
<ce:source-text>Pelissier Vatter, F.A., Cioffi, M., Hanna, S.J., Castarede, I., Caielli, S., Pascual, V., et al.: Extracellular vesicle- and particle-mediated communication shapes innate and adaptive immune responses. J. Exp. Med. 218(8) (2021). https://doi.org/10.1084/jem.20202579</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Pre-metastatic niches: Organ-specific homes for metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="3">
<ce:initials>I.R.</ce:initials>
<ce:surname>Matei</ce:surname>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>302</first-page>
<last-page>317</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nrc.2017.6</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Peinado, H., Zhang, H., Matei, I.R., Costa-Silva, B., Hoshino, A., Rodrigues, G., et al.: Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer. 17(5), 302–317 (2017). https://doi.org/10.1038/nrc.2017.6</ref-fulltext>
<ce:source-text>Peinado, H., Zhang, H., Matei, I.R., Costa-Silva, B., Hoshino, A., Rodrigues, G., et al.: Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer. 17(5), 302–317 (2017). https://doi.org/10.1038/nrc.2017.6</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Priming the ‘soil’ for breast cancer metastasis: The pre-metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Psaila</ce:surname>
</author>
<author seq="2">
<ce:initials>R.N.</ce:initials>
<ce:surname>Kaplan</ce:surname>
</author>
<author seq="3">
<ce:initials>E.R.</ce:initials>
<ce:surname>Port</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Breast Dis</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>65</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.3233/bd-2007-26106</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Psaila, B., Kaplan, R.N., Port, E.R., Lyden, D.: Priming the ‘soil’ for breast cancer metastasis: The pre-metastatic niche. Breast Dis. 26, 65–74 (2006). https://doi.org/10.3233/bd-2007-26106</ref-fulltext>
<ce:source-text>Psaila, B., Kaplan, R.N., Port, E.R., Lyden, D.: Priming the ‘soil’ for breast cancer metastasis: The pre-metastatic niche. Breast Dis. 26, 65–74 (2006). https://doi.org/10.3233/bd-2007-26106</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>The metastatic niche: Adapting the foreign soil</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Psaila</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>285</first-page>
<last-page>293</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1038/nrc2621</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Psaila, B., Lyden, D.: The metastatic niche: Adapting the foreign soil. Nat. Rev. Cancer. 9(4), 285–293 (2009). https://doi.org/10.1038/nrc2621</ref-fulltext>
<ce:source-text>Psaila, B., Lyden, D.: The metastatic niche: Adapting the foreign soil. Nat. Rev. Cancer. 9(4), 285–293 (2009). https://doi.org/10.1038/nrc2621</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Precision oncology framework for investigation of exercise as treatment for cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.W.</ce:initials>
<ce:surname>Jones</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>35</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4134</first-page>
<last-page>4137</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1200/JCO.2015.62.7687</ce:e-address>
</ref-website>
</ref-info>
<ref-fulltext>Jones, L.W.: Precision oncology framework for investigation of exercise as treatment for cancer. J. Clin. Oncol. 33(35), 4134–4137 (2015). https://doi.org/10.1200/JCO.2015.62.7687</ref-fulltext>
<ce:source-text>Jones, L.W.: Precision oncology framework for investigation of exercise as treatment for cancer. J. Clin. Oncol. 33(35), 4134–4137 (2015). https://doi.org/10.1200/JCO.2015.62.7687</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.S.</ce:initials>
<ce:surname>Solheim</ce:surname>
</author>
<author seq="2">
<ce:initials>B.J.A.</ce:initials>
<ce:surname>Laird</ce:surname>
</author>
<author seq="3">
<ce:initials>T.R.</ce:initials>
<ce:surname>Balstad</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Bye</ce:surname>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Stene</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>258</first-page>
<last-page>265</last-page>
</pages>
</page-information>
</volisspag>
<ref-website>
<ce:e-address type="url">https://doi.org/10.1136/bmjspcare-2017-001440</ce:e-address>
</ref-website>
<ref-text>BMJ Support.Palliat.Care.</ref-text>
</ref-info>
<ref-fulltext>Solheim, T.S., Laird, B.J.A., Balstad, T.R., Bye, A., Stene, G., Baracos, V., et al.: Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support. Palliat. Care. 8(3), 258–265 (2018). https://doi.org/10.1136/bmjspcare-2017-001440</ref-fulltext>
<ce:source-text>Solheim, T.S., Laird, B.J.A., Balstad, T.R., Bye, A., Stene, G., Baracos, V., et al.: Cancer cachexia: rationale for the MENAC (Multimodal-Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial. BMJ Support. Palliat. Care. 8(3), 258–265 (2018). https://doi.org/10.1136/bmjspcare-2017-001440</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_2</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>Extracellular vesicle</author-keyword>
<author-keyword>Exosome</author-keyword>
<author-keyword>Pre-metastatic niche</author-keyword>
<author-keyword>Metastasis</author-keyword>
<author-keyword>Tumor microenvironment</author-keyword>
<author-keyword>Immune modulation</author-keyword>
<author-keyword>Angiogenesis</author-keyword>
<author-keyword>Vascular permeability</author-keyword>
<author-keyword>Metastatic organotropism</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Systemic Regulation of Metastatic Disease by Extracellular Vesicles and Particles</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
<ce:given-name>Gang</ce:given-name>
</author>
<author seq="2">
<ce:initials>C.M.</ce:initials>
<ce:surname>Kenific</ce:surname>
<ce:given-name>Candia M.</ce:given-name>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Lieberman</ce:surname>
<ce:given-name>Grace</ce:given-name>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
<ce:given-name>Haiying</ce:given-name>
<ce:e-address>haz2005@med.cornell.edu</ce:e-address>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
<ce:given-name>David</ce:given-name>
<ce:e-address>dcl2001@med.cornell.edu</ce:e-address>
</author>
<affiliation>
<organization>Children’s Cancer and Blood Foundation Laboratories</organization>
<organization>Departments of Pediatrics, and Cell and Developmental Biology</organization>
<organization>Drukier Institute for Children’s Health</organization>
<organization>Meyer Cancer Center, Weill Cornell Medicine</organization>
<city>New York</city>
<state>NY</state>
<country iso-code="USA"/>
<ce:source-text>Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
<ce:given-name>David</ce:given-name>
</person>
<affiliation>
<organization>Children’s Cancer and Blood Foundation Laboratories</organization>
<organization>Departments of Pediatrics, and Cell and Developmental Biology</organization>
<organization>Drukier Institute for Children’s Health</organization>
<organization>Meyer Cancer Center, Weill Cornell Medicine</organization>
<city>New York</city>
<state>NY</state>
<country iso-code="USA"/>
<ce:source-text>Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA</ce:source-text>
</affiliation>
<ce:e-address>dcl2001@med.cornell.edu</ce:e-address>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
<ce:para>Cancer is a systemic disease that induces functional dysregulation in multiple tissues and organs. The great majority of cancer-related deaths are due to metastasis, a multistep process involving crosstalk between cancer cells and stromal cells and immune cells in pre-metastatic niches (PMNs) at distant organs. As message carriers, extracellular vesicles and particles (EVPs) derived from cancer cells can modulate the phenotype of recipient cells by transferring various biomolecules, including nucleic acids, proteins, metabolites and lipids, thereby contributing to PMN formation and metastasis. In this chapter, we highlight the roles of cancer cell-derived EVPs in metastasis progression, with a focus on PMN establishment.</ce:para>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: a Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: a Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>39</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>09</month>
<day>21</day>
</publicationdate>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="231">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer: An old disease, a new disease or something in between?</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.R.</ce:initials>
<ce:surname>David</ce:surname>
</author>
<author seq="2">
<ce:initials>M.R.</ce:initials>
<ce:surname>Zimmerman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>728</first-page>
<last-page>733</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>David, A.R., Zimmerman, M.R.: Cancer: An old disease, a new disease or something in between? Nat. Rev. Cancer. 10, 728–733 (2010)</ref-fulltext>
<ce:source-text>David, A.R., Zimmerman, M.R.: Cancer: An old disease, a new disease or something in between? Nat. Rev. Cancer. 10, 728–733 (2010)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, 2020</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
</author>
<author seq="2">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020)</ref-fulltext>
<ce:source-text>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2020. CA Cancer J. Clin. 70, 7–30 (2020)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging biological principles of metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Lambert</ce:surname>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Pattabiraman</ce:surname>
</author>
<author seq="3">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>670</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging biological principles of metastasis. Cell. 168, 670–691 (2017)</ref-fulltext>
<ce:source-text>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging biological principles of metastasis. Cell. 168, 670–691 (2017)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Surviving at a distance: Organ-specific metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>76</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1, 76–91 (2015)</ref-fulltext>
<ce:source-text>Obenauf, A.C., Massague, J.: Surviving at a distance: organ-specific metastasis. Trends Cancer. 1, 76–91 (2015)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic colonization by circulating tumour cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>529</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>298</first-page>
<last-page>306</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ref-fulltext>
<ce:source-text>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor metastasis: Molecular insights and evolving paradigms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Valastyan</ce:surname>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>147</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>275</first-page>
<last-page>292</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Valastyan, S., Weinberg, R.A.: Tumor metastasis: molecular insights and evolving paradigms. Cell. 147, 275–292 (2011)</ref-fulltext>
<ce:source-text>Valastyan, S., Weinberg, R.A.: Tumor metastasis: molecular insights and evolving paradigms. Cell. 147, 275–292 (2011)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>883</first-page>
<last-page>891</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Peinado, H., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012)</ref-fulltext>
<ce:source-text>Peinado, H., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 18, 883–891 (2012)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>816</first-page>
<last-page>826</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Costa-Silva, B., et al.: Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015)</ref-fulltext>
<ce:source-text>Costa-Silva, B., et al.: Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 17, 816–826 (2015)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosome integrins determine organotropic metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>335</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hoshino, A., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ref-fulltext>
<ce:source-text>Hoshino, A., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1403</first-page>
<last-page>1412</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rodrigues, G., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat. Cell Biol. 21, 1403–1412 (2019)</ref-fulltext>
<ce:source-text>Rodrigues, G., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat. Cell Biol. 21, 1403–1412 (2019)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of secondary growths in cancer of the breast</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Paget</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="1889"/>
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>571</first-page>
<last-page>573</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 571–573 (1889)</ref-fulltext>
<ce:source-text>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 571–573 (1889)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Pre-metastatic niches: Organ-specific homes for metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>302</first-page>
<last-page>317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Peinado, H., et al.: Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer. 17, 302–317 (2017)</ref-fulltext>
<ce:source-text>Peinado, H., et al.: Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer. 17, 302–317 (2017)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.N.</ce:initials>
<ce:surname>Kaplan</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>438</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>820</first-page>
<last-page>827</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kaplan, R.N., et al.: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438, 820–827 (2005)</ref-fulltext>
<ce:source-text>Kaplan, R.N., et al.: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 438, 820–827 (2005)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-mediated metastasis: Communication from a distance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Wortzel</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Dror</ce:surname>
</author>
<author seq="3">
<ce:initials>C.M.</ce:initials>
<ce:surname>Kenific</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Lyden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>347</first-page>
<last-page>360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wortzel, I., Dror, S., Kenific, C.M., Lyden, D.: Exosome-mediated metastasis: Communication from a distance. Dev. Cell. 49, 347–360 (2019)</ref-fulltext>
<ce:source-text>Wortzel, I., Dror, S., Kenific, C.M., Lyden, D.: Exosome-mediated metastasis: Communication from a distance. Dev. Cell. 49, 347–360 (2019)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer cells rely on environmental pyruvate to shape the metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>568</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>117</first-page>
<last-page>121</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., et al.: Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature. 568, 117–121 (2019)</ref-fulltext>
<ce:source-text>Elia, I., et al.: Breast cancer cells rely on environmental pyruvate to shape the metastatic niche. Nature. 568, 117–121 (2019)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>243</first-page>
<last-page>256</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, Y., et al.: Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell. 30, 243–256 (2016)</ref-fulltext>
<ce:source-text>Liu, Y., et al.: Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating Alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell. 30, 243–256 (2016)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.Y.</ce:initials>
<ce:surname>Fong</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>194</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fong, M.Y., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194 (2015)</ref-fulltext>
<ce:source-text>Fong, M.Y., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat. Cell Biol. 17, 183–194 (2015)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>501</first-page>
<last-page>515</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, W., et al.: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 25, 501–515 (2014)</ref-fulltext>
<ce:source-text>Zhou, W., et al.: Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Cancer Cell. 25, 501–515 (2014)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular vesicles and metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.E.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cold Spring Harb. Perspect. Med</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Wang, S.E.: Extracellular vesicles and metastasis. Cold Spring Harb. Perspect. Med. (2019)</ref-fulltext>
<ce:source-text>Wang, S.E.: Extracellular vesicles and metastasis. Cold Spring Harb. Perspect. Med. (2019)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mathieu</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin-Jaular</ce:surname>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Lavieu</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Thery</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>17</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mathieu, M., Martin-Jaular, L., Lavieu, G., Thery, C.: Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17 (2019)</ref-fulltext>
<ce:source-text>Mathieu, M., Martin-Jaular, L., Lavieu, G., Thery, C.: Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat. Cell Biol. 21, 9–17 (2019)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>332</first-page>
<last-page>343</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., et al.: Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343 (2018)</ref-fulltext>
<ce:source-text>Zhang, H., et al.: Identification of distinct nanoparticles and subsets of extracellular vesicles by asymmetric flow field-flow fractionation. Nat. Cell Biol. 20, 332–343 (2018)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Colombo</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Raposo</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Thery</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Cell Dev. Biol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>289</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Colombo, M., Raposo, G., Thery, C.: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014)</ref-fulltext>
<ce:source-text>Colombo, M., Raposo, G., Thery, C.: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 30, 255–289 (2014)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Al-Nedawi</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>619</first-page>
<last-page>624</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Al-Nedawi, K., et al.: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619–624 (2008)</ref-fulltext>
<ce:source-text>Al-Nedawi, K., et al.: Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619–624 (2008)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Di Vizio</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5601</first-page>
<last-page>5609</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di Vizio, D., et al.: Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69, 5601–5609 (2009)</ref-fulltext>
<ce:source-text>Di Vizio, D., et al.: Oncosome formation in prostate cancer: Association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res. 69, 5601–5609 (2009)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Transfer of functional cargo in exomeres</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>940</first-page>
<last-page>954</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, Q., et al.: Transfer of functional cargo in exomeres. Cell Rep. 27, 940–954 e946 (2019)</ref-fulltext>
<ce:source-text>Zhang, Q., et al.: Transfer of functional cargo in exomeres. Cell Rep. 27, 940–954 e946 (2019)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: Formation of exosomes as a mechanism for shedding membrane proteins. Biochem</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnstone</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Biol</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>179</first-page>
<last-page>190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnstone, R.M.: The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem. Cell Biol. 70, 179–190 (1992)</ref-fulltext>
<ce:source-text>Johnstone, R.M.: The Jeanne Manery-Fisher Memorial Lecture 1991. Maturation of reticulocytes: formation of exosomes as a mechanism for shedding membrane proteins. Biochem. Cell Biol. 70, 179–190 (1992)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Harding</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Heuser</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Stahl</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="1983"/>
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>339</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Harding, C., Heuser, J., Stahl, P.: Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97, 329–339 (1983)</ref-fulltext>
<ce:source-text>Harding, C., Heuser, J., Stahl, P.: Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J. Cell Biol. 97, 329–339 (1983)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: Selective externalization of the receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.T.</ce:initials>
<ce:surname>Pan</ce:surname>
</author>
<author seq="2">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnstone</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="1983"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>967</first-page>
<last-page>978</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pan, B.T., Johnstone, R.M.: Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 33, 967–978 (1983)</ref-fulltext>
<ce:source-text>Pan, B.T., Johnstone, R.M.: Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 33, 967–978 (1983)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Haraszti</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J Extracell Vesicles</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>32570</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Haraszti, R.A., et al.: High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 5, 32570 (2016)</ref-fulltext>
<ce:source-text>Haraszti, R.A., et al.: High-resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources. J Extracell Vesicles. 5, 32570 (2016)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zakharova</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Svetlova</ce:surname>
</author>
<author seq="3">
<ce:initials>A.F.</ce:initials>
<ce:surname>Fomina</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>212</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>174</first-page>
<last-page>181</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zakharova, L., Svetlova, M., Fomina, A.F.: T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. J. Cell. Physiol. 212, 174–181 (2007)</ref-fulltext>
<ce:source-text>Zakharova, L., Svetlova, M., Fomina, A.F.: T cell exosomes induce cholesterol accumulation in human monocytes via phosphatidylserine receptor. J. Cell. Physiol. 212, 174–181 (2007)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Clement</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>EMBO J</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Clement, E., et al.: Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J. 39, e102525 (2020)</ref-fulltext>
<ce:source-text>Clement, E., et al.: Adipocyte extracellular vesicles carry enzymes and fatty acids that stimulate mitochondrial metabolism and remodeling in tumor cells. EMBO J. 39, e102525 (2020)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>The role of exosomes in cancer metastasis. Semin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.B.</ce:initials>
<ce:surname>Steinbichler</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Dudas</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Riechelmann</ce:surname>
</author>
<author seq="4">
<ce:initials>I.I.</ce:initials>
<ce:surname>Skvortsova</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Biol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>44</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>170</first-page>
<last-page>181</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Steinbichler, T.B., Dudas, J., Riechelmann, H., Skvortsova, I.I.: The role of exosomes in cancer metastasis. Semin. Cancer Biol. 44, 170–181 (2017)</ref-fulltext>
<ce:source-text>Steinbichler, T.B., Dudas, J., Riechelmann, H., Skvortsova, I.I.: The role of exosomes in cancer metastasis. Semin. Cancer Biol. 44, 170–181 (2017)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-derived microRNAs in cancer metabolism: Possible implications in cancer diagnostics and therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Tomasetti</ce:surname>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Santarelli</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Neuzil</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Exp. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Tomasetti, M., Lee, W., Santarelli, L., Neuzil, J.: Exosome-derived microRNAs in cancer metabolism: Possible implications in cancer diagnostics and therapy. Exp. Mol. Med. 49, e285 (2017)</ref-fulltext>
<ce:source-text>Tomasetti, M., Lee, W., Santarelli, L., Neuzil, J.: Exosome-derived microRNAs in cancer metabolism: Possible implications in cancer diagnostics and therapy. Exp. Mol. Med. 49, e285 (2017)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Decoding the biology of exosomes in metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Adem</ce:surname>
</author>
<author seq="2">
<ce:initials>P.F.</ce:initials>
<ce:surname>Vieira</ce:surname>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Melo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>20</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Adem, B., Vieira, P.F., Melo, S.A.: Decoding the biology of exosomes in metastasis. Trends Cancer. 6, 20–30 (2020)</ref-fulltext>
<ce:source-text>Adem, B., Vieira, P.F., Melo, S.A.: Decoding the biology of exosomes in metastasis. Trends Cancer. 6, 20–30 (2020)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>The importance of exosomal PDL1 in tumour immune evasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Daassi</ce:surname>
</author>
<author seq="2">
<ce:initials>K.M.</ce:initials>
<ce:surname>Mahoney</ce:surname>
</author>
<author seq="3">
<ce:initials>G.J.</ce:initials>
<ce:surname>Freeman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Daassi, D., Mahoney, K.M., Freeman, G.J.: The importance of exosomal PDL1 in tumour immune evasion. Nat. Rev. Immunol. (2020)</ref-fulltext>
<ce:source-text>Daassi, D., Mahoney, K.M., Freeman, G.J.: The importance of exosomal PDL1 in tumour immune evasion. Nat. Rev. Immunol. (2020)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Matrix metalloproteinases: Regulators of the tumor microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Kessenbrock</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Plaks</ce:surname>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>141</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>52</first-page>
<last-page>67</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kessenbrock, K., Plaks, V., Werb, Z.: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141, 52–67 (2010)</ref-fulltext>
<ce:source-text>Kessenbrock, K., Plaks, V., Werb, Z.: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 141, 52–67 (2010)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Ginestra</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>272</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17216</first-page>
<last-page>17222</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ginestra, A., et al.: Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J. Biol. Chem. 272, 17216–17222 (1997)</ref-fulltext>
<ce:source-text>Ginestra, A., et al.: Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J. Biol. Chem. 272, 17216–17222 (1997)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Dolo</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>58</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4468</first-page>
<last-page>4474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dolo, V., et al.: Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res. 58, 4468–4474 (1998)</ref-fulltext>
<ce:source-text>Dolo, V., et al.: Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res. 58, 4468–4474 (1998)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shan</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Death Dis</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>382</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shan, Y., et al.: Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases. Cell Death Dis. 9, 382 (2018)</ref-fulltext>
<ce:source-text>Shan, Y., et al.: Hypoxia-induced matrix metalloproteinase-13 expression in exosomes from nasopharyngeal carcinoma enhances metastases. Cell Death Dis. 9, 382 (2018)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Hakulinen</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Sankkila</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Sugiyama</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Lehti</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Keski-Oja</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Biochem</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>105</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1211</first-page>
<last-page>1218</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hakulinen, J., Sankkila, L., Sugiyama, N., Lehti, K., Keski-Oja, J.: Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J. Cell. Biochem. 105, 1211–1218 (2008)</ref-fulltext>
<ce:source-text>Hakulinen, J., Sankkila, L., Sugiyama, N., Lehti, K., Keski-Oja, J.: Secretion of active membrane type 1 matrix metalloproteinase (MMP-14) into extracellular space in microvesicular exosomes. J. Cell. Biochem. 105, 1211–1218 (2008)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Host matrix modulation by tumor exosomes promotes motility and invasiveness</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Mu</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Rana</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Zoller</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neoplasia</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>875</first-page>
<last-page>887</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mu, W., Rana, S., Zoller, M.: Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia. 15, 875–887 (2013)</ref-fulltext>
<ce:source-text>Mu, W., Rana, S., Zoller, M.: Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia. 15, 875–887 (2013)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Redzic</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Redzic, J.S., et al.: Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN. PLoS One. 8, e71225 (2013)</ref-fulltext>
<ce:source-text>Redzic, J.S., et al.: Extracellular vesicles secreted from cancer cell lines stimulate secretion of MMP-9, IL-6, TGF-beta1 and EMMPRIN. PLoS One. 8, e71225 (2013)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.A.</ce:initials>
<ce:surname>Sanchez</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3993</first-page>
<last-page>4008</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanchez, C.A., et al.: Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 7, 3993–4008 (2016)</ref-fulltext>
<ce:source-text>Sanchez, C.A., et al.: Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 7, 3993–4008 (2016)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Atay</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>711</first-page>
<last-page>716</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Atay, S., et al.: Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc. Natl. Acad. Sci. USA. 111, 711–716 (2014)</ref-fulltext>
<ce:source-text>Atay, S., et al.: Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc. Natl. Acad. Sci. USA. 111, 711–716 (2014)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Alpha-smooth muscle actin expression upregulates fibroblast contractile activity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Hinz</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Celetta</ce:surname>
</author>
<author seq="3">
<ce:initials>J.J.</ce:initials>
<ce:surname>Tomasek</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Gabbiani</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Chaponnier</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Biol. Cell</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2730</first-page>
<last-page>2741</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hinz, B., Celetta, G., Tomasek, J.J., Gabbiani, G., Chaponnier, C.: Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell. 12, 2730–2741 (2001)</ref-fulltext>
<ce:source-text>Hinz, B., Celetta, G., Tomasek, J.J., Gabbiani, G., Chaponnier, C.: Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell. 12, 2730–2741 (2001)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>The biology and function of fibroblasts in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Kalluri</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>582</first-page>
<last-page>598</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kalluri, R.: The biology and function of fibroblasts in cancer. Nat. Rev. Cancer. 16, 582–598 (2016)</ref-fulltext>
<ce:source-text>Kalluri, R.: The biology and function of fibroblasts in cancer. Nat. Rev. Cancer. 16, 582–598 (2016)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer exosomes trigger fibroblast to myofibroblast differentiation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Webber</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Steadman</ce:surname>
</author>
<author seq="3">
<ce:initials>M.D.</ce:initials>
<ce:surname>Mason</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Tabi</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Clayton</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9621</first-page>
<last-page>9630</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webber, J., Steadman, R., Mason, M.D., Tabi, Z., Clayton, A.: Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70, 9621–9630 (2010)</ref-fulltext>
<ce:source-text>Webber, J., Steadman, R., Mason, M.D., Tabi, Z., Clayton, A.: Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Res. 70, 9621–9630 (2010)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.P.</ce:initials>
<ce:surname>Webber</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>290</first-page>
<last-page>302</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Webber, J.P., et al.: Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene. 34, 290–302 (2015)</ref-fulltext>
<ce:source-text>Webber, J.P., et al.: Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. Oncogene. 34, 290–302 (2015)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Rab27a and Rab27b control different steps of the exosome secretion pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Ostrowski</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>19</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ostrowski, M., et al.: Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol 12, 19–30.; sup pp 11-13 (2010)</ref-fulltext>
<ce:source-text>Ostrowski, M., et al.: Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat. Cell Biol 12, 19–30.; sup pp 11-13 (2010)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Exp. Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>324</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, Y., et al.: Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J. Exp. Clin. Cancer Res. 37, 324 (2018)</ref-fulltext>
<ce:source-text>Zhou, Y., et al.: Hepatocellular carcinoma-derived exosomal miRNA-21 contributes to tumor progression by converting hepatocyte stellate cells to cancer-associated fibroblasts. J. Exp. Clin. Cancer Res. 37, 324 (2018)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Paggetti</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>126</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1106</first-page>
<last-page>1117</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paggetti, J., et al.: Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 126, 1106–1117 (2015)</ref-fulltext>
<ce:source-text>Paggetti, J., et al.: Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 126, 1106–1117 (2015)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Chowdhury</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>715</first-page>
<last-page>731</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chowdhury, R., et al.: Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 6, 715–731 (2015)</ref-fulltext>
<ce:source-text>Chowdhury, R., et al.: Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. Oncotarget. 6, 715–731 (2015)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Cho</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Gynecol. Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>123</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>379</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cho, J.A., et al.: Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol. Oncol. 123, 379–386 (2011)</ref-fulltext>
<ce:source-text>Cho, J.A., et al.: Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Gynecol. Oncol. 123, 379–386 (2011)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Natural innate and adaptive immunity to cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Vesely</ce:surname>
</author>
<author seq="2">
<ce:initials>M.H.</ce:initials>
<ce:surname>Kershaw</ce:surname>
</author>
<author seq="3">
<ce:initials>R.D.</ce:initials>
<ce:surname>Schreiber</ce:surname>
</author>
<author seq="4">
<ce:initials>M.J.</ce:initials>
<ce:surname>Smyth</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>235</first-page>
<last-page>271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J.: Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011)</ref-fulltext>
<ce:source-text>Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J.: Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 29, 235–271 (2011)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Concise review: Modulating cancer immunity with hematopoietic stem and progenitor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Wildes</ce:surname>
</author>
<author seq="2">
<ce:initials>C.T.</ce:initials>
<ce:surname>Flores</ce:surname>
</author>
<author seq="3">
<ce:initials>D.A.</ce:initials>
<ce:surname>Mitchell</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Stem Cells</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>166</first-page>
<last-page>175</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wildes, T.J., Flores, C.T., Mitchell, D.A.: Concise review: modulating cancer immunity with hematopoietic stem and progenitor cells. Stem Cells. 37, 166–175 (2019)</ref-fulltext>
<ce:source-text>Wildes, T.J., Flores, C.T., Mitchell, D.A.: Concise review: modulating cancer immunity with hematopoietic stem and progenitor cells. Stem Cells. 37, 166–175 (2019)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>Roles of the immune system in cancer: From tumor initiation to metastatic progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Hagerling</ce:surname>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Werb</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Genes Dev</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1267</first-page>
<last-page>1284</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267–1284 (2018)</ref-fulltext>
<ce:source-text>Gonzalez, H., Hagerling, C., Werb, Z.: Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267–1284 (2018)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Wellenstein</ce:surname>
</author>
<author seq="2">
<ce:initials>K.E.</ce:initials>
<ce:surname>de Visser</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>399</first-page>
<last-page>416</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wellenstein, M.D., de Visser, K.E.: Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity. 48, 399–416 (2018)</ref-fulltext>
<ce:source-text>Wellenstein, M.D., de Visser, K.E.: Cancer-cell-intrinsic mechanisms shaping the tumor immune landscape. Immunity. 48, 399–416 (2018)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Allele-specific HLA loss and immune escape in lung cancer evolution</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>McGranahan</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>171</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1259</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McGranahan, N., et al.: Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 171, 1259–1271 e1211 (2017)</ref-fulltext>
<ce:source-text>McGranahan, N., et al.: Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 171, 1259–1271 e1211 (2017)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.V.F.</ce:initials>
<ce:surname>Tauriello</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>554</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>538</first-page>
<last-page>543</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tauriello, D.V.F., et al.: TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 554, 538–543 (2018)</ref-fulltext>
<ce:source-text>Tauriello, D.V.F., et al.: TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 554, 538–543 (2018)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Inflammatory modulation of HSCs: Viewing the HSC as a foundation for the immune response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.Y.</ce:initials>
<ce:surname>King</ce:surname>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Goodell</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>685</first-page>
<last-page>692</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>King, K.Y., Goodell, M.A.: Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11, 685–692 (2011)</ref-fulltext>
<ce:source-text>King, K.Y., Goodell, M.A.: Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11, 685–692 (2011)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Ortiz</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>33</first-page>
<last-page>45</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ortiz, A., et al.: An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles. Cancer Cell. 35, 33–45 e36 (2019)</ref-fulltext>
<ce:source-text>Ortiz, A., et al.: An interferon-driven oxysterol-based defense against tumor-derived extracellular vesicles. Cancer Cell. 35, 33–45 e36 (2019)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Innate or adaptive immunity? The example of natural killer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Vivier</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>331</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>44</first-page>
<last-page>49</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vivier, E., et al.: Innate or adaptive immunity? The example of natural killer cells. Science. 331, 44–49 (2011)</ref-fulltext>
<ce:source-text>Vivier, E., et al.: Innate or adaptive immunity? The example of natural killer cells. Science. 331, 44–49 (2011)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.I.</ce:initials>
<ce:surname>Hornick</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Sci. Signal</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hornick, N.I., et al.: AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Sci. Signal. 9, ra88 (2016)</ref-fulltext>
<ce:source-text>Hornick, N.I., et al.: AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Sci. Signal. 9, ra88 (2016)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor exosomes inhibit differentiation of bone marrow dendritic cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>178</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6867</first-page>
<last-page>6875</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yu, S., et al.: Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 178, 6867–6875 (2007)</ref-fulltext>
<ce:source-text>Yu, S., et al.: Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J. Immunol. 178, 6867–6875 (2007)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of myeloid-derived suppressor cells by tumor exosomes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Xiang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2621</first-page>
<last-page>2633</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiang, X., et al.: Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer. 124, 2621–2633 (2009)</ref-fulltext>
<ce:source-text>Xiang, X., et al.: Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer. 124, 2621–2633 (2009)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Myeloid-derived suppressor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.I.</ce:initials>
<ce:surname>Gabrilovich</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Immunol. Res</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
<last-page>8</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gabrilovich, D.I.: Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8 (2017)</ref-fulltext>
<ce:source-text>Gabrilovich, D.I.: Myeloid-derived suppressor cells. Cancer Immunol. Res. 5, 3–8 (2017)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Chalmin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>120</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>457</first-page>
<last-page>471</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chalmin, F., et al.: Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120, 457–471 (2010)</ref-fulltext>
<ce:source-text>Chalmin, F., et al.: Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 120, 457–471 (2010)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Fleming</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>79</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4715</first-page>
<last-page>4728</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fleming, V., et al.: Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 79, 4715–4728 (2019)</ref-fulltext>
<ce:source-text>Fleming, V., et al.: Melanoma extracellular vesicles generate immunosuppressive myeloid cells by upregulating PD-L1 via TLR4 signaling. Cancer Res. 79, 4715–4728 (2019)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Huber</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>128</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5505</first-page>
<last-page>5516</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Huber, V., et al.: Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J. Clin. Invest. 128, 5505–5516 (2018)</ref-fulltext>
<ce:source-text>Huber, V., et al.: Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. J. Clin. Invest. 128, 5505–5516 (2018)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Guo</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4239</first-page>
<last-page>4259</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, X., et al.: Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways. Oncogene. 37, 4239–4259 (2018)</ref-fulltext>
<ce:source-text>Guo, X., et al.: Immunosuppressive effects of hypoxia-induced glioma exosomes through myeloid-derived suppressor cells via the miR-10a/Rora and miR-21/Pten Pathways. Oncogene. 37, 4239–4259 (2018)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogen recognition and innate immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Akira</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Uematsu</ce:surname>
</author>
<author seq="3">
<ce:initials>O.</ce:initials>
<ce:surname>Takeuchi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>783</first-page>
<last-page>801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Akira, S., Uematsu, S., Takeuchi, O.: Pathogen recognition and innate immunity. Cell. 124, 783–801 (2006)</ref-fulltext>
<ce:source-text>Akira, S., Uematsu, S., Takeuchi, O.: Pathogen recognition and innate immunity. Cell. 124, 783–801 (2006)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Macrophages and metabolism in the tumor microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Vitale</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Manic</ce:surname>
</author>
<author seq="3">
<ce:initials>L.M.</ce:initials>
<ce:surname>Coussens</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Kroemer</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Galluzzi</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>36</first-page>
<last-page>50</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vitale, I., Manic, G., Coussens, L.M., Kroemer, G., Galluzzi, L.: Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36–50 (2019)</ref-fulltext>
<ce:source-text>Vitale, I., Manic, G., Coussens, L.M., Kroemer, G., Galluzzi, L.: Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36–50 (2019)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Fabbri</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E2110</first-page>
<last-page>E2116</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fabbri, M., et al.: MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA. 109, E2110–E2116 (2012)</ref-fulltext>
<ce:source-text>Fabbri, M., et al.: MicroRNAs bind to toll-like receptors to induce prometastatic inflammatory response. Proc. Natl. Acad. Sci. USA. 109, E2110–E2116 (2012)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Ying</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>43076</first-page>
<last-page>43087</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ying, X., et al.: Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 7, 43076–43087 (2016)</ref-fulltext>
<ce:source-text>Ying, X., et al.: Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 7, 43076–43087 (2016)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Cooks</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>771</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cooks, T., et al.: Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9, 771 (2018)</ref-fulltext>
<ce:source-text>Cooks, T., et al.: Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246. Nat. Commun. 9, 771 (2018)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Park</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5158</first-page>
<last-page>5173</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, J.E., et al.: Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene. 38, 5158–5173 (2019)</ref-fulltext>
<ce:source-text>Park, J.E., et al.: Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene. 38, 5158–5173 (2019)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer immunotherapy via dendritic cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Palucka</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Banchereau</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>265</first-page>
<last-page>277</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Palucka, K., Banchereau, J.: Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer. 12, 265–277 (2012)</ref-fulltext>
<ce:source-text>Palucka, K., Banchereau, J.: Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer. 12, 265–277 (2012)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Yu, S., et al.: EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene. (2020)</ref-fulltext>
<ce:source-text>Yu, S., et al.: EGFR E746-A750 deletion in lung cancer represses antitumor immunity through the exosome-mediated inhibition of dendritic cells. Oncogene. (2020)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Ding</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>29877</first-page>
<last-page>29888</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ding, G., et al.: Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 6, 29877–29888 (2015)</ref-fulltext>
<ce:source-text>Ding, G., et al.: Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. Oncotarget. 6, 29877–29888 (2015)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting natural killer cells in cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Guillerey</ce:surname>
</author>
<author seq="2">
<ce:initials>N.D.</ce:initials>
<ce:surname>Huntington</ce:surname>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Smyth</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Immunol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1025</first-page>
<last-page>1036</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guillerey, C., Huntington, N.D., Smyth, M.J.: Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025–1036 (2016)</ref-fulltext>
<ce:source-text>Guillerey, C., Huntington, N.D., Smyth, M.J.: Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17, 1025–1036 (2016)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Baginska</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Immunol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>490</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baginska, J., et al.: The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front. Immunol. 4, 490 (2013)</ref-fulltext>
<ce:source-text>Baginska, J., et al.: The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. Front. Immunol. 4, 490 (2013)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Han</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J Immunol Res</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>2018</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Han, B., et al.: Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J Immunol Res. 2018, 6248590 (2018)</ref-fulltext>
<ce:source-text>Han, B., et al.: Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer. J Immunol Res. 2018, 6248590 (2018)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Viel</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Sci. Signal</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Viel, S., et al.: TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016)</ref-fulltext>
<ce:source-text>Viel, S., et al.: TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal. 9, ra19 (2016)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.G.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, J.G., et al.: Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers. 11 (2019)</ref-fulltext>
<ce:source-text>Zhao, J.G., et al.: Tumor-derived extracellular vesicles inhibit natural killer cell function in pancreatic cancer. Cancers. 11 (2019)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: Mechanism of immune evasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Lundholm</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Lundholm, M., et al.: Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One. 9, e108925 (2014)</ref-fulltext>
<ce:source-text>Lundholm, M., et al.: Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion. PLoS One. 9, e108925 (2014)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>176</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1375</first-page>
<last-page>1385</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, C., et al.: Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 176, 1375–1385 (2006)</ref-fulltext>
<ce:source-text>Liu, C., et al.: Murine mammary carcinoma exosomes promote tumor growth by suppression of NK cell function. J. Immunol. 176, 1375–1385 (2006)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophils in cancer: Neutral no more</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Coffelt</ce:surname>
</author>
<author seq="2">
<ce:initials>M.D.</ce:initials>
<ce:surname>Wellenstein</ce:surname>
</author>
<author seq="3">
<ce:initials>K.E.</ce:initials>
<ce:surname>de Visser</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>431</first-page>
<last-page>446</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coffelt, S.B., Wellenstein, M.D., de Visser, K.E.: Neutrophils in cancer: neutral no more. Nat. Rev. Cancer. 16, 431–446 (2016)</ref-fulltext>
<ce:source-text>Coffelt, S.B., Wellenstein, M.D., de Visser, K.E.: Neutrophils in cancer: neutral no more. Nat. Rev. Cancer. 16, 431–446 (2016)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Kowanetz</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>107</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21248</first-page>
<last-page>21255</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kowanetz, M., et al.: Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA. 107, 21248–21255 (2010)</ref-fulltext>
<ce:source-text>Kowanetz, M., et al.: Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. USA. 107, 21248–21255 (2010)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor entrained neutrophils inhibit seeding in the premetastatic lung</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Granot</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>300</first-page>
<last-page>314</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Granot, Z., et al.: Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 20, 300–314 (2011)</ref-fulltext>
<ce:source-text>Granot, Z., et al.: Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell. 20, 300–314 (2011)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.W.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Hepatol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>54</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>497</first-page>
<last-page>505</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, Y.W., et al.: Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection. J. Hepatol. 54, 497–505 (2011)</ref-fulltext>
<ce:source-text>Li, Y.W., et al.: Intratumoral neutrophils: A poor prognostic factor for hepatocellular carcinoma following resection. J. Hepatol. 54, 497–505 (2011)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhao, J.J., et al.: The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One. 7, e33655 (2012)</ref-fulltext>
<ce:source-text>Zhao, J.J., et al.: The prognostic value of tumor-infiltrating neutrophils in gastric adenocarcinoma after resection. PLoS One. 7, e33655 (2012)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.K.</ce:initials>
<ce:surname>Jensen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4709</first-page>
<last-page>4717</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jensen, H.K., et al.: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 27, 4709–4717 (2009)</ref-fulltext>
<ce:source-text>Jensen, H.K., et al.: Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J. Clin. Oncol. 27, 4709–4717 (2009)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: A prognostic model</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Schmidt</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>273</first-page>
<last-page>278</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schmidt, H., et al.: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: A prognostic model. Br. J. Cancer. 93, 273–278 (2005)</ref-fulltext>
<ce:source-text>Schmidt, H., et al.: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: A prognostic model. Br. J. Cancer. 93, 273–278 (2005)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.J.</ce:initials>
<ce:surname>Casbon</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>112</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E566</first-page>
<last-page>E575</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Casbon, A.J., et al.: Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl. Acad. Sci. USA. 112, E566–E575 (2015)</ref-fulltext>
<ce:source-text>Casbon, A.J., et al.: Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl. Acad. Sci. USA. 112, E566–E575 (2015)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Bayne</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>822</first-page>
<last-page>835</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bayne, L.J., et al.: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21, 822–835 (2012)</ref-fulltext>
<ce:source-text>Bayne, L.J., et al.: Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell. 21, 822–835 (2012)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.B.</ce:initials>
<ce:surname>Coffelt</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>522</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>345</first-page>
<last-page>348</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coffelt, S.B., et al.: IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 522, 345–348 (2015)</ref-fulltext>
<ce:source-text>Coffelt, S.B., et al.: IL-17-producing gammadelta T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 522, 345–348 (2015)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Cen</ce:surname>
</author>
<author seq="5">
<ce:initials>R.N.</ce:initials>
<ce:surname>Dubois</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>77</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3655</first-page>
<last-page>3665</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, D., Sun, H., Wei, J., Cen, B., DuBois, R.N.: CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 77, 3655–3665 (2017)</ref-fulltext>
<ce:source-text>Wang, D., Sun, H., Wei, J., Cen, B., DuBois, R.N.: CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. Cancer Res. 77, 3655–3665 (2017)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-associated neutrophils in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Shaul</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.G.</ce:initials>
<ce:surname>Fridlender</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>601</first-page>
<last-page>620</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shaul, M.E., Fridlender, Z.G.: Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol. 16, 601–620 (2019)</ref-fulltext>
<ce:source-text>Shaul, M.E., Fridlender, Z.G.: Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol. 16, 601–620 (2019)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Andzinski</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>138</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1982</first-page>
<last-page>1993</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Andzinski, L., et al.: Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int. J. Cancer. 138, 1982–1993 (2016)</ref-fulltext>
<ce:source-text>Andzinski, L., et al.: Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human. Int. J. Cancer. 138, 1982–1993 (2016)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.G.</ce:initials>
<ce:surname>Fridlender</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
<last-page>194</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fridlender, Z.G., et al.: Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 16, 183–194 (2009)</ref-fulltext>
<ce:source-text>Fridlender, Z.G., et al.: Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer Cell. 16, 183–194 (2009)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Mol. Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>146</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, X., et al.: Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol. Cancer. 17, 146 (2018)</ref-fulltext>
<ce:source-text>Zhang, X., et al.: Tumor-derived exosomes induce N2 polarization of neutrophils to promote gastric cancer cell migration. Mol. Cancer. 17, 146 (2018)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.L.</ce:initials>
<ce:surname>Hwang</ce:surname>
</author>
<author seq="2">
<ce:initials>H.Y.</ce:initials>
<ce:surname>Lan</ce:surname>
</author>
<author seq="3">
<ce:initials>W.C.</ce:initials>
<ce:surname>Cheng</ce:surname>
</author>
<author seq="4">
<ce:initials>S.C.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="5">
<ce:initials>M.H.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Hematol. Oncol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hwang, W.L., Lan, H.Y., Cheng, W.C., Huang, S.C., Yang, M.H.: Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer. J. Hematol. Oncol. 12, 10 (2019)</ref-fulltext>
<ce:source-text>Hwang, W.L., Lan, H.Y., Cheng, W.C., Huang, S.C., Yang, M.H.: Tumor stem-like cell-derived exosomal RNAs prime neutrophils for facilitating tumorigenesis of colon cancer. J. Hematol. Oncol. 12, 10 (2019)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomes induce the formation of neutrophil extracellular traps: Implications for the establishment of cancer-associated thrombosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Leal</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6438</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Leal, A.C., et al.: Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci. Rep. 7, 6438 (2017)</ref-fulltext>
<ce:source-text>Leal, A.C., et al.: Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci. Rep. 7, 6438 (2017)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophil extracellular traps kill bacteria</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Brinkmann</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>303</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1532</first-page>
<last-page>1535</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brinkmann, V., et al.: Neutrophil extracellular traps kill bacteria. Science. 303, 1532–1535 (2004)</ref-fulltext>
<ce:source-text>Brinkmann, V., et al.: Neutrophil extracellular traps kill bacteria. Science. 303, 1532–1535 (2004)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Demers</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13076</first-page>
<last-page>13081</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Demers, M., et al.: Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl. Acad. Sci. USA. 109, 13076–13081 (2012)</ref-fulltext>
<ce:source-text>Demers, M., et al.: Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl. Acad. Sci. USA. 109, 13076–13081 (2012)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Park</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Sci. Transl. Med</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Park, J., et al.: Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci. Transl. Med. 8, 361ra138 (2016)</ref-fulltext>
<ce:source-text>Park, J., et al.: Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci. Transl. Med. 8, 361ra138 (2016)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Cools-Lartigue</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Invest</ref-sourcetitle>
<ref-publicationyear first="2013"/>
</ref-info>
<ref-fulltext>Cools-Lartigue, J., et al.: Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. (2013)</ref-fulltext>
<ce:source-text>Cools-Lartigue, J., et al.: Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Invest. (2013)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>The origins of vertebrate adaptive immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.W.</ce:initials>
<ce:surname>Litman</ce:surname>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Rast</ce:surname>
</author>
<author seq="3">
<ce:initials>S.D.</ce:initials>
<ce:surname>Fugmann</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>543</first-page>
<last-page>553</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Litman, G.W., Rast, J.P., Fugmann, S.D.: The origins of vertebrate adaptive immunity. Nat. Rev. Immunol. 10, 543–553 (2010)</ref-fulltext>
<ce:source-text>Litman, G.W., Rast, J.P., Fugmann, S.D.: The origins of vertebrate adaptive immunity. Nat. Rev. Immunol. 10, 543–553 (2010)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.M.</ce:initials>
<ce:surname>Razzo</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Carcinogenesis</ref-sourcetitle>
<ref-publicationyear first="2019"/>
</ref-info>
<ref-fulltext>Razzo, B.M., et al.: Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. Carcinogenesis. (2019)</ref-fulltext>
<ce:source-text>Razzo, B.M., et al.: Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. Carcinogenesis. (2019)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Death Dis</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>159</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, X., et al.: 14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes. Cell Death Dis. 9, 159 (2018)</ref-fulltext>
<ce:source-text>Wang, X., et al.: 14-3-3zeta delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes. Cell Death Dis. 9, 159 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Mirzaei</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Onco. Targets. Ther</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Mirzaei, R., et al.: Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Onco. Targets. Ther. 7, e1478647 (2018)</ref-fulltext>
<ce:source-text>Mirzaei, R., et al.: Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity. Onco. Targets. Ther. 7, e1478647 (2018)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Griss</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4186</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Griss, J., et al.: B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019)</ref-fulltext>
<ce:source-text>Griss, J., et al.: B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. Nat. Commun. 10, 4186 (2019)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Garaud</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>JCI Insight</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<page-information>
<pages>
<first-page>5</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Garaud, S., et al.: Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 5 (2019)</ref-fulltext>
<ce:source-text>Garaud, S., et al.: Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer. JCI Insight. 5 (2019)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Meng</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Valentini</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Rao</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Maeurer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front. Oncol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>384</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Meng, Q., Valentini, D., Rao, M., Maeurer, M.: KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer. Front. Oncol. 8, 384 (2018)</ref-fulltext>
<ce:source-text>Meng, Q., Valentini, D., Rao, M., Maeurer, M.: KRAS renaissance(s) in tumor infiltrating B cells in pancreatic cancer. Front. Oncol. 8, 384 (2018)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>IL35-producing B cells promote the development of pancreatic neoplasia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Pylayeva-Gupta</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Discov</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>247</first-page>
<last-page>255</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pylayeva-Gupta, Y., et al.: IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov. 6, 247–255 (2016)</ref-fulltext>
<ce:source-text>Pylayeva-Gupta, Y., et al.: IL35-producing B cells promote the development of pancreatic neoplasia. Cancer Discov. 6, 247–255 (2016)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Xiao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Discov</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>546</first-page>
<last-page>559</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ref-fulltext>
<ce:source-text>Xiao, X., et al.: PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression. Cancer Discov. 6, 546–559 (2016)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Ye</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Immunother. Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>145</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ye, L., et al.: Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J. Immunother. Cancer. 6, 145 (2018)</ref-fulltext>
<ce:source-text>Ye, L., et al.: Tumor-derived exosomal HMGB1 fosters hepatocellular carcinoma immune evasion by promoting TIM-1(+) regulatory B cell expansion. J. Immunother. Cancer. 6, 145 (2018)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutics targeting angiogenesis: Genetics and epigenetics, extracellular miRNAs and signaling networks (Review)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Katoh</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Med</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>763</first-page>
<last-page>767</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Katoh, M.: Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int. J. Mol. Med. 32, 763–767 (2013)</ref-fulltext>
<ce:source-text>Katoh, M.: Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int. J. Mol. Med. 32, 763–767 (2013)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Microenvironmental regulation of tumour angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>de Palma</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Biziato</ce:surname>
</author>
<author seq="3">
<ce:initials>T.V.</ce:initials>
<ce:surname>Petrova</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>457</first-page>
<last-page>474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>De Palma, M., Biziato, D., Petrova, T.V.: Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer. 17, 457–474 (2017)</ref-fulltext>
<ce:source-text>De Palma, M., Biziato, D., Petrova, T.V.: Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer. 17, 457–474 (2017)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Sawamiphak</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>465</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>487</first-page>
<last-page>491</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sawamiphak, S., et al.: Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 465, 487–491 (2010)</ref-fulltext>
<ce:source-text>Sawamiphak, S., et al.: Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 465, 487–491 (2010)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Sato</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>JCI Insight</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<page-information>
<pages>
<first-page>4</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sato, S., et al.: EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. JCI Insight. 4 (2019)</ref-fulltext>
<ce:source-text>Sato, S., et al.: EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling. JCI Insight. 4 (2019)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.O.</ce:initials>
<ce:surname>Jung</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Youn</ce:surname>
</author>
<author seq="3">
<ce:initials>C.H.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="4">
<ce:initials>K.W.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
<author seq="5">
<ce:initials>J.K.</ce:initials>
<ce:surname>Chung</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9899</first-page>
<last-page>9910</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jung, K.O., Youn, H., Lee, C.H., Kang, K.W., Chung, J.K.: Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget. 8, 9899–9910 (2017)</ref-fulltext>
<ce:source-text>Jung, K.O., Youn, H., Lee, C.H., Kang, K.W., Chung, J.K.: Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget. 8, 9899–9910 (2017)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.A.</ce:initials>
<ce:surname>Lanahan</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Circulation</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>902</first-page>
<last-page>909</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lanahan, A.A., et al.: PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells. Circulation. 130, 902–909 (2014)</ref-fulltext>
<ce:source-text>Lanahan, A.A., et al.: PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells. Circulation. 130, 902–909 (2014)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Umezu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Blood</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>124</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3748</first-page>
<last-page>3757</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Umezu, T., et al.: Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 124, 3748–3757 (2014)</ref-fulltext>
<ce:source-text>Umezu, T., et al.: Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. Blood. 124, 3748–3757 (2014)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>piRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.B.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5227</first-page>
<last-page>5238</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, B.B., et al.: PiRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. Oncogene. 38, 5227–5238 (2019)</ref-fulltext>
<ce:source-text>Li, B.B., et al.: PiRNA-823 delivered by multiple myeloma-derived extracellular vesicles promoted tumorigenesis through re-educating endothelial cells in the tumor environment. Oncogene. 38, 5227–5238 (2019)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Treps</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Perret</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Edmond</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Ricard</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Gavard</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Extracell. Vesicles</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
</volisspag>
<ref-text>1359479</ref-text>
</ref-info>
<ref-fulltext>Treps, L., Perret, R., Edmond, S., Ricard, D., Gavard, J.: Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J. Extracell. Vesicles. 6, 1359479 (2017)</ref-fulltext>
<ce:source-text>Treps, L., Perret, R., Edmond, S., Ricard, D., Gavard, J.: Glioblastoma stem-like cells secrete the pro-angiogenic VEGF-A factor in extracellular vesicles. J. Extracell. Vesicles. 6, 1359479 (2017)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.Y.</ce:initials>
<ce:surname>Ko</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Commun. Biol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>386</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ko, S.Y., et al.: Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun. Biol. 2, 386 (2019)</ref-fulltext>
<ce:source-text>Ko, S.Y., et al.: Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun. Biol. 2, 386 (2019)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Intravascular survival and extravasation of tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Strilic</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Offermanns</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>282</first-page>
<last-page>293</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Strilic, B., Offermanns, S.: Intravascular survival and extravasation of tumor cells. Cancer Cell. 32, 282–293 (2017)</ref-fulltext>
<ce:source-text>Strilic, B., Offermanns, S.: Intravascular survival and extravasation of tumor cells. Cancer Cell. 32, 282–293 (2017)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Mohme</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>155</first-page>
<last-page>167</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mohme, M., Riethdorf, S., Pantel, K.: Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 14, 155–167 (2017)</ref-fulltext>
<ce:source-text>Mohme, M., Riethdorf, S., Pantel, K.: Circulating and disseminated tumour cells – mechanisms of immune surveillance and escape. Nat. Rev. Clin. Oncol. 14, 155–167 (2017)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Treps</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2615</first-page>
<last-page>2623</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Treps, L., et al.: Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene. 35, 2615–2623 (2016)</ref-fulltext>
<ce:source-text>Treps, L., et al.: Extracellular vesicle-transported Semaphorin3A promotes vascular permeability in glioblastoma. Oncogene. 35, 2615–2623 (2016)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Zeng</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5395</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zeng, Z., et al.: Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat. Commun. 9, 5395 (2018)</ref-fulltext>
<ce:source-text>Zeng, Z., et al.: Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat. Commun. 9, 5395 (2018)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Bhattacharya</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>280</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>28848</first-page>
<last-page>28851</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bhattacharya, R., et al.: Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J. Biol. Chem. 280, 28848–28851 (2005)</ref-fulltext>
<ce:source-text>Bhattacharya, R., et al.: Inhibition of vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis by the Kruppel-like factor KLF2. J. Biol. Chem. 280, 28848–28851 (2005)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Kruppel-like factor 4 regulates blood-tumor barrier permeability via ZO-1, occludin and claudin-5</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>229</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>916</first-page>
<last-page>926</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ma, J., et al.: Kruppel-like factor 4 regulates blood-tumor barrier permeability via ZO-1, occludin and claudin-5. J. Cell. Physiol. 229, 916–926 (2014)</ref-fulltext>
<ce:source-text>Ma, J., et al.: Kruppel-like factor 4 regulates blood-tumor barrier permeability via ZO-1, occludin and claudin-5. J. Cell. Physiol. 229, 916–926 (2014)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.L.</ce:initials>
<ce:surname>Hsu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4929</first-page>
<last-page>4942</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hsu, Y.L., et al.: Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 36, 4929–4942 (2017)</ref-fulltext>
<ce:source-text>Hsu, Y.L., et al.: Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 36, 4929–4942 (2017)</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Di Modica</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Lett</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>384</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>100</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di Modica, M., et al.: Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. Cancer Lett. 384, 94–100 (2017)</ref-fulltext>
<ce:source-text>Di Modica, M., et al.: Breast cancer-secreted miR-939 downregulates VE-cadherin and destroys the barrier function of endothelial monolayers. Cancer Lett. 384, 94–100 (2017)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.H.</ce:initials>
<ce:surname>Fang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Hepatology</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>68</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1459</first-page>
<last-page>1475</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fang, J.H., et al.: Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology. 68, 1459–1475 (2018)</ref-fulltext>
<ce:source-text>Fang, J.H., et al.: Hepatoma cell-secreted exosomal microRNA-103 increases vascular permeability and promotes metastasis by targeting junction proteins. Hepatology. 68, 1459–1475 (2018)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Exp. Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<page-information>
<pages>
<first-page>37</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, J., et al.: Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J. Exp. Clin. Cancer Res. 37 (2018)</ref-fulltext>
<ce:source-text>Li, J., et al.: Circular RNA IARS (circ-IARS) secreted by pancreatic cancer cells and located within exosomes regulates endothelial monolayer permeability to promote tumor metastasis. J. Exp. Clin. Cancer Res. 37 (2018)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Natural RNA circles function as efficient microRNA sponges</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.B.</ce:initials>
<ce:surname>Hansen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>495</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>384</first-page>
<last-page>388</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hansen, T.B., et al.: Natural RNA circles function as efficient microRNA sponges. Nature. 495, 384–388 (2013)</ref-fulltext>
<ce:source-text>Hansen, T.B., et al.: Natural RNA circles function as efficient microRNA sponges. Nature. 495, 384–388 (2013)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.J.</ce:initials>
<ce:surname>Fidler</ce:surname>
</author>
<author seq="2">
<ce:initials>G.L.</ce:initials>
<ce:surname>Nicolson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Natl. Cancer Inst</ref-sourcetitle>
<ref-publicationyear first="1976"/>
<volisspag>
<volume-issue-number>
<vol-first>57</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1199</first-page>
<last-page>1202</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fidler, I.J., Nicolson, G.L.: Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 57, 1199–1202 (1976)</ref-fulltext>
<ce:source-text>Fidler, I.J., Nicolson, G.L.: Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J. Natl. Cancer Inst. 57, 1199–1202 (1976)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Role of organ selectivity in the determination of metastatic patterns of B16 melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.R.</ce:initials>
<ce:surname>Hart</ce:surname>
</author>
<author seq="2">
<ce:initials>I.J.</ce:initials>
<ce:surname>Fidler</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1980"/>
<volisspag>
<volume-issue-number>
<vol-first>40</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2281</first-page>
<last-page>2287</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hart, I.R., Fidler, I.J.: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40, 2281–2287 (1980)</ref-fulltext>
<ce:source-text>Hart, I.R., Fidler, I.J.: Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40, 2281–2287 (1980)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis organotropism: Redefining the congenial soil</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>375</first-page>
<last-page>391</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, Y., et al.: Metastasis organotropism: redefining the congenial soil. Dev. Cell. 49, 375–391 (2019)</ref-fulltext>
<ce:source-text>Gao, Y., et al.: Metastasis organotropism: redefining the congenial soil. Dev. Cell. 49, 375–391 (2019)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis: From dissemination to organ-specific colonization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.X.</ce:initials>
<ce:surname>Nguyen</ce:surname>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Bos</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>U265</first-page>
<last-page>U274</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer. 9, 274–U265 (2009)</ref-fulltext>
<ce:source-text>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ-specific colonization. Nat. Rev. Cancer. 9, 274–U265 (2009)</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.L.</ce:initials>
<ce:surname>Hood</ce:surname>
</author>
<author seq="2">
<ce:initials>R.S.</ce:initials>
<ce:surname>San</ce:surname>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Wickline</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>71</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3792</first-page>
<last-page>3801</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hood, J.L., San, R.S., Wickline, S.A.: Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71, 3792–3801 (2011)</ref-fulltext>
<ce:source-text>Hood, J.L., San, R.S., Wickline, S.A.: Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 71, 3792–3801 (2011)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanism underlying lymphatic metastasis in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Xiao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Biomed. Res. Int</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>2014</vol-first>
</volume-issue-number>
</volisspag>
<ref-text>925845</ref-text>
</ref-info>
<ref-fulltext>Xiao, Z., et al.: Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Biomed. Res. Int. 2014, 925845 (2014)</ref-fulltext>
<ce:source-text>Xiao, Z., et al.: Molecular mechanism underlying lymphatic metastasis in pancreatic cancer. Biomed. Res. Int. 2014, 925845 (2014)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Pucci</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>352</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>242</first-page>
<last-page>246</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pucci, F., et al.: SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 352, 242–246 (2016)</ref-fulltext>
<ce:source-text>Pucci, F., et al.: SCS macrophages suppress melanoma by restricting tumor-derived vesicle-B cell interactions. Science. 352, 242–246 (2016)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.G.</ce:initials>
<ce:surname>Maus</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Immunol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>358</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Maus, R.L.G., et al.: Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front. Immunol. 8, 358 (2017)</ref-fulltext>
<ce:source-text>Maus, R.L.G., et al.: Human melanoma-derived extracellular vesicles regulate dendritic cell maturation. Front. Immunol. 8, 358 (2017)</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal tumor microRNA modulates premetastatic organ cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Rana</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Malinowska</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Zoller</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neoplasia</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>281</first-page>
<last-page>295</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rana, S., Malinowska, K., Zoller, M.: Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 15, 281–295 (2013)</ref-fulltext>
<ce:source-text>Rana, S., Malinowska, K., Zoller, M.: Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia. 15, 281–295 (2013)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Srinivasan</ce:surname>
</author>
<author seq="2">
<ce:initials>F.O.</ce:initials>
<ce:surname>Vannberg</ce:surname>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Dixon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24436</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Srinivasan, S., Vannberg, F.O., Dixon, J.B.: Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node. Sci. Rep. 6, 24436 (2016)</ref-fulltext>
<ce:source-text>Srinivasan, S., Vannberg, F.O., Dixon, J.B.: Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node. Sci. Rep. 6, 24436 (2016)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>404</first-page>
<last-page>421</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, C., et al.: Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J. Clin. Invest. 130, 404–421 (2020)</ref-fulltext>
<ce:source-text>Chen, C., et al.: Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer. J. Clin. Invest. 130, 404–421 (2020)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>145</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1648</first-page>
<last-page>1659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, B., et al.: Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes. Int. J. Cancer. 145, 1648–1659 (2019)</ref-fulltext>
<ce:source-text>Sun, B., et al.: Colorectal cancer exosomes induce lymphatic network remodeling in lymph nodes. Int. J. Cancer. 145, 1648–1659 (2019)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>The lymphatic system: Integral roles in immunity. Annu</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.J.</ce:initials>
<ce:surname>Randolph</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ivanov</ce:surname>
</author>
<author seq="3">
<ce:initials>B.H.</ce:initials>
<ce:surname>Zinselmeyer</ce:surname>
</author>
<author seq="4">
<ce:initials>J.P.</ce:initials>
<ce:surname>Scallan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Rev. Immunol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>31</first-page>
<last-page>52</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Randolph, G.J., Ivanov, S., Zinselmeyer, B.H., Scallan, J.P.: The lymphatic system: integral roles in immunity. Annu. Rev. Immunol. 35, 31–52 (2017)</ref-fulltext>
<ce:source-text>Randolph, G.J., Ivanov, S., Zinselmeyer, B.H., Scallan, J.P.: The lymphatic system: integral roles in immunity. Annu. Rev. Immunol. 35, 31–52 (2017)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Chow</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5750</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chow, A., et al.: Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB. Sci. Rep. 4, 5750 (2014)</ref-fulltext>
<ce:source-text>Chow, A., et al.: Macrophage immunomodulation by breast cancer-derived exosomes requires toll-like receptor 2-mediated activation of NF-kappaB. Sci. Rep. 4, 5750 (2014)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma growth and lymph node metastasis is independent of host CD169 expression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.R.</ce:initials>
<ce:surname>Muhsin-Sharafaldine</ce:surname>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Saunderson</ce:surname>
</author>
<author seq="3">
<ce:initials>A.C.</ce:initials>
<ce:surname>Dunn</ce:surname>
</author>
<author seq="4">
<ce:initials>A.D.</ce:initials>
<ce:surname>McLellan</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>486</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>965</first-page>
<last-page>970</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Muhsin-Sharafaldine, M.R., Saunderson, S.C., Dunn, A.C., McLellan, A.D.: Melanoma growth and lymph node metastasis is independent of host CD169 expression. Biochem. Biophys. Res. Commun. 486, 965–970 (2017)</ref-fulltext>
<ce:source-text>Muhsin-Sharafaldine, M.R., Saunderson, S.C., Dunn, A.C., McLellan, A.D.: Melanoma growth and lymph node metastasis is independent of host CD169 expression. Biochem. Biophys. Res. Commun. 486, 965–970 (2017)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Skobe</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>198</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Skobe, M., et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192–198 (2001)</ref-fulltext>
<ce:source-text>Skobe, M., et al.: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7, 192–198 (2001)</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>VEGF-D promotes the metastatic spread of tumor cells via the lymphatics</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stacker</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>186</first-page>
<last-page>191</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stacker, S.A., et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7, 186–191 (2001)</ref-fulltext>
<ce:source-text>Stacker, S.A., et al.: VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7, 186–191 (2001)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Lymphangiogenesis and lymphatic vessel remodelling in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stacker</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>159</first-page>
<last-page>172</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stacker, S.A., et al.: Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer. 14, 159–172 (2014)</ref-fulltext>
<ce:source-text>Stacker, S.A., et al.: Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat. Rev. Cancer. 14, 159–172 (2014)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes as a communication tool between the lymphatic system and bladder cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Park</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.J.</ce:initials>
<ce:surname>Hong</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="4">
<ce:initials>P.M.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="5">
<ce:initials>Y.K.</ce:initials>
<ce:surname>Hong</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. Neurourol. J</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>220</first-page>
<last-page>224</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, R.J., Hong, Y.J., Wu, Y., Kim, P.M., Hong, Y.K.: Exosomes as a communication tool between the lymphatic system and bladder cancer. Int. Neurourol. J. 22, 220–224 (2018)</ref-fulltext>
<ce:source-text>Park, R.J., Hong, Y.J., Wu, Y., Kim, P.M., Hong, Y.K.: Exosomes as a communication tool between the lymphatic system and bladder cancer. Int. Neurourol. J. 22, 220–224 (2018)</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english>Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.F.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1256</first-page>
<last-page>1268</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhou, C.F., et al.: Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 38, 1256–1268 (2019)</ref-fulltext>
<ce:source-text>Zhou, C.F., et al.: Cervical squamous cell carcinoma-secreted exosomal miR-221-3p promotes lymphangiogenesis and lymphatic metastasis by targeting VASH1. Oncogene. 38, 1256–1268 (2019)</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: Long-term results in 1100 patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Hautmann</ce:surname>
</author>
<author seq="2">
<ce:initials>R.C.</ce:initials>
<ce:surname>de Petriconi</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Pfeiffer</ce:surname>
</author>
<author seq="4">
<ce:initials>B.G.</ce:initials>
<ce:surname>Volkmer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Eur. Urol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1039</first-page>
<last-page>1047</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hautmann, R.E., de Petriconi, R.C., Pfeiffer, C., Volkmer, B.G.: Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol. 61, 1039–1047 (2012)</ref-fulltext>
<ce:source-text>Hautmann, R.E., de Petriconi, R.C., Pfeiffer, C., Volkmer, B.G.: Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol. 61, 1039–1047 (2012)</ce:source-text>
</reference>
<reference seq="160">
<ref-info>
<ref-title>
<ref-titletext-english>CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Gastric Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>766</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, D., et al.: CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent. Gastric Cancer. 19, 754–766 (2016)</ref-fulltext>
<ce:source-text>Liu, D., et al.: CD97 promotion of gastric carcinoma lymphatic metastasis is exosome dependent. Gastric Cancer. 19, 754–766 (2016)</ce:source-text>
</reference>
<reference seq="161">
<ref-info>
<ref-title>
<ref-titletext-english>Sentinel-node biopsy or nodal observation in melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Morton</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>355</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1307</first-page>
<last-page>1317</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morton, D.L., et al.: Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355, 1307–1317 (2006)</ref-fulltext>
<ce:source-text>Morton, D.L., et al.: Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355, 1307–1317 (2006)</ce:source-text>
</reference>
<reference seq="162">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer volume of lymph node metastasis predicts progression in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Cheng</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Am. J. Surg. Pathol</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>22</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1491</first-page>
<last-page>1500</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cheng, L., et al.: Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am. J. Surg. Pathol. 22, 1491–1500 (1998)</ref-fulltext>
<ce:source-text>Cheng, L., et al.: Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am. J. Surg. Pathol. 22, 1491–1500 (1998)</ce:source-text>
</reference>
<reference seq="163">
<ref-info>
<ref-title>
<ref-titletext-english>Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.J.</ce:initials>
<ce:surname>Im</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1387</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Im, E.J., et al.: Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat. Commun. 10, 1387 (2019)</ref-fulltext>
<ce:source-text>Im, E.J., et al.: Sulfisoxazole inhibits the secretion of small extracellular vesicles by targeting the endothelin receptor A. Nat. Commun. 10, 1387 (2019)</ce:source-text>
</reference>
<reference seq="164">
<ref-info>
<ref-title>
<ref-titletext-english>The lung microenvironment: An important regulator of tumour growth and metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.K.</ce:initials>
<ce:surname>Altorki</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>9</first-page>
<last-page>31</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Altorki, N.K., et al.: The lung microenvironment: An important regulator of tumour growth and metastasis. Nat. Rev. Cancer. 19, 9–31 (2019)</ref-fulltext>
<ce:source-text>Altorki, N.K., et al.: The lung microenvironment: An important regulator of tumour growth and metastasis. Nat. Rev. Cancer. 19, 9–31 (2019)</ce:source-text>
</reference>
<reference seq="165">
<ref-info>
<ref-title>
<ref-titletext-english>Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Erler</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>35</first-page>
<last-page>44</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Erler, J.T., et al.: Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 15, 35–44 (2009)</ref-fulltext>
<ce:source-text>Erler, J.T., et al.: Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 15, 35–44 (2009)</ce:source-text>
</reference>
<reference seq="166">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Fang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>191</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fang, T., et al.: Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat. Commun. 9, 191 (2018)</ref-fulltext>
<ce:source-text>Fang, T., et al.: Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer. Nat. Commun. 9, 191 (2018)</ce:source-text>
</reference>
<reference seq="167">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Trefts</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Gannon</ce:surname>
</author>
<author seq="3">
<ce:initials>D.H.</ce:initials>
<ce:surname>Wasserman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>The Liver. Curr. Biol.</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>R1147</first-page>
<last-page>R1151</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Trefts, E., Gannon, M., Wasserman, D.H.: The liver. Curr. Biol. 27, R1147–R1151 (2017)</ref-fulltext>
<ce:source-text>Trefts, E., Gannon, M., Wasserman, D.H.: The liver. Curr. Biol. 27, R1147–R1151 (2017)</ce:source-text>
</reference>
<reference seq="168">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15016</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, H., et al.: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat. Commun. 8, 15016 (2017)</ref-fulltext>
<ce:source-text>Zhang, H., et al.: Exosome-delivered EGFR regulates liver microenvironment to promote gastric cancer liver metastasis. Nat. Commun. 8, 15016 (2017)</ce:source-text>
</reference>
<reference seq="169">
<ref-info>
<ref-title>
<ref-titletext-english>Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Carcinogenesis</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>39</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1368</first-page>
<last-page>1379</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shao, Y., et al.: Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. Carcinogenesis. 39, 1368–1379 (2018)</ref-fulltext>
<ce:source-text>Shao, Y., et al.: Colorectal cancer-derived small extracellular vesicles establish an inflammatory premetastatic niche in liver metastasis. Carcinogenesis. 39, 1368–1379 (2018)</ce:source-text>
</reference>
<reference seq="170">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis to bone: Causes, consequences and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>584</first-page>
<last-page>593</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mundy, G.R.: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2, 584–593 (2002)</ref-fulltext>
<ce:source-text>Mundy, G.R.: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2, 584–593 (2002)</ce:source-text>
</reference>
<reference seq="171">
<ref-info>
<ref-title>
<ref-titletext-english>RANKL-RANK signaling regulates osteoblast differentiation and bone formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Cao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Bone Res</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>35</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cao, X.: RANKL-RANK signaling regulates osteoblast differentiation and bone formation. Bone Res. 6, 35 (2018)</ref-fulltext>
<ce:source-text>Cao, X.: RANKL-RANK signaling regulates osteoblast differentiation and bone formation. Bone Res. 6, 35 (2018)</ce:source-text>
</reference>
<reference seq="172">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Tiedemann</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>462</first-page>
<last-page>474</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tiedemann, K., et al.: Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl. Oncol. 12, 462–474 (2019)</ref-fulltext>
<ce:source-text>Tiedemann, K., et al.: Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl. Oncol. 12, 462–474 (2019)</ce:source-text>
</reference>
<reference seq="173">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Guo</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Med</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5687</first-page>
<last-page>5701</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guo, L., et al.: Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1. Cancer Med. 8, 5687–5701 (2019)</ref-fulltext>
<ce:source-text>Guo, L., et al.: Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1. Cancer Med. 8, 5687–5701 (2019)</ce:source-text>
</reference>
<reference seq="174">
<ref-info>
<ref-title>
<ref-titletext-english>Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Probert</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1751</first-page>
<last-page>1763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Probert, C., et al.: Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene. 38, 1751–1763 (2019)</ref-fulltext>
<ce:source-text>Probert, C., et al.: Communication of prostate cancer cells with bone cells via extracellular vesicle RNA; a potential mechanism of metastasis. Oncogene. 38, 1751–1763 (2019)</ce:source-text>
</reference>
<reference seq="175">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Ye</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94834</first-page>
<last-page>94849</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ye, Y., et al.: Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer. Oncotarget. 8, 94834–94849 (2017)</ref-fulltext>
<ce:source-text>Ye, Y., et al.: Exosomal miR-141-3p regulates osteoblast activity to promote the osteoblastic metastasis of prostate cancer. Oncotarget. 8, 94834–94849 (2017)</ce:source-text>
</reference>
<reference seq="176">
<ref-info>
<ref-title>
<ref-titletext-english>Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Lacey</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Drug Discov</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>401</first-page>
<last-page>419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lacey, D.L., et al.: Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401–419 (2012)</ref-fulltext>
<ce:source-text>Lacey, D.L., et al.: Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat. Rev. Drug Discov. 11, 401–419 (2012)</ce:source-text>
</reference>
<reference seq="177">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Hashimoto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>115</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2204</first-page>
<last-page>2209</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hashimoto, K., et al.: Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc. Natl. Acad. Sci. USA. 115, 2204–2209 (2018)</ref-fulltext>
<ce:source-text>Hashimoto, K., et al.: Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A. Proc. Natl. Acad. Sci. USA. 115, 2204–2209 (2018)</ce:source-text>
</reference>
<reference seq="178">
<ref-info>
<ref-title>
<ref-titletext-english>Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Tominaga</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6716</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tominaga, N., et al.: Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat. Commun. 6, 6716 (2015)</ref-fulltext>
<ce:source-text>Tominaga, N., et al.: Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat. Commun. 6, 6716 (2015)</ce:source-text>
</reference>
<reference seq="179">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Xing</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4316</first-page>
<last-page>4330</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xing, F., et al.: Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 78, 4316–4330 (2018)</ref-fulltext>
<ce:source-text>Xing, F., et al.: Loss of XIST in breast cancer activates MSN-c-Met and reprograms microglia via exosomal miRNA to promote brain metastasis. Cancer Res. 78, 4316–4330 (2018)</ce:source-text>
</reference>
<reference seq="180">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Gener Lahav</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Int. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>145</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2521</first-page>
<last-page>2534</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gener Lahav, T., et al.: Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment. Int. J. Cancer. 145, 2521–2534 (2019)</ref-fulltext>
<ce:source-text>Gener Lahav, T., et al.: Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment. Int. J. Cancer. 145, 2521–2534 (2019)</ce:source-text>
</reference>
<reference seq="181">
<ref-info>
<ref-title>
<ref-titletext-english>Blood-brain barrier: From physiology to disease and back</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.D.</ce:initials>
<ce:surname>Sweeney</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Montagne</ce:surname>
</author>
<author seq="4">
<ce:initials>A.R.</ce:initials>
<ce:surname>Nelson</ce:surname>
</author>
<author seq="5">
<ce:initials>B.V.</ce:initials>
<ce:surname>Zlokovic</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Physiol. Rev</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>99</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
<last-page>78</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A.R., Zlokovic, B.V.: Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21–78 (2019)</ref-fulltext>
<ce:source-text>Sweeney, M.D., Zhao, Z., Montagne, A., Nelson, A.R., Zlokovic, B.V.: Blood-brain barrier: from physiology to disease and back. Physiol. Rev. 99, 21–78 (2019)</ce:source-text>
</reference>
<reference seq="182">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Morad</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>ACS Nano</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13853</first-page>
<last-page>13865</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morad, G., et al.: Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS Nano. 13, 13853–13865 (2019)</ref-fulltext>
<ce:source-text>Morad, G., et al.: Tumor-derived extracellular vesicles breach the intact blood-brain barrier via transcytosis. ACS Nano. 13, 13853–13865 (2019)</ce:source-text>
</reference>
<reference seq="183">
<ref-info>
<ref-title>
<ref-titletext-english>Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.H.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>FASEB J</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1742</first-page>
<last-page>1757</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, Z.H., et al.: Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain. FASEB J. 33, 1742–1757 (2019)</ref-fulltext>
<ce:source-text>Xu, Z.H., et al.: Brain microvascular endothelial cell exosome-mediated S100A16 up-regulation confers small-cell lung cancer cell survival in brain. FASEB J. 33, 1742–1757 (2019)</ce:source-text>
</reference>
<reference seq="184">
<ref-info>
<ref-title>
<ref-titletext-english>Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>100</first-page>
<last-page>104</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, L., et al.: Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 527, 100–104 (2015)</ref-fulltext>
<ce:source-text>Zhang, L., et al.: Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature. 527, 100–104 (2015)</ce:source-text>
</reference>
<reference seq="185">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>560</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>382</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, G., et al.: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 560, 382–386 (2018)</ref-fulltext>
<ce:source-text>Chen, G., et al.: Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 560, 382–386 (2018)</ce:source-text>
</reference>
<reference seq="186">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Balaj</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>180</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Balaj, L., et al.: Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011)</ref-fulltext>
<ce:source-text>Balaj, L., et al.: Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011)</ce:source-text>
</reference>
<reference seq="187">
<ref-info>
<ref-title>
<ref-titletext-english>Astrocytes and Glioblastoma cells release exosomes carrying mtDNA</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Guescini</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Genedani</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Stocchi</ce:surname>
</author>
<author seq="4">
<ce:initials>L.F.</ce:initials>
<ce:surname>Agnati</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Neural Transm. (Vienna).</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>117</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1</first-page>
<last-page>4</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Guescini, M., Genedani, S., Stocchi, V., Agnati, L.F.: Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. (Vienna). 117, 1–4 (2010)</ref-fulltext>
<ce:source-text>Guescini, M., Genedani, S., Stocchi, V., Agnati, L.F.: Astrocytes and Glioblastoma cells release exosomes carrying mtDNA. J. Neural Transm. (Vienna). 117, 1–4 (2010)</ce:source-text>
</reference>
<reference seq="188">
<ref-info>
<ref-title>
<ref-titletext-english>Double-stranded DNA in exosomes: A novel biomarker in cancer detection</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.K.</ce:initials>
<ce:surname>Thakur</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Res</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>766</first-page>
<last-page>769</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thakur, B.K., et al.: Double-stranded DNA in exosomes: A novel biomarker in cancer detection. Cell Res. 24, 766–769 (2014)</ref-fulltext>
<ce:source-text>Thakur, B.K., et al.: Double-stranded DNA in exosomes: A novel biomarker in cancer detection. Cell Res. 24, 766–769 (2014)</ce:source-text>
</reference>
<reference seq="189">
<ref-info>
<ref-title>
<ref-titletext-english>Exosome DNA: Critical regulator of tumor immunity and a diagnostic biomarker</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Sharma</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>235</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1921</first-page>
<last-page>1932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sharma, A., Johnson, A.: Exosome DNA: Critical regulator of tumor immunity and a diagnostic biomarker. J. Cell. Physiol. 235, 1921–1932 (2020)</ref-fulltext>
<ce:source-text>Sharma, A., Johnson, A.: Exosome DNA: Critical regulator of tumor immunity and a diagnostic biomarker. J. Cell. Physiol. 235, 1921–1932 (2020)</ce:source-text>
</reference>
<reference seq="190">
<ref-info>
<ref-title>
<ref-titletext-english>DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kitai</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Immunol</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>198</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1649</first-page>
<last-page>1659</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kitai, Y., et al.: DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J. Immunol. 198, 1649–1659 (2017)</ref-fulltext>
<ce:source-text>Kitai, Y., et al.: DNA-containing exosomes derived from cancer cells treated with topotecan activate a STING-dependent pathway and reinforce antitumor immunity. J. Immunol. 198, 1649–1659 (2017)</ce:source-text>
</reference>
<reference seq="191">
<ref-info>
<ref-title>
<ref-titletext-english>Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.M.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>47</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>363</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Xu, M.M., et al.: Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity. 47, 363-+ (2017)</ref-fulltext>
<ce:source-text>Xu, M.M., et al.: Dendritic cells but not macrophages sense tumor mitochondrial DNA for cross-priming through signal regulatory protein alpha signaling. Immunity. 47, 363-+ (2017)</ce:source-text>
</reference>
<reference seq="192">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Puhka</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Theranostics</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3824</first-page>
<last-page>3841</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Puhka, M., et al.: Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes. Theranostics. 7, 3824–3841 (2017)</ref-fulltext>
<ce:source-text>Puhka, M., et al.: Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes. Theranostics. 7, 3824–3841 (2017)</ce:source-text>
</reference>
<reference seq="193">
<ref-info>
<ref-title>
<ref-titletext-english>Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.P.</ce:initials>
<ce:surname>Lai</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7029</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lai, C.P., et al.: Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat. Commun. 6, 7029 (2015)</ref-fulltext>
<ce:source-text>Lai, C.P., et al.: Visualization and tracking of tumour extracellular vesicle delivery and RNA translation using multiplexed reporters. Nat. Commun. 6, 7029 (2015)</ce:source-text>
</reference>
<reference seq="194">
<ref-info>
<ref-title>
<ref-titletext-english>In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Zomer</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>161</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1046</first-page>
<last-page>1057</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zomer, A., et al.: In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 161, 1046–1057 (2015)</ref-fulltext>
<ce:source-text>Zomer, A., et al.: In vivo imaging reveals extracellular vesicle-mediated phenocopying of metastatic behavior. Cell. 161, 1046–1057 (2015)</ce:source-text>
</reference>
<reference seq="195">
<ref-info>
<ref-title>
<ref-titletext-english>Studying extracellular vesicle transfer by a Cre-loxP method</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Zomer</ce:surname>
</author>
<author seq="2">
<ce:initials>S.C.</ce:initials>
<ce:surname>Steenbeek</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Maynard</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>van Rheenen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Protoc</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>87</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zomer, A., Steenbeek, S.C., Maynard, C., van Rheenen, J.: Studying extracellular vesicle transfer by a Cre-loxP method. Nat. Protoc. 11, 87–101 (2016)</ref-fulltext>
<ce:source-text>Zomer, A., Steenbeek, S.C., Maynard, C., van Rheenen, J.: Studying extracellular vesicle transfer by a Cre-loxP method. Nat. Protoc. 11, 87–101 (2016)</ce:source-text>
</reference>
<reference seq="196">
<ref-info>
<ref-title>
<ref-titletext-english>Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.</ce:initials>
<ce:surname>Hyenne</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Dev. Cell</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>554</first-page>
<last-page>572</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hyenne, V., et al.: Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo. Dev. Cell. 48, 554–572 e557 (2019)</ref-fulltext>
<ce:source-text>Hyenne, V., et al.: Studying the fate of tumor extracellular vesicles at high spatiotemporal resolution using the zebrafish embryo. Dev. Cell. 48, 554–572 e557 (2019)</ce:source-text>
</reference>
<reference seq="197">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer cachexia: Mediators, signaling, and metabolic pathways</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.C.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<author seq="2">
<ce:initials>D.J.</ce:initials>
<ce:surname>Glass</ce:surname>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>153</first-page>
<last-page>166</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K.C., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153–166 (2012)</ref-fulltext>
<ce:source-text>Fearon, K.C., Glass, D.J., Guttridge, D.C.: Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16, 153–166 (2012)</ce:source-text>
</reference>
<reference seq="198">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding cachexia as a cancer metabolism syndrome</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.E.</ce:initials>
<ce:surname>Porporato</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncogenesis</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<page-information>
<pages>
<first-page>5</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5 (2016)</ref-fulltext>
<ce:source-text>Porporato, P.E.: Understanding cachexia as a cancer metabolism syndrome. Oncogenesis. 5 (2016)</ce:source-text>
</reference>
<reference seq="199">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>770</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ref-fulltext>
<ce:source-text>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24, 770–781 (2018)</ce:source-text>
</reference>
<reference seq="200">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Korc</ce:surname>
</author>
<author seq="4">
<ce:initials>D.C.</ce:initials>
<ce:surname>Guttridge</ce:surname>
</author>
<author seq="5">
<ce:initials>K.C.H.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17105</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C., Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., Martin, L., Korc, M., Guttridge, D.C., Fearon, K.C.H.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="201">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Miao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Mol. Ther. Nucleic Acids</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>923</first-page>
<last-page>938</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miao, C., et al.: Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia. Mol. Ther. Nucleic Acids. 24, 923–938 (2021)</ref-fulltext>
<ce:source-text>Miao, C., et al.: Cancer-derived exosome miRNAs induce skeletal muscle wasting by Bcl-2-mediated apoptosis in colon cancer cachexia. Mol. Ther. Nucleic Acids. 24, 923–938 (2021)</ce:source-text>
</reference>
<reference seq="202">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Commun</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>589</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8, 589 (2017)</ref-fulltext>
<ce:source-text>Zhang, G., et al.: Tumor induces muscle wasting in mice through releasing extracellular Hsp70 and Hsp90. Nat. Commun. 8, 589 (2017)</ce:source-text>
</reference>
<reference seq="203">
<ref-info>
<ref-title>
<ref-titletext-english>Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.A.</ce:initials>
<ce:surname>He</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>111</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4525</first-page>
<last-page>4529</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>He, W.A., et al.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111, 4525–4529 (2014)</ref-fulltext>
<ce:source-text>He, W.A., et al.: Microvesicles containing miRNAs promote muscle cell death in cancer cachexia via TLR7. Proc. Natl. Acad. Sci. USA. 111, 4525–4529 (2014)</ce:source-text>
</reference>
<reference seq="204">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Sagar</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Gut</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1165</first-page>
<last-page>1174</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sagar, G., et al.: Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 65, 1165–1174 (2016)</ref-fulltext>
<ce:source-text>Sagar, G., et al.: Pathogenesis of pancreatic cancer exosome-induced lipolysis in adipose tissue. Gut. 65, 1165–1174 (2016)</ce:source-text>
</reference>
<reference seq="205">
<ref-info>
<ref-title>
<ref-titletext-english>Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGFbeta signaling pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="5">
<ce:initials>R.C.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol. Cell. Biochem</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>435</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>59</first-page>
<last-page>66</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, S., Li, X., Xu, M., Wang, J., Zhao, R.C.: Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGFbeta signaling pathway. Mol. Cell. Biochem. 435, 59–66 (2017)</ref-fulltext>
<ce:source-text>Wang, S., Li, X., Xu, M., Wang, J., Zhao, R.C.: Reduced adipogenesis after lung tumor exosomes priming in human mesenchymal stem cells via TGFbeta signaling pathway. Mol. Cell. Biochem. 435, 59–66 (2017)</ce:source-text>
</reference>
<reference seq="206">
<ref-info>
<ref-title>
<ref-titletext-english>A switch from white to brown fat increases energy expenditure in cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Petruzzelli</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>433</first-page>
<last-page>447</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014)</ref-fulltext>
<ce:source-text>Petruzzelli, M., et al.: A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20, 433–447 (2014)</ce:source-text>
</reference>
<reference seq="207">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Mol. Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>155</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wu, Q., et al.: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression. Mol. Cancer. 17, 155 (2018)</ref-fulltext>
<ce:source-text>Wu, Q., et al.: Tumour-originated exosomal miR-155 triggers cancer-associated cachexia to promote tumour progression. Mol. Cancer. 17, 155 (2018)</ce:source-text>
</reference>
<reference seq="208">
<ref-info>
<ref-title>
<ref-titletext-english>Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.J.</ce:initials>
<ce:surname>Di</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Cell. Physiol</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<volume-issue-number>
<vol-first>236</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5399</first-page>
<last-page>5410</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Di, W.J., et al.: Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p. J. Cell. Physiol. 236, 5399–5410 (2021)</ref-fulltext>
<ce:source-text>Di, W.J., et al.: Colorectal cancer prompted adipose tissue browning and cancer cachexia through transferring exosomal miR-146b-5p. J. Cell. Physiol. 236, 5399–5410 (2021)</ce:source-text>
</reference>
<reference seq="209">
<ref-info>
<ref-title>
<ref-titletext-english>Paraneoplastic syndromes in rheumatology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Manger</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Schett</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Rheumatol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>662</first-page>
<last-page>670</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Manger, B., Schett, G.: Paraneoplastic syndromes in rheumatology. Nat. Rev. Rheumatol. 10, 662–670 (2014)</ref-fulltext>
<ce:source-text>Manger, B., Schett, G.: Paraneoplastic syndromes in rheumatology. Nat. Rev. Rheumatol. 10, 662–670 (2014)</ce:source-text>
</reference>
<reference seq="210">
<ref-info>
<ref-title>
<ref-titletext-english>Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Javeed</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1722</first-page>
<last-page>1733</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Javeed, N., et al.: Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction. Clin. Cancer Res. 21, 1722–1733 (2015)</ref-fulltext>
<ce:source-text>Javeed, N., et al.: Pancreatic cancer-derived exosomes cause paraneoplastic beta-cell dysfunction. Clin. Cancer Res. 21, 1722–1733 (2015)</ce:source-text>
</reference>
<reference seq="211">
<ref-info>
<ref-title>
<ref-titletext-english>Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.G.</ce:initials>
<ce:surname>Lima</ce:surname>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Leal</ce:surname>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Vargas</ce:surname>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Porto-Carreiro</ce:surname>
</author>
<author seq="5">
<ce:initials>R.Q.</ce:initials>
<ce:surname>Monteiro</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Thromb. Res</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>450</first-page>
<last-page>456</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lima, L.G., Leal, A.C., Vargas, G., Porto-Carreiro, I., Monteiro, R.Q.: Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thromb. Res. 132, 450–456 (2013)</ref-fulltext>
<ce:source-text>Lima, L.G., Leal, A.C., Vargas, G., Porto-Carreiro, I., Monteiro, R.Q.: Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thromb. Res. 132, 450–456 (2013)</ce:source-text>
</reference>
<reference seq="212">
<ref-info>
<ref-title>
<ref-titletext-english>Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.G.</ce:initials>
<ce:surname>Gomes</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Thromb. Res</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>159</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24</first-page>
<last-page>32</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gomes, F.G., et al.: Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms. Thromb. Res. 159, 24–32 (2017)</ref-fulltext>
<ce:source-text>Gomes, F.G., et al.: Breast-cancer extracellular vesicles induce platelet activation and aggregation by tissue factor-independent and -dependent mechanisms. Thromb. Res. 159, 24–32 (2017)</ce:source-text>
</reference>
<reference seq="213">
<ref-info>
<ref-title>
<ref-titletext-english>International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Wefel</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Vardy</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Ahles</ce:surname>
</author>
<author seq="4">
<ce:initials>S.B.</ce:initials>
<ce:surname>Schagen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>703</first-page>
<last-page>708</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wefel, J.S., Vardy, J., Ahles, T., Schagen, S.B.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12, 703–708 (2011)</ref-fulltext>
<ce:source-text>Wefel, J.S., Vardy, J., Ahles, T., Schagen, S.B.: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 12, 703–708 (2011)</ce:source-text>
</reference>
<reference seq="214">
<ref-info>
<ref-title>
<ref-titletext-english>Role of exosomes in cancer-related cognitive impairment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.Q.</ce:initials>
<ce:surname>Koh</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<page-information>
<pages>
<first-page>21</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Koh, Y.Q., et al.: Role of exosomes in cancer-related cognitive impairment. Int. J. Mol. Sci. 21 (2020)</ref-fulltext>
<ce:source-text>Koh, Y.Q., et al.: Role of exosomes in cancer-related cognitive impairment. Int. J. Mol. Sci. 21 (2020)</ce:source-text>
</reference>
<reference seq="215">
<ref-info>
<ref-title>
<ref-titletext-english>Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: A possible way to communicate resistance against radiotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Jabbari</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Nawaz</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Rezaie</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int. J. Mol. Sci</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<page-information>
<pages>
<first-page>20</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jabbari, N., Nawaz, M., Rezaie, J.: Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: A possible way to communicate resistance against radiotherapy. Int. J. Mol. Sci. 20 (2019)</ref-fulltext>
<ce:source-text>Jabbari, N., Nawaz, M., Rezaie, J.: Ionizing radiation increases the activity of exosomal secretory pathway in MCF-7 human breast cancer cells: A possible way to communicate resistance against radiotherapy. Int. J. Mol. Sci. 20 (2019)</ce:source-text>
</reference>
<reference seq="216">
<ref-info>
<ref-title>
<ref-titletext-english>Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.K.</ce:initials>
<ce:surname>Bandari</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Matrix Biol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>104</first-page>
<last-page>118</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bandari, S.K., et al.: Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 65, 104–118 (2018)</ref-fulltext>
<ce:source-text>Bandari, S.K., et al.: Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol. 65, 104–118 (2018)</ce:source-text>
</reference>
<reference seq="217">
<ref-info>
<ref-title>
<ref-titletext-english>Identifying predictors of taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.I.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<page-information>
<pages>
<first-page>10</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, E.I., et al.: Identifying predictors of taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology. PLoS One. 10 (2015)</ref-fulltext>
<ce:source-text>Chen, E.I., et al.: Identifying predictors of taxane-induced peripheral neuropathy using mass spectrometry-based proteomics technology. PLoS One. 10 (2015)</ce:source-text>
</reference>
<reference seq="218">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes as a multicomponent biomarker platform in cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.S.</ce:initials>
<ce:surname>Lebleu</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Kalluri</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>LeBleu, V.S., Kalluri, R.: Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer. (2020)</ref-fulltext>
<ce:source-text>LeBleu, V.S., Kalluri, R.: Exosomes as a multicomponent biomarker platform in cancer. Trends Cancer. (2020)</ce:source-text>
</reference>
<reference seq="219">
<ref-info>
<ref-title>
<ref-titletext-english>MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Eur. Urol. Focus</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>412</first-page>
<last-page>419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, W., et al.: MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur. Urol. Focus. 4, 412–419 (2018)</ref-fulltext>
<ce:source-text>Zhang, W., et al.: MicroRNAs in serum exosomes as potential biomarkers in clear-cell renal cell carcinoma. Eur. Urol. Focus. 4, 412–419 (2018)</ce:source-text>
</reference>
<reference seq="220">
<ref-info>
<ref-title>
<ref-titletext-english>Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Sci. Transl. Med</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<page-information>
<pages>
<first-page>9</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yang, K.S., et al.: Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci. Transl. Med. 9 (2017)</ref-fulltext>
<ce:source-text>Yang, K.S., et al.: Multiparametric plasma EV profiling facilitates diagnosis of pancreatic malignancy. Sci. Transl. Med. 9 (2017)</ce:source-text>
</reference>
<reference seq="221">
<ref-info>
<ref-title>
<ref-titletext-english>Progress in exosome isolation techniques</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Kaslan</ce:surname>
</author>
<author seq="3">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Yao</ce:surname>
</author>
<author seq="5">
<ce:initials>Z.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Theranostics</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>789</first-page>
<last-page>804</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Li, P., Kaslan, M., Lee, S.H., Yao, J., Gao, Z.: Progress in exosome isolation techniques. Theranostics. 7, 789–804 (2017)</ref-fulltext>
<ce:source-text>Li, P., Kaslan, M., Lee, S.H., Yao, J., Gao, Z.: Progress in exosome isolation techniques. Theranostics. 7, 789–804 (2017)</ce:source-text>
</reference>
<reference seq="222">
<ref-info>
<ref-title>
<ref-titletext-english>Cardiovascular effects of systemic cancer treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Senkus</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Jassem</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Treat. Rev</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>300</first-page>
<last-page>311</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Senkus, E., Jassem, J.: Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 37, 300–311 (2011)</ref-fulltext>
<ce:source-text>Senkus, E., Jassem, J.: Cardiovascular effects of systemic cancer treatment. Cancer Treat. Rev. 37, 300–311 (2011)</ce:source-text>
</reference>
<reference seq="223">
<ref-info>
<ref-title>
<ref-titletext-english>A paradigm shift in cancer immunotherapy: From enhancement to normalization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.F.</ce:initials>
<ce:surname>Sanmamed</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>175</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>313</first-page>
<last-page>326</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanmamed, M.F., Chen, L.: A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 175, 313–326 (2018)</ref-fulltext>
<ce:source-text>Sanmamed, M.F., Chen, L.: A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 175, 313–326 (2018)</ce:source-text>
</reference>
<reference seq="224">
<ref-info>
<ref-title>
<ref-titletext-english>Anti-PD-1/PD-L1 therapy of human cancer: Past, present, and future</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Han</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>125</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3384</first-page>
<last-page>3391</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, L., Han, X.: Anti-PD-1/PD-L1 therapy of human cancer: Past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015)</ref-fulltext>
<ce:source-text>Chen, L., Han, X.: Anti-PD-1/PD-L1 therapy of human cancer: Past, present, and future. J. Clin. Invest. 125, 3384–3391 (2015)</ce:source-text>
</reference>
<reference seq="225">
<ref-info>
<ref-title>
<ref-titletext-english>Immune modulation in cancer with antibodies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.B.</ce:initials>
<ce:surname>Page</ce:surname>
</author>
<author seq="2">
<ce:initials>M.A.</ce:initials>
<ce:surname>Postow</ce:surname>
</author>
<author seq="3">
<ce:initials>M.K.</ce:initials>
<ce:surname>Callahan</ce:surname>
</author>
<author seq="4">
<ce:initials>J.P.</ce:initials>
<ce:surname>Allison</ce:surname>
</author>
<author seq="5">
<ce:initials>J.D.</ce:initials>
<ce:surname>Wolchok</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Annu. Rev. Med</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>65</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>185</first-page>
<last-page>202</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., Wolchok, J.D.: Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185–202 (2014)</ref-fulltext>
<ce:source-text>Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., Wolchok, J.D.: Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185–202 (2014)</ce:source-text>
</reference>
<reference seq="226">
<ref-info>
<ref-title>
<ref-titletext-english>Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Poggio</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>177</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>414</first-page>
<last-page>427</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Poggio, M., et al.: Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 177, 414–427 e413 (2019)</ref-fulltext>
<ce:source-text>Poggio, M., et al.: Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 177, 414–427 e413 (2019)</ce:source-text>
</reference>
<reference seq="227">
<ref-info>
<ref-title>
<ref-titletext-english>Engineering exosomes as refined biological nanoplatforms for drug delivery</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Luan</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Acta Pharmacol. Sin</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>38</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>754</first-page>
<last-page>763</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Luan, X., et al.: Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017)</ref-fulltext>
<ce:source-text>Luan, X., et al.: Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacol. Sin. 38, 754–763 (2017)</ce:source-text>
</reference>
<reference seq="228">
<ref-info>
<ref-title>
<ref-titletext-english>Treatment of brain metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Lin</ce:surname>
</author>
<author seq="2">
<ce:initials>L.M.</ce:initials>
<ce:surname>Deangelis</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3475</first-page>
<last-page>3484</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lin, X., DeAngelis, L.M.: Treatment of brain metastases. J. Clin. Oncol. 33, 3475–3484 (2015)</ref-fulltext>
<ce:source-text>Lin, X., DeAngelis, L.M.: Treatment of brain metastases. J. Clin. Oncol. 33, 3475–3484 (2015)</ce:source-text>
</reference>
<reference seq="229">
<ref-info>
<ref-title>
<ref-titletext-english>A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tian</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Biomaterials</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2383</first-page>
<last-page>2390</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tian, Y., et al.: A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 35, 2383–2390 (2014)</ref-fulltext>
<ce:source-text>Tian, Y., et al.: A doxorubicin delivery platform using engineered natural membrane vesicle exosomes for targeted tumor therapy. Biomaterials. 35, 2383–2390 (2014)</ce:source-text>
</reference>
<reference seq="230">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Kamerkar</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>546</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>498</first-page>
<last-page>503</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kamerkar, S., et al.: Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 546, 498–503 (2017)</ref-fulltext>
<ce:source-text>Kamerkar, S., et al.: Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature. 546, 498–503 (2017)</ce:source-text>
</reference>
<reference seq="231">
<ref-info>
<ref-title>
<ref-titletext-english>Exosomal formulation of anthocyanidins against multiple cancer types</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Munagala</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Lett</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>393</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>102</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Munagala, R., et al.: Exosomal formulation of anthocyanidins against multiple cancer types. Cancer Lett. 393, 94–102 (2017)</ref-fulltext>
<ce:source-text>Munagala, R., et al.: Exosomal formulation of anthocyanidins against multiple cancer types. Cancer Lett. 393, 94–102 (2017)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_3</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>Bone</author-keyword>
<author-keyword>Muscle</author-keyword>
<author-keyword>TGF-beta</author-keyword>
<author-keyword>Metastasis</author-keyword>
<author-keyword>Crosstalk</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Bone Metastases: Systemic Regulation and Impact on Host</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Suresh</ce:surname>
<ce:given-name>Sukanya</ce:given-name>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>Theresa A.</ce:given-name>
<ce:e-address>TAGuise@mdanderson.org</ce:e-address>
</author>
<affiliation>
<organization>Department of Endocrine Neoplasia and Hormonal Disorders</organization>
<organization>The University of Texas MD Anderson Cancer Center</organization>
<city>Houston</city>
<state>TX</state>
<country iso-code="USA"/>
<ce:source-text>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
<ce:given-name>Theresa A.</ce:given-name>
</person>
<affiliation>
<organization>Department of Endocrine Neoplasia and Hormonal Disorders</organization>
<organization>The University of Texas MD Anderson Cancer Center</organization>
<city>Houston</city>
<state>TX</state>
<country iso-code="USA"/>
<ce:source-text>Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, USA</ce:source-text>
</affiliation>
<ce:e-address>TAGuise@mdanderson.org</ce:e-address>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: a Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: a Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>41</first-page>
<last-page>49</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>09</month>
<day>21</day>
</publicationdate>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="72">
<reference seq="1">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer statistics, 2020</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
</author>
<author seq="2">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J. Clin</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>70</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7</first-page>
<last-page>30</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020)</ref-fulltext>
<ce:source-text>Siegel, R.L., Miller, K.D., Jemal, A.: Cancer statistics, 2020. CA Cancer J. Clin. 70(1), 7–30 (2020)</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Cytokines and advanced cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Dunlop</ce:surname>
</author>
<author seq="2">
<ce:initials>C.W.</ce:initials>
<ce:surname>Campbell</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Pain Symptom Manag</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>214</first-page>
<last-page>232</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dunlop, R.J., Campbell, C.W.: Cytokines and advanced cancer. J. Pain Symptom Manag. 20(3), 214–232 (2000)</ref-fulltext>
<ce:source-text>Dunlop, R.J., Campbell, C.W.: Cytokines and advanced cancer. J. Pain Symptom Manag. 20(3), 214–232 (2000)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Bone Metastases. Nat. Rev. Dis. Primers.</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>83</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coleman, R.E., et al.: Bone metastases. Nat. Rev. Dis. Primers. 6(1), 83 (2020)</ref-fulltext>
<ce:source-text>Coleman, R.E., et al.: Bone metastases. Nat. Rev. Dis. Primers. 6(1), 83 (2020)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.K.</ce:initials>
<ce:surname>Hernandez</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>BMC Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>44</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hernandez, R.K., et al.: Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States. BMC Cancer. 18(1), 44 (2018)</ref-fulltext>
<ce:source-text>Hernandez, R.K., et al.: Incidence of bone metastases in patients with solid tumors: Analysis of oncology electronic medical records in the United States. BMC Cancer. 18(1), 44 (2018)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Clinical features of metastatic bone disease and risk of skeletal morbidity.</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>20</iss-first>
<part>Part 2</part>
</volume-issue-number>
<page-information>
<pages>
<first-page>6243s</first-page>
<last-page>6249s</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coleman, R.E.: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), 6243s–6249s (2006)</ref-fulltext>
<ce:source-text>Coleman, R.E.: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), 6243s–6249s (2006)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Pathogenesis of myeloma bone disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.D.</ce:initials>
<ce:surname>Roodman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell. Biochem</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>109</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>283</first-page>
<last-page>291</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Roodman, G.D.: Pathogenesis of myeloma bone disease. J. Cell. Biochem. 109(2), 283–291 (2010)</ref-fulltext>
<ce:source-text>Roodman, G.D.: Pathogenesis of myeloma bone disease. J. Cell. Biochem. 109(2), 283–291 (2010)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal complications of malignancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.E.</ce:initials>
<ce:surname>Coleman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer</ref-sourcetitle>
<ref-publicationyear first="1997"/>
<volisspag>
<volume-issue-number>
<vol-first>80</vol-first>
<iss-first>8</iss-first>
<suppl>Supplement</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>1588</first-page>
<last-page>1594</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Coleman, R.E.: Skeletal complications of malignancy. Cancer. 80(8 Suppl), 1588–1594 (1997)</ref-fulltext>
<ce:source-text>Coleman, R.E.: Skeletal complications of malignancy. Cancer. 80(8 Suppl), 1588–1594 (1997)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of secondary growths in cancer of the breast. 1889</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Paget</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Metastasis Rev</ref-sourcetitle>
<ref-publicationyear first="1989"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>98</first-page>
<last-page>101</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paget, S.: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8(2), 98–101 (1989)</ref-fulltext>
<ce:source-text>Paget, S.: The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8(2), 98–101 (1989)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer to bone: A fatal attraction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.N.</ce:initials>
<ce:surname>Weilbaecher</ce:surname>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
<author seq="3">
<ce:initials>L.K.</ce:initials>
<ce:surname>McCauley</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: A fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011)</ref-fulltext>
<ce:source-text>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: A fatal attraction. Nat. Rev. Cancer. 11(6), 411–425 (2011)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the bone in cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Fornetti</ce:surname>
</author>
<author seq="2">
<ce:initials>A.L.</ce:initials>
<ce:surname>Welm</ce:surname>
</author>
<author seq="3">
<ce:initials>S.A.</ce:initials>
<ce:surname>Stewart</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2099</first-page>
<last-page>2113</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fornetti, J., Welm, A.L., Stewart, S.A.: Understanding the bone in cancer metastasis. J. Bone Miner. Res. 33(12), 2099–2113 (2018)</ref-fulltext>
<ce:source-text>Fornetti, J., Welm, A.L., Stewart, S.A.: Understanding the bone in cancer metastasis. J. Bone Miner. Res. 33(12), 2099–2113 (2018)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Cellular and molecular mechanisms of bone remodeling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.J.</ce:initials>
<ce:surname>Raggatt</ce:surname>
</author>
<author seq="2">
<ce:initials>N.C.</ce:initials>
<ce:surname>Partridge</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>285</vol-first>
<iss-first>33</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>25103</first-page>
<last-page>25108</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Raggatt, L.J., Partridge, N.C.: Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285(33), 25103–25108 (2010)</ref-fulltext>
<ce:source-text>Raggatt, L.J., Partridge, N.C.: Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285(33), 25103–25108 (2010)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer cells interact with osteoblasts to support osteoclast formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Thomas</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Endocrinology</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>140</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4451</first-page>
<last-page>4458</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Thomas, R.J., et al.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140(10), 4451–4458 (1999)</ref-fulltext>
<ce:source-text>Thomas, R.J., et al.: Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 140(10), 4451–4458 (1999)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Sethi</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>205</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sethi, N., et al.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011)</ref-fulltext>
<ce:source-text>Sethi, N., et al.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19(2), 192–205 (2011)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Yin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Clin. Invest</ref-sourcetitle>
<ref-publicationyear first="1999"/>
<volisspag>
<volume-issue-number>
<vol-first>103</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>197</first-page>
<last-page>206</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, J.J., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ref-fulltext>
<ce:source-text>Yin, J.J., et al.: TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103(2), 197–206 (1999)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis to bone: Causes, consequences and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>584</first-page>
<last-page>593</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mundy, G.R.: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2(8), 584–593 (2002)</ref-fulltext>
<ce:source-text>Mundy, G.R.: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat. Rev. Cancer. 2(8), 584–593 (2002)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic strategies to target TGF-beta in the treatment of bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.T.</ce:initials>
<ce:surname>Buijs</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Juarez</ce:surname>
</author>
<author seq="3">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Curr. Pharm. Biotechnol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2121</first-page>
<last-page>2137</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Buijs, J.T., Juarez, P., Guise, T.A.: Therapeutic strategies to target TGF-beta in the treatment of bone metastases. Curr. Pharm. Biotechnol. 12(12), 2121–2137 (2011)</ref-fulltext>
<ce:source-text>Buijs, J.T., Juarez, P., Guise, T.A.: Therapeutic strategies to target TGF-beta in the treatment of bone metastases. Curr. Pharm. Biotechnol. 12(12), 2121–2137 (2011)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.T.</ce:initials>
<ce:surname>Stopeck</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>35</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5132</first-page>
<last-page>5139</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stopeck, A.T., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J. Clin. Oncol. 28(35), 5132–5139 (2010)</ref-fulltext>
<ce:source-text>Stopeck, A.T., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J. Clin. Oncol. 28(35), 5132–5139 (2010)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.N.</ce:initials>
<ce:surname>Hortobagyi</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>335</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1785</first-page>
<last-page>1791</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hortobagyi, G.N., et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335(24), 1785–1791 (1996)</ref-fulltext>
<ce:source-text>Hortobagyi, G.N., et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335(24), 1785–1791 (1996)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Berenson</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>N. Engl. J. Med</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>334</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>488</first-page>
<last-page>493</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Berenson, J.R., et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 334(8), 488–493 (1996)</ref-fulltext>
<ce:source-text>Berenson, J.R., et al.: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N. Engl. J. Med. 334(8), 488–493 (1996)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Reddington</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Surg. Neurol. Int</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
<suppl>Supplement 13</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>S361</first-page>
<last-page>S365</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Reddington, J.A., et al.: Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic. Surg. Neurol. Int. 7(Suppl 13), S361–S365 (2016)</ref-fulltext>
<ce:source-text>Reddington, J.A., et al.: Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: osteolytic versus osteoblastic. Surg. Neurol. Int. 7(Suppl 13), S361–S365 (2016)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.E.</ce:initials>
<ce:surname>Brown</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Natl. Cancer Inst</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>97</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>59</first-page>
<last-page>69</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brown, J.E., et al.: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 97(1), 59–69 (2005)</ref-fulltext>
<ce:source-text>Brown, J.E., et al.: Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J. Natl. Cancer Inst. 97(1), 59–69 (2005)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Usefulness of radium-223 in patients with bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Gupta</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc. (Bayl. Univ. Med. Cent.).</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>424</first-page>
<last-page>426</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gupta, N., et al.: Usefulness of radium-223 in patients with bone metastases. Proc. (Bayl. Univ. Med. Cent.). 30(4), 424–426 (2017)</ref-fulltext>
<ce:source-text>Gupta, N., et al.: Usefulness of radium-223 in patients with bone metastases. Proc. (Bayl. Univ. Med. Cent.). 30(4), 424–426 (2017)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Autzen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Br. J. Cancer</ref-sourcetitle>
<ref-publicationyear first="1998"/>
<volisspag>
<volume-issue-number>
<vol-first>78</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1219</first-page>
<last-page>1223</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Autzen, P., et al.: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer. 78(9), 1219–1223 (1998)</ref-fulltext>
<ce:source-text>Autzen, P., et al.: Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies. Br. J. Cancer. 78(9), 1219–1223 (1998)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.J.</ce:initials>
<ce:surname>Yin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>100</vol-first>
<iss-first>19</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>10954</first-page>
<last-page>10959</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yin, J.J., et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA. 100(19), 10954–10959 (2003)</ref-fulltext>
<ce:source-text>Yin, J.J., et al.: A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. USA. 100(19), 10954–10959 (2003)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.B.</ce:initials>
<ce:surname>Nelson</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="1995"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>944</first-page>
<last-page>949</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nelson, J.B., et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1(9), 944–949 (1995)</ref-fulltext>
<ce:source-text>Nelson, J.B., et al.: Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1(9), 944–949 (1995)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.F.</ce:initials>
<ce:surname>Shariat</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2856</first-page>
<last-page>2864</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shariat, S.F., et al.: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19(11), 2856–2864 (2001)</ref-fulltext>
<ce:source-text>Shariat, S.F., et al.: Preoperative plasma levels of transforming growth factor beta(1) (TGF-beta(1)) strongly predict progression in patients undergoing radical prostatectomy. J. Clin. Oncol. 19(11), 2856–2864 (2001)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Jiao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>179</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1177</first-page>
<last-page>1190</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>e13</ref-text>
</ref-info>
<ref-fulltext>Jiao, S., et al.: Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 179(5), 1177–1190 e13 (2019)</ref-fulltext>
<ce:source-text>Jiao, S., et al.: Differences in tumor microenvironment dictate T helper lineage polarization and response to immune checkpoint therapy. Cell. 179(5), 1177–1190 e13 (2019)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoblasts in prostate cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Logothetis</ce:surname>
</author>
<author seq="2">
<ce:initials>S.H.</ce:initials>
<ce:surname>Lin</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
<last-page>28</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Logothetis, C.J., Lin, S.H.: Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer. 5(1), 21–28 (2005)</ref-fulltext>
<ce:source-text>Logothetis, C.J., Lin, S.H.: Osteoblasts in prostate cancer metastasis to bone. Nat. Rev. Cancer. 5(1), 21–28 (2005)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.</ce:initials>
<ce:surname>Asadi</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Hum. Pathol</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>12</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1319</first-page>
<last-page>1323</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Asadi, F., et al.: Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum. Pathol. 27(12), 1319–1323 (1996)</ref-fulltext>
<ce:source-text>Asadi, F., et al.: Enhanced expression of parathyroid hormone-related protein in prostate cancer as compared with benign prostatic hyperplasia. Hum. Pathol. 27(12), 1319–1323 (1996)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.D.</ce:initials>
<ce:surname>Schluter</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Katzer</ce:surname>
</author>
<author seq="3">
<ce:initials>H.M.</ce:initials>
<ce:surname>Piper</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Br. J. Pharmacol</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>427</first-page>
<last-page>432</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schluter, K.D., Katzer, C., Piper, H.M.: A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. Br. J. Pharmacol. 132(2), 427–432 (2001)</ref-fulltext>
<ce:source-text>Schluter, K.D., Katzer, C., Piper, H.M.: A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. Br. J. Pharmacol. 132(2), 427–432 (2001)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.D.</ce:initials>
<ce:surname>Ottewell</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Clin. Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2922</first-page>
<last-page>2932</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ottewell, P.D., et al.: Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin. Cancer Res. 20(11), 2922–2932 (2014)</ref-fulltext>
<ce:source-text>Ottewell, P.D., et al.: Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin. Cancer Res. 20(11), 2922–2932 (2014)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.E.</ce:initials>
<ce:surname>Wright</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Oncotarget</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8406</first-page>
<last-page>8419</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wright, L.E., et al.: Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget. 8(5), 8406–8419 (2017)</ref-fulltext>
<ce:source-text>Wright, L.E., et al.: Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget. 8(5), 8406–8419 (2017)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.D.</ce:initials>
<ce:surname>Ottewell</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Endocr. Relat. Cancer</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>769</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ottewell, P.D., et al.: Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr. Relat. Cancer. 21(5), 769–781 (2014)</ref-fulltext>
<ce:source-text>Ottewell, P.D., et al.: Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. Endocr. Relat. Cancer. 21(5), 769–781 (2014)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding cachexia in the context of metastatic progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.K.</ce:initials>
<ce:surname>Biswas</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Acharyya</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Cancer</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>274</first-page>
<last-page>284</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Biswas, A.K., Acharyya, S.: Understanding cachexia in the context of metastatic progression. Nat. Rev. Cancer. 20(5), 274–284 (2020)</ref-fulltext>
<ce:source-text>Biswas, A.K., Acharyya, S.: Understanding cachexia in the context of metastatic progression. Nat. Rev. Cancer. 20(5), 274–284 (2020)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-title>
<ref-titletext-english>Definition and classification of cancer cachexia: An international consensus</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fearon</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Lancet Oncol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>5</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>489</first-page>
<last-page>495</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ref-fulltext>
<ce:source-text>Fearon, K., et al.: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12(5), 489–495 (2011)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Prevalence, incidence and clinical impact of cachexia: Facts and numbers-update 2014</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>von Haehling</ce:surname>
</author>
<author seq="2">
<ce:initials>S.D.</ce:initials>
<ce:surname>Anker</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>261</first-page>
<last-page>263</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Haehling, S., Anker, S.D.: Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J. Cachexia. Sarcopenia Muscle. 5(4), 261–263 (2014)</ref-fulltext>
<ce:source-text>von Haehling, S., Anker, S.D.: Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J. Cachexia. Sarcopenia Muscle. 5(4), 261–263 (2014)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="2">
<ce:initials>X.Q.</ce:initials>
<ce:surname>Quan</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nutr. Cancer</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>67</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1056</first-page>
<last-page>1062</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sun, L., Quan, X.Q., Yu, S.: An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr. Cancer. 67(7), 1056–1062 (2015)</ref-fulltext>
<ce:source-text>Sun, L., Quan, X.Q., Yu, S.: An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr. Cancer. 67(7), 1056–1062 (2015)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer-associated cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.E.</ce:initials>
<ce:surname>Baracos</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Rev. Dis. Primers</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>17105</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ref-fulltext>
<ce:source-text>Baracos, V.E., et al.: Cancer-associated cachexia. Nat. Rev. Dis. Primers. 4, 17105 (2018)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Visser</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Am. Geriatr. Soc</ref-sourcetitle>
<ref-publicationyear first="2000"/>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>381</first-page>
<last-page>386</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Visser, M., et al.: Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women. J. Am. Geriatr. Soc. 48(4), 381–386 (2000)</ref-fulltext>
<ce:source-text>Visser, M., et al.: Skeletal muscle mass and muscle strength in relation to lower-extremity performance in older men and women. J. Am. Geriatr. Soc. 48(4), 381–386 (2000)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.B.</ce:initials>
<ce:surname>Newman</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Gerontol. A Biol. Sci. Med. Sci</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>72</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Newman, A.B., et al.: Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J. Gerontol. A Biol. Sci. Med. Sci. 61(1), 72–77 (2006)</ref-fulltext>
<ce:source-text>Newman, A.B., et al.: Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J. Gerontol. A Biol. Sci. Med. Sci. 61(1), 72–77 (2006)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.H.</ce:initials>
<ce:surname>Goodpaster</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Gerontol. a Biol. Sci. Med. Sci</ref-sourcetitle>
<ref-publicationyear first="2006"/>
<volisspag>
<volume-issue-number>
<vol-first>61</vol-first>
<iss-first>10</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1059</first-page>
<last-page>1064</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Goodpaster, B.H., et al.: The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study. J. Gerontol. A Biol. Sci. Med. Sci. 61(10), 1059–1064 (2006)</ref-fulltext>
<ce:source-text>Goodpaster, B.H., et al.: The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study. J. Gerontol. A Biol. Sci. Med. Sci. 61(10), 1059–1064 (2006)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Muscle strength in breast cancer patients receiving different treatment regimes</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Klassen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>305</first-page>
<last-page>316</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ref-fulltext>
<ce:source-text>Klassen, O., et al.: Muscle strength in breast cancer patients receiving different treatment regimes. J. Cachexia. Sarcopenia Muscle. 8(2), 305–316 (2017)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Physical activity and fitness in women with metastatic breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Yee</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Cancer Surviv</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>647</first-page>
<last-page>656</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Yee, J., et al.: Physical activity and fitness in women with metastatic breast cancer. J. Cancer Surviv. 8(4), 647–656 (2014)</ref-fulltext>
<ce:source-text>Yee, J., et al.: Physical activity and fitness in women with metastatic breast cancer. J. Cancer Surviv. 8(4), 647–656 (2014)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.J.</ce:initials>
<ce:surname>Ballinger</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Treat</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>172</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>445</first-page>
<last-page>452</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ballinger, T.J., et al.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. 172(2), 445–452 (2018)</ref-fulltext>
<ce:source-text>Ballinger, T.J., et al.: Impact of primary breast cancer therapy on energetic capacity and body composition. Breast Cancer Res. Treat. 172(2), 445–452 (2018)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Moreau</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Med</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3677</first-page>
<last-page>3684</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Moreau, J., et al.: Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy. Cancer Med. 8(8), 3677–3684 (2019)</ref-fulltext>
<ce:source-text>Moreau, J., et al.: Correlation between muscle mass and handgrip strength in digestive cancer patients undergoing chemotherapy. Cancer Med. 8(8), 3677–3684 (2019)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.A.</ce:initials>
<ce:surname>Galvao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Prostate Cancer Prostatic Dis</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>198</first-page>
<last-page>203</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Galvao, D.A., et al.: Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 12(2), 198–203 (2009)</ref-fulltext>
<ce:source-text>Galvao, D.A., et al.: Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: A comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis. 12(2), 198–203 (2009)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.E.</ce:initials>
<ce:surname>Daly</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Cachexia. Sarcopenia Muscle</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>315</first-page>
<last-page>325</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Daly, L.E., et al.: Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J. Cachexia. Sarcopenia Muscle. 9(2), 315–325 (2018)</ref-fulltext>
<ce:source-text>Daly, L.E., et al.: Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J. Cachexia. Sarcopenia Muscle. 9(2), 315–325 (2018)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebo-controlled study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Antoun</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Clin. Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1054</first-page>
<last-page>1060</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Antoun, S., et al.: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J. Clin. Oncol. 28(6), 1054–1060 (2010)</ref-fulltext>
<ce:source-text>Antoun, S., et al.: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J. Clin. Oncol. 28(6), 1054–1060 (2010)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.R.</ce:initials>
<ce:surname>Huot</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancers (Basel)</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Huot, J.R., et al., Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel), 2019. 11(4)</ref-fulltext>
<ce:source-text>Huot, J.R., et al., Chronic treatment with multi-kinase inhibitors causes differential toxicities on skeletal and cardiac muscles. Cancers (Basel), 2019. 11(4)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid improves muscle function in healthy mice treated with chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.A.</ce:initials>
<ce:surname>Hain</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Bone Miner. Res</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>368</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ref-fulltext>
<ce:source-text>Hain, B.A., et al.: Zoledronic acid improves muscle function in healthy mice treated with chemotherapy. J. Bone Miner. Res. 35(2), 368–381 (2020)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.N.</ce:initials>
<ce:surname>Regan</ce:surname>
</author>
<author seq="2">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
</author>
<author seq="3">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Semin. Cell Dev. Biol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>49</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>24</first-page>
<last-page>29</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Regan, J.N., Waning, D.L., Guise, T.A.: Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling. Semin. Cell Dev. Biol. 49, 24–29 (2016)</ref-fulltext>
<ce:source-text>Regan, J.N., Waning, D.L., Guise, T.A.: Skeletal muscle Ca(2+) mishandling: Another effect of bone-to-muscle signaling. Semin. Cell Dev. Biol. 49, 24–29 (2016)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Endocrine regulation of energy metabolism by the skeleton</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.K.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>130</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>456</first-page>
<last-page>469</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, N.K., et al.: Endocrine regulation of energy metabolism by the skeleton. Cell. 130(3), 456–469 (2007)</ref-fulltext>
<ce:source-text>Lee, N.K., et al.: Endocrine regulation of energy metabolism by the skeleton. Cell. 130(3), 456–469 (2007)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Riquelme-Gallego</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Sci. Rep</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1840</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Riquelme-Gallego, B., et al.: Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients. Sci. Rep. 10(1), 1840 (2020)</ref-fulltext>
<ce:source-text>Riquelme-Gallego, B., et al.: Circulating undercarboxylated osteocalcin as estimator of cardiovascular and type 2 diabetes risk in metabolic syndrome patients. Sci. Rep. 10(1), 1840 (2020)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Levinger</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>64</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8</first-page>
<last-page>12</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Levinger, I., et al.: Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women. Bone. 64, 8–12 (2014)</ref-fulltext>
<ce:source-text>Levinger, I., et al.: Undercarboxylated osteocalcin, muscle strength and indices of bone health in older women. Bone. 64, 8–12 (2014)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshida</ce:surname>
</author>
<author seq="2">
<ce:initials>P.</ce:initials>
<ce:surname>Delafontaine</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
<iss-first>9</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Yoshida, T., Delafontaine, P.: Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cell. 9(9) (2020)</ref-fulltext>
<ce:source-text>Yoshida, T., Delafontaine, P.: Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cell. 9(9) (2020)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>BMP signaling controls muscle mass</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Sartori</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Genet</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1309</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sartori, R., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309 (2013)</ref-fulltext>
<ce:source-text>Sartori, R., et al.: BMP signaling controls muscle mass. Nat. Genet. 45(11), 1309 (2013)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="2">
<ce:initials>B.L.</ce:initials>
<ce:surname>Black</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Derynck</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Genes Dev</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>22</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2950</first-page>
<last-page>2966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ref-fulltext>
<ce:source-text>Liu, D., Black, B.L., Derynck, R.: TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3. Genes Dev. 15(22), 2950–2966 (2001)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Narola</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Narola, J., et al.: Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS One. 8(11), e79356 (2013)</ref-fulltext>
<ce:source-text>Narola, J., et al.: Conditional expression of TGF-beta1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS One. 8(11), e79356 (2013)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.L.</ce:initials>
<ce:surname>Mendias</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Muscle Nerve</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>55</first-page>
<last-page>59</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mendias, C.L., et al.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ref-fulltext>
<ce:source-text>Mendias, C.L., et al.: Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve. 45(1), 55–59 (2012)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>Aberrant repair and fibrosis development in skeletal muscle. Skelet</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Mann</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Muscle</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
<iss-first>1</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mann, C.J., et al.: Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle. 1(1), 21 (2011)</ref-fulltext>
<ce:source-text>Mann, C.J., et al.: Aberrant repair and fibrosis development in skeletal muscle. Skelet. Muscle. 1(1), 21 (2011)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.E.</ce:initials>
<ce:surname>Benny Klimek</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Biochem. Biophys. Res. Commun</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>391</vol-first>
<iss-first>3</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1548</first-page>
<last-page>1554</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ref-fulltext>
<ce:source-text>Benny Klimek, M.E., et al.: Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem. Biophys. Res. Commun. 391(3), 1548–1554 (2010)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.L.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>114</vol-first>
<iss-first>26</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>E5266</first-page>
<last-page>E5275</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J.L., et al.: Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc. Natl. Acad. Sci. USA. 114(26), E5266–E5275 (2017)</ref-fulltext>
<ce:source-text>Chen, J.L., et al.: Specific targeting of TGF-beta family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease. Proc. Natl. Acad. Sci. USA. 114(26), E5266–E5275 (2017)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.L.</ce:initials>
<ce:surname>Dallas</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J. Biol. Chem</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>277</vol-first>
<iss-first>24</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21352</first-page>
<last-page>21360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dallas, S.L., et al.: Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ref-fulltext>
<ce:source-text>Dallas, S.L., et al.: Proteolysis of latent transforming growth factor-beta (TGF-beta)-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J. Biol. Chem. 277(24), 21352–21360 (2002)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Tang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>7</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>757</first-page>
<last-page>765</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tang, Y., et al.: TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15(7), 757–765 (2009)</ref-fulltext>
<ce:source-text>Tang, Y., et al.: TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med. 15(7), 757–765 (2009)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Erlebacher</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Derynck</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J. Cell Biol</ref-sourcetitle>
<ref-publicationyear first="1996"/>
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
<iss-first>1</iss-first>
<iss-last>2</iss-last>
</volume-issue-number>
<page-information>
<pages>
<first-page>195</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Erlebacher, A., Derynck, R.: Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132(1–2), 195–210 (1996)</ref-fulltext>
<ce:source-text>Erlebacher, A., Derynck, R.: Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J. Cell Biol. 132(1–2), 195–210 (1996)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.S.</ce:initials>
<ce:surname>Mohammad</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Plos One</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>4</vol-first>
<iss-first>4</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Mohammad, K.S., et al.: Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 4(4), e5275 (2009)</ref-fulltext>
<ce:source-text>Mohammad, K.S., et al.: Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 4(4), e5275 (2009)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc. Natl. Acad. Sci. USA</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>102</vol-first>
<iss-first>39</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>13909</first-page>
<last-page>13914</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ref-fulltext>
<ce:source-text>Kang, Y., et al.: Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA. 102(39), 13909–13914 (2005)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>A multigenic program mediating breast cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>537</first-page>
<last-page>549</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ref-fulltext>
<ce:source-text>Kang, Y., et al.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3(6), 537–549 (2003)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Korpal</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
<iss-first>8</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>960</first-page>
<last-page>966</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Korpal, M., et al.: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ref-fulltext>
<ce:source-text>Korpal, M., et al.: Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15(8), 960–966 (2009)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>Excess TGF-beta mediates muscle weakness associated with bone metastases in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
<iss-first>11</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1262</first-page>
<last-page>1271</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ref-fulltext>
<ce:source-text>Waning, D.L., et al.: Excess TGF-beta mediates muscle weakness associated with bone metastases in mice. Nat. Med. 21(11), 1262–1271 (2015)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.C.</ce:initials>
<ce:surname>Andersson</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
<iss-first>2</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>196</first-page>
<last-page>207</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Andersson, D.C., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ref-fulltext>
<ce:source-text>Andersson, D.C., et al.: Ryanodine receptor oxidation causes intracellular calcium leak and muscle weakness in aging. Cell Metab. 14(2), 196–207 (2011)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat. Med</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>24</vol-first>
<iss-first>6</iss-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>770</first-page>
<last-page>781</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24(6), 770–781 (2018)</ref-fulltext>
<ce:source-text>Wang, G., et al.: Metastatic cancers promote cachexia through ZIP14 upregulation in skeletal muscle. Nat. Med. 24(6), 770–781 (2018)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
<bibrecord>
<item-info>
<status state="new" stage="S300"/>
<itemidlist>
<ce:doi>10.1007/978-3-031-09518-4_4</ce:doi>
<itemid idtype="TPB-ID">20232000349315</itemid>
</itemidlist>
</item-info>
<head>
<citation-info>
<citation-type code="ch"/>
<citation-language xml:lang="ENG"/>
<abstract-language xml:lang="ENG"/>
<author-keywords>
<author-keyword>Cancer metastasis</author-keyword>
<author-keyword>Epithelial-mesenchymal transition</author-keyword>
<author-keyword>Metastatic niche</author-keyword>
<author-keyword>Colonization</author-keyword>
<author-keyword>Dormancy</author-keyword>
<author-keyword>Immunotherapy</author-keyword>
<author-keyword>Cancer metabolism</author-keyword>
</author-keywords>
</citation-info>
<citation-title>
<titletext xml:lang="ENG" original="y">Targeting Metastatic Disease: Challenges and New Opportunities</titletext>
</citation-title>
<author-group seq="1">
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Haitian</ce:given-name>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Zheng</ce:surname>
<ce:given-name>Hanqiu</ce:given-name>
<ce:e-address>hanzheng@tsinghua.edu.cn</ce:e-address>
</author>
<affiliation>
<organization>Department of Basic Medical Sciences</organization>
<organization>School of Medicine</organization>
<organization>Tsinghua University</organization>
<city>Beijing</city>
<country iso-code="CHN"/>
<ce:source-text>Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China</ce:source-text>
</affiliation>
</author-group>
<author-group seq="2">
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
<ce:given-name>Zeping</ce:given-name>
</author>
<affiliation>
<organization>School of Pharmaceutical Sciences</organization>
<organization>Tsinghua University</organization>
<city>Beijing</city>
<country iso-code="CHN"/>
<ce:source-text>School of Pharmaceutical Sciences, Tsinghua University, Beijing, China</ce:source-text>
</affiliation>
</author-group>
<correspondence>
<person>
<ce:initials>H.</ce:initials>
<ce:surname>Zheng</ce:surname>
<ce:given-name>Hanqiu</ce:given-name>
</person>
<affiliation>
<organization>Department of Basic Medical Sciences</organization>
<organization>School of Medicine</organization>
<organization>Tsinghua University</organization>
<city>Beijing</city>
<country iso-code="CHN"/>
<ce:source-text>Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China</ce:source-text>
</affiliation>
<ce:e-address>hanzheng@tsinghua.edu.cn</ce:e-address>
</correspondence>
<abstracts>
<abstract xml:lang="ENG" original="y">
<publishercopyright>© Springer Nature Switzerland AG 2022.</publishercopyright>
</abstract>
</abstracts>
<source type="book" country="CHE">
<sourcetitle>The Systemic Effects of Advanced Cancer: a Textbook on Cancer-Associated Cachexia</sourcetitle>
<sourcetitle-abbrev>The Systemic Effects of Advanced Cancer: a Textbook on Cancer-Associated Cachexia</sourcetitle-abbrev>
<isbn type="print" length="13">9783031072727</isbn>
<isbn type="electronic" length="13">9783031095184</isbn>
<volisspag>
<page-information>
<pages>
<first-page>51</first-page>
<last-page>68</last-page>
</pages>
</page-information>
</volisspag>
<publicationyear first="2022"/>
<publicationdate>
<year>2022</year>
<month>09</month>
<day>21</day>
</publicationdate>
<publisher>
<publishername>Springer International Publishing</publishername>
</publisher>
</source>
<enhancement>
<classificationgroup>
<classifications type="ASJC">
<classification>
<classification-code>2700</classification-code>
<classification-code>2400</classification-code>
<classification-code>1300</classification-code>
</classification>
</classifications>
</classificationgroup>
</enhancement>
</head>
<tail>
<bibliography refcount="159">
<reference seq="1">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>C.P.</ce:initials>
<ce:surname>Wild</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Weiderpass</ce:surname>
</author>
<author seq="3">
<ce:initials>B.W.</ce:initials>
<ce:surname>Stewart</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>World Cancer Report: Cancer Research for Cancer Prevention</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Wild CP, Weiderpass E, Stewart BW (2020). World Cancer Report: Cancer Research for Cancer Prevention.</ref-fulltext>
<ce:source-text>Wild CP, Weiderpass E, Stewart BW (2020). World Cancer Report: Cancer Research for Cancer Prevention.</ce:source-text>
</reference>
<reference seq="2">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis: Quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.J.</ce:initials>
<ce:surname>Fidler</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Natl Cancer Inst</ref-sourcetitle>
<ref-publicationyear first="1970"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>773</first-page>
<last-page>782</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fidler, I.J.: Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst. 45, 773–782 (1970)</ref-fulltext>
<ce:source-text>Fidler, I.J.: Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst. 45, 773–782 (1970)</ce:source-text>
</reference>
<reference seq="3">
<ref-info>
<ref-title>
<ref-titletext-english>Dissemination and growth of cancer cells in metastatic sites</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.F.</ce:initials>
<ce:surname>Chambers</ce:surname>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Groom</ce:surname>
</author>
<author seq="3">
<ce:initials>I.C.</ce:initials>
<ce:surname>Macdonald</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>563</first-page>
<last-page>572</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chambers, A.F., Groom, A.C., MacDonald, I.C.: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2, 563–572 (2002)</ref-fulltext>
<ce:source-text>Chambers, A.F., Groom, A.C., MacDonald, I.C.: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2, 563–572 (2002)</ce:source-text>
</reference>
<reference seq="4">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.S.</ce:initials>
<ce:surname>Steeg</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature Reviews Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>201</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Steeg, P.S.: Targeting metastasis. Nature Reviews Cancer. 16, 201 (2016)</ref-fulltext>
<ce:source-text>Steeg, P.S.: Targeting metastasis. Nature Reviews Cancer. 16, 201 (2016)</ce:source-text>
</reference>
<reference seq="5">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis to bone: Causes, consequences and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.R.</ce:initials>
<ce:surname>Mundy</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature Reviews Cancer</ref-sourcetitle>
<ref-publicationyear first="2002"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>584</first-page>
<last-page>593</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mundy, G.R.: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature reviews Cancer. 2, 584–593 (2002)</ref-fulltext>
<ce:source-text>Mundy, G.R.: Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature reviews Cancer. 2, 584–593 (2002)</ce:source-text>
</reference>
<reference seq="6">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer to bone: A fatal attraction</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.N.</ce:initials>
<ce:surname>Weilbaecher</ce:surname>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
<author seq="3">
<ce:initials>L.K.</ce:initials>
<ce:surname>McCauley</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature Reviews Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>411</first-page>
<last-page>425</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: A fatal attraction. Nature reviews Cancer. 11, 411–425 (2011)</ref-fulltext>
<ce:source-text>Weilbaecher, K.N., Guise, T.A., McCauley, L.K.: Cancer to bone: A fatal attraction. Nature reviews Cancer. 11, 411–425 (2011)</ce:source-text>
</reference>
<reference seq="7">
<ref-info>
<ref-title>
<ref-titletext-english>Bone metastasis and the metastatic niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Ren</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Esposito</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Journal of Molecular Medicine</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>93</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1203</first-page>
<last-page>1212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ren, G., Esposito, M., Kang, Y.: Bone metastasis and the metastatic niche. Journal of molecular medicine. 93, 1203–1212 (2015)</ref-fulltext>
<ce:source-text>Ren, G., Esposito, M., Kang, Y.: Bone metastasis and the metastatic niche. Journal of molecular medicine. 93, 1203–1212 (2015)</ce:source-text>
</reference>
<reference seq="8">
<ref-info>
<ref-title>
<ref-titletext-english>The distribution of secondary growths in cancer of the breast</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Paget</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="1889"/>
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 3 (1889)</ref-fulltext>
<ce:source-text>Paget, S.: The distribution of secondary growths in cancer of the breast. Lancet. 133, 3 (1889)</ce:source-text>
</reference>
<reference seq="9">
<ref-info>
<ref-title>
<ref-titletext-english>SnapShot: Bone Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Ell</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>151</vol-first>
<iss-first>690</iss-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Ell, B., Kang, Y.: SnapShot: Bone Metastasis. Cell. 151(690-690), e691 (2012)</ref-fulltext>
<ce:source-text>Ell, B., Kang, Y.: SnapShot: Bone Metastasis. Cell. 151(690-690), e691 (2012)</ce:source-text>
</reference>
<reference seq="10">
<ref-info>
<ref-title>
<ref-titletext-english>Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Endocrinol Metab (Seoul)</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>206</first-page>
<last-page>212</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y.: Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis. Endocrinol Metab (Seoul). 31, 206–212 (2016)</ref-fulltext>
<ce:source-text>Kang, Y.: Dissecting Tumor-Stromal Interactions in Breast Cancer Bone Metastasis. Endocrinol Metab (Seoul). 31, 206–212 (2016)</ce:source-text>
</reference>
<reference seq="11">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms of bone metastasis and associated muscle weakness</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.L.</ce:initials>
<ce:surname>Waning</ce:surname>
</author>
<author seq="2">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3071</first-page>
<last-page>3077</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Waning, D.L., Guise, T.A.: Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res. 20, 3071–3077 (2014)</ref-fulltext>
<ce:source-text>Waning, D.L., Guise, T.A.: Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res. 20, 3071–3077 (2014)</ce:source-text>
</reference>
<reference seq="12">
<ref-info>
<ref-title>
<ref-titletext-english>A G protein- linked receptor for parathyroid hormone and parathyroid hormone-related peptide</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Juppner</ce:surname>
</author>
<author seq="2">
<ce:initials>A.B.</ce:initials>
<ce:surname>Abou-Samra</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Freeman</ce:surname>
</author>
<author seq="4">
<ce:initials>X.F.</ce:initials>
<ce:surname>Kong</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Schipani</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Richards</ce:surname>
</author>
<author seq="7">
<ce:initials>L.F.</ce:initials>
<ce:surname>Kolakowski</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Hock</ce:surname>
</author>
<author seq="9">
<ce:initials>J.T.</ce:initials>
<ce:surname>Potts</ce:surname>
</author>
<author seq="10">
<ce:initials>H.M.</ce:initials>
<ce:surname>Kronenberg</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>254</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1024</first-page>
<last-page>1026</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Juppner, H., Abou-Samra, A.B., Freeman, M., Kong, X.F., Schipani, E., Richards, J., Kolakowski Jr., L.F., Hock, J., Potts Jr., J.T., Kronenberg, H.M., et al.: A G protein- linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 254, 1024–1026 (1991)</ref-fulltext>
<ce:source-text>Juppner, H., Abou-Samra, A.B., Freeman, M., Kong, X.F., Schipani, E., Richards, J., Kolakowski Jr., L.F., Hock, J., Potts Jr., J.T., Kronenberg, H.M., et al.: A G protein- linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 254, 1024–1026 (1991)</ce:source-text>
</reference>
<reference seq="13">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Sethi</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Dai</ce:surname>
</author>
<author seq="3">
<ce:initials>C.G.</ce:initials>
<ce:surname>Winter</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>192</first-page>
<last-page>205</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sethi, N., Dai, X., Winter, C.G., Kang, Y.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19, 192–205 (2011)</ref-fulltext>
<ce:source-text>Sethi, N., Dai, X., Winter, C.G., Kang, Y.: Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19, 192–205 (2011)</ce:source-text>
</reference>
<reference seq="14">
<ref-info>
<ref-title>
<ref-titletext-english>Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Kohno</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Aogi</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Minami</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Nakamura</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Asaga</ce:surname>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Iino</ce:surname>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Watanabe</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Goessl</ce:surname>
</author>
<author seq="9">
<ce:initials>Y.</ce:initials>
<ce:surname>Ohashi</ce:surname>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:surname>Takashima</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3314</first-page>
<last-page>3321</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., Takashima, S.: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol. 23, 3314–3321 (2005)</ref-fulltext>
<ce:source-text>Kohno, N., Aogi, K., Minami, H., Nakamura, S., Asaga, T., Iino, Y., Watanabe, T., Goessl, C., Ohashi, Y., Takashima, S.: Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. J Clin Oncol. 23, 3314–3321 (2005)</ce:source-text>
</reference>
<reference seq="15">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab and bisphosphonates: Different mechanisms of action and effects</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Baron</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Ferrari</ce:surname>
</author>
<author seq="3">
<ce:initials>R.G.</ce:initials>
<ce:surname>Russell</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Bone</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>677</first-page>
<last-page>692</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Baron, R., Ferrari, S., Russell, R.G.: Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 48, 677–692 (2011)</ref-fulltext>
<ce:source-text>Baron, R., Ferrari, S., Russell, R.G.: Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 48, 677–692 (2011)</ce:source-text>
</reference>
<reference seq="16">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Fizazi</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Carducci</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Smith</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Damiao</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Brown</ce:surname>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Karsh</ce:surname>
</author>
<author seq="7">
<ce:initials>P.</ce:initials>
<ce:surname>Milecki</ce:surname>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Shore</ce:surname>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Rader</ce:surname>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>377</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>813</first-page>
<last-page>822</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 377, 813–822 (2011)</ref-fulltext>
<ce:source-text>Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh, L., Milecki, P., Shore, N., Rader, M., Wang, H., et al.: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 377, 813–822 (2011)</ce:source-text>
</reference>
<reference seq="17">
<ref-info>
<ref-title>
<ref-titletext-english>Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.T.</ce:initials>
<ce:surname>Stopeck</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Lipton</ce:surname>
</author>
<author seq="3">
<ce:initials>J.J.</ce:initials>
<ce:surname>Body</ce:surname>
</author>
<author seq="4">
<ce:initials>G.G.</ce:initials>
<ce:surname>Steger</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Tonkin</ce:surname>
</author>
<author seq="6">
<ce:initials>R.H.</ce:initials>
<ce:surname>de Boer</ce:surname>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Lichinitser</ce:surname>
</author>
<author seq="8">
<ce:initials>Y.</ce:initials>
<ce:surname>Fujiwara</ce:surname>
</author>
<author seq="9">
<ce:initials>D.A.</ce:initials>
<ce:surname>Yardley</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Viniegra</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5132</first-page>
<last-page>5139</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Viniegra, M., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol. 28, 5132–5139 (2010)</ref-fulltext>
<ce:source-text>Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Viniegra, M., et al.: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. J Clin Oncol. 28, 5132–5139 (2010)</ce:source-text>
</reference>
<reference seq="18">
<ref-info>
<ref-title>
<ref-titletext-english>Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Durgeau</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Virk</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Corgnac</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Mami-Chouaib</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Front Immunol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>14</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Durgeau, A., Virk, Y., Corgnac, S., Mami-Chouaib, F.: Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front Immunol. 9, 14 (2018)</ref-fulltext>
<ce:source-text>Durgeau, A., Virk, Y., Corgnac, S., Mami-Chouaib, F.: Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy. Front Immunol. 9, 14 (2018)</ce:source-text>
</reference>
<reference seq="19">
<ref-info>
<ref-title>
<ref-titletext-english>CD8(+) T cell states in human cancer: Insights from single-cell analysis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.M.</ce:initials>
<ce:surname>Van der Leun</ce:surname>
</author>
<author seq="2">
<ce:initials>D.S.</ce:initials>
<ce:surname>Thommen</ce:surname>
</author>
<author seq="3">
<ce:initials>T.N.</ce:initials>
<ce:surname>Schumacher</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>218</first-page>
<last-page>232</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van der Leun, A.M., Thommen, D.S., Schumacher, T.N.: CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 20, 218–232 (2020)</ref-fulltext>
<ce:source-text>van der Leun, A.M., Thommen, D.S., Schumacher, T.N.: CD8(+) T cell states in human cancer: insights from single-cell analysis. Nat Rev Cancer. 20, 218–232 (2020)</ce:source-text>
</reference>
<reference seq="20">
<ref-info>
<ref-title>
<ref-titletext-english>Immune evasion in cancer: Mechanistic basis and therapeutic strategies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.S.</ce:initials>
<ce:surname>Vinay</ce:surname>
</author>
<author seq="2">
<ce:initials>E.P.</ce:initials>
<ce:surname>Ryan</ce:surname>
</author>
<author seq="3">
<ce:initials>G.</ce:initials>
<ce:surname>Pawelec</ce:surname>
</author>
<author seq="4">
<ce:initials>W.H.</ce:initials>
<ce:surname>Talib</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Stagg</ce:surname>
</author>
<author seq="6">
<ce:initials>E.</ce:initials>
<ce:surname>Elkord</ce:surname>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Lichtor</ce:surname>
</author>
<author seq="8">
<ce:initials>W.K.</ce:initials>
<ce:surname>Decker</ce:surname>
</author>
<author seq="9">
<ce:initials>R.L.</ce:initials>
<ce:surname>Whelan</ce:surname>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Kumara</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Semin Cancer Biol</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>35</vol-first>
<suppl>Supplement</suppl>
</volume-issue-number>
<page-information>
<pages>
<first-page>S185</first-page>
<last-page>S198</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vinay, D.S., Ryan, E.P., Pawelec, G., Talib, W.H., Stagg, J., Elkord, E., Lichtor, T., Decker, W.K., Whelan, R.L., Kumara, H., et al.: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 35(Suppl), S185–S198 (2015)</ref-fulltext>
<ce:source-text>Vinay, D.S., Ryan, E.P., Pawelec, G., Talib, W.H., Stagg, J., Elkord, E., Lichtor, T., Decker, W.K., Whelan, R.L., Kumara, H., et al.: Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin Cancer Biol. 35(Suppl), S185–S198 (2015)</ce:source-text>
</reference>
<reference seq="21">
<ref-info>
<ref-title>
<ref-titletext-english>Current issues and perspectives in PD-1 blockade cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Chamoto</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Hatae</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Honjo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int J Clin Oncol</ref-sourcetitle>
<ref-publicationyear first="2020"/>
</ref-info>
<ref-fulltext>Chamoto, K., Hatae, R., Honjo, T.: Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol. (2020)</ref-fulltext>
<ce:source-text>Chamoto, K., Hatae, R., Honjo, T.: Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol. (2020)</ce:source-text>
</reference>
<reference seq="22">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular mechanisms of T cell co-stimulation and co- inhibition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="2">
<ce:initials>D.B.</ce:initials>
<ce:surname>Flies</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Immunol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>13</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>227</first-page>
<last-page>242</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, L., Flies, D.B.: Molecular mechanisms of T cell co-stimulation and co- inhibition. Nat Rev Immunol. 13, 227–242 (2013)</ref-fulltext>
<ce:source-text>Chen, L., Flies, D.B.: Molecular mechanisms of T cell co-stimulation and co- inhibition. Nat Rev Immunol. 13, 227–242 (2013)</ce:source-text>
</reference>
<reference seq="23">
<ref-info>
<ref-title>
<ref-titletext-english>Dissecting the mechanisms of immune checkpoint therapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Sharma</ce:surname>
</author>
<author seq="2">
<ce:initials>J.P.</ce:initials>
<ce:surname>Allison</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Immunol</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>75</first-page>
<last-page>76</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sharma, P., Allison, J.P.: Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 20, 75–76 (2020)</ref-fulltext>
<ce:source-text>Sharma, P., Allison, J.P.: Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 20, 75–76 (2020)</ce:source-text>
</reference>
<reference seq="24">
<ref-info>
<ref-title>
<ref-titletext-english>Immune checkpoint inhibitors of PD-L1 as cancer therapeutics</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Akinleye</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Rasool</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Hematol Oncol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>92</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Akinleye, A., Rasool, Z.: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 12, 92 (2019)</ref-fulltext>
<ce:source-text>Akinleye, A., Rasool, Z.: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 12, 92 (2019)</ce:source-text>
</reference>
<reference seq="25">
<ref-info>
<ref-title>
<ref-titletext-english>Improved survival with ipilimumab in patients with metastatic melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.S.</ce:initials>
<ce:surname>Hodi</ce:surname>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>O'day</ce:surname>
</author>
<author seq="3">
<ce:initials>D.F.</ce:initials>
<ce:surname>McDermott</ce:surname>
</author>
<author seq="4">
<ce:initials>R.W.</ce:initials>
<ce:surname>Weber</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Sosman</ce:surname>
</author>
<author seq="6">
<ce:initials>J.B.</ce:initials>
<ce:surname>Haanen</ce:surname>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Robert</ce:surname>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Schadendorf</ce:surname>
</author>
<author seq="10">
<ce:initials>J.C.</ce:initials>
<ce:surname>Hassel</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2010"/>
<volisspag>
<volume-issue-number>
<vol-first>363</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>711</first-page>
<last-page>723</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363, 711–723 (2010)</ref-fulltext>
<ce:source-text>Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 363, 711–723 (2010)</ce:source-text>
</reference>
<reference seq="26">
<ref-info>
<ref-title>
<ref-titletext-english>Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>McDermott</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Lebbe</ce:surname>
</author>
<author seq="3">
<ce:initials>F.S.</ce:initials>
<ce:surname>Hodi</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Maio</ce:surname>
</author>
<author seq="5">
<ce:initials>J.S.</ce:initials>
<ce:surname>Weber</ce:surname>
</author>
<author seq="6">
<ce:initials>J.D.</ce:initials>
<ce:surname>Wolchok</ce:surname>
</author>
<author seq="7">
<ce:initials>J.A.</ce:initials>
<ce:surname>Thompson</ce:surname>
</author>
<author seq="8">
<ce:initials>C.M.</ce:initials>
<ce:surname>Balch</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Treat Rev</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>40</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1056</first-page>
<last-page>1064</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McDermott, D., Lebbe, C., Hodi, F.S., Maio, M., Weber, J.S., Wolchok, J.D., Thompson, J.A., Balch, C.M.: Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 40, 1056–1064 (2014)</ref-fulltext>
<ce:source-text>McDermott, D., Lebbe, C., Hodi, F.S., Maio, M., Weber, J.S., Wolchok, J.D., Thompson, J.A., Balch, C.M.: Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treat Rev. 40, 1056–1064 (2014)</ce:source-text>
</reference>
<reference seq="27">
<ref-info>
<ref-title>
<ref-titletext-english>Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.D.</ce:initials>
<ce:surname>Wolchok</ce:surname>
</author>
<author seq="2">
<ce:initials>V.</ce:initials>
<ce:surname>Chiarion-Sileni</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Rutkowski</ce:surname>
</author>
<author seq="5">
<ce:initials>J.J.</ce:initials>
<ce:surname>Grob</ce:surname>
</author>
<author seq="6">
<ce:initials>C.L.</ce:initials>
<ce:surname>Cowey</ce:surname>
</author>
<author seq="7">
<ce:initials>C.D.</ce:initials>
<ce:surname>Lao</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Wagstaff</ce:surname>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Schadendorf</ce:surname>
</author>
<author seq="10">
<ce:initials>P.F.</ce:initials>
<ce:surname>Ferrucci</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>377</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1345</first-page>
<last-page>1356</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., et al.: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 377, 1345–1356 (2017)</ref-fulltext>
<ce:source-text>Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J.J., Cowey, C.L., Lao, C.D., Wagstaff, J., Schadendorf, D., Ferrucci, P.F., et al.: Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 377, 1345–1356 (2017)</ce:source-text>
</reference>
<reference seq="28">
<ref-info>
<ref-title>
<ref-titletext-english>Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603)</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hara</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Fukuoka</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Takahashi</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Kojima</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Kawazoe</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Asayama</ce:surname>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Yoshii</ce:surname>
</author>
<author seq="8">
<ce:initials>D.</ce:initials>
<ce:surname>Kotani</ce:surname>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Tamura</ce:surname>
</author>
<author seq="10">
<ce:initials>Y.</ce:initials>
<ce:surname>Mikamoto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Ann Oncol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<suppl>Supplement 4</suppl>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Hara, H., Fukuoka, S., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al.: Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). Ann Oncol. 30 Suppl 4, iv124 (2019)</ref-fulltext>
<ce:source-text>Hara, H., Fukuoka, S., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al.: Regorafenib plus nivolumab in patients with advanced colorectal or gastric cancer: An open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). Ann Oncol. 30 Suppl 4, iv124 (2019)</ce:source-text>
</reference>
<reference seq="29">
<ref-info>
<ref-title>
<ref-titletext-english>CAR T cell therapy: Inroads to response and resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.E.</ce:initials>
<ce:surname>Brown</ce:surname>
</author>
<author seq="2">
<ce:initials>C.L.</ce:initials>
<ce:surname>Mackall</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Immunol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>73</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Brown, C.E., Mackall, C.L.: CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol. 19, 73–74 (2019)</ref-fulltext>
<ce:source-text>Brown, C.E., Mackall, C.L.: CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol. 19, 73–74 (2019)</ce:source-text>
</reference>
<reference seq="30">
<ref-info>
<ref-title>
<ref-titletext-english>Engineered T cells: The promise and challenges of cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.D.</ce:initials>
<ce:surname>Fesnak</ce:surname>
</author>
<author seq="2">
<ce:initials>C.H.</ce:initials>
<ce:surname>June</ce:surname>
</author>
<author seq="3">
<ce:initials>B.L.</ce:initials>
<ce:surname>Levine</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>566</first-page>
<last-page>581</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fesnak, A.D., June, C.H., Levine, B.L.: Engineered T cells: The promise and challenges of cancer immunotherapy. Nat Rev Cancer. 16, 566–581 (2016)</ref-fulltext>
<ce:source-text>Fesnak, A.D., June, C.H., Levine, B.L.: Engineered T cells: The promise and challenges of cancer immunotherapy. Nat Rev Cancer. 16, 566–581 (2016)</ce:source-text>
</reference>
<reference seq="31">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer vaccines: Between the idea and the reality</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.J.</ce:initials>
<ce:surname>Finn</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Immunol</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>630</first-page>
<last-page>641</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Finn, O.J.: Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 3, 630–641 (2003)</ref-fulltext>
<ce:source-text>Finn, O.J.: Cancer vaccines: between the idea and the reality. Nat Rev Immunol. 3, 630–641 (2003)</ce:source-text>
</reference>
<reference seq="32">
<ref-info>
<ref-title>
<ref-titletext-english>Personalized vaccines for cancer immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.</ce:initials>
<ce:surname>Sahin</ce:surname>
</author>
<author seq="2">
<ce:initials>O.</ce:initials>
<ce:surname>Tureci</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>359</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1355</first-page>
<last-page>1360</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sahin, U., Tureci, O.: Personalized vaccines for cancer immunotherapy. Science. 359, 1355–1360 (2018)</ref-fulltext>
<ce:source-text>Sahin, U., Tureci, O.: Personalized vaccines for cancer immunotherapy. Science. 359, 1355–1360 (2018)</ce:source-text>
</reference>
<reference seq="33">
<ref-info>
<ref-title>
<ref-titletext-english>An immunogenic personal neoantigen vaccine for patients with melanoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.A.</ce:initials>
<ce:surname>Ott</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="3">
<ce:initials>D.B.</ce:initials>
<ce:surname>Keskin</ce:surname>
</author>
<author seq="4">
<ce:initials>S.A.</ce:initials>
<ce:surname>Shukla</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="6">
<ce:initials>D.J.</ce:initials>
<ce:surname>Bozym</ce:surname>
</author>
<author seq="7">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Luoma</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Giobbie-Hurder</ce:surname>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Peter</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>547</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>217</first-page>
<last-page>221</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ott, P.A., Hu, Z., Keskin, D.B., Shukla, S.A., Sun, J., Bozym, D.J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al.: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547, 217–221 (2017)</ref-fulltext>
<ce:source-text>Ott, P.A., Hu, Z., Keskin, D.B., Shukla, S.A., Sun, J., Bozym, D.J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al.: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 547, 217–221 (2017)</ce:source-text>
</reference>
<reference seq="34">
<ref-info>
<ref-title>
<ref-titletext-english>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>U.</ce:initials>
<ce:surname>Sahin</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Derhovanessian</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="4">
<ce:initials>B.P.</ce:initials>
<ce:surname>Kloke</ce:surname>
</author>
<author seq="5">
<ce:initials>P.</ce:initials>
<ce:surname>Simon</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Lower</ce:surname>
</author>
<author seq="7">
<ce:initials>V.</ce:initials>
<ce:surname>Bukur</ce:surname>
</author>
<author seq="8">
<ce:initials>A.D.</ce:initials>
<ce:surname>Tadmor</ce:surname>
</author>
<author seq="9">
<ce:initials>U.</ce:initials>
<ce:surname>Luxemburger</ce:surname>
</author>
<author seq="10">
<ce:initials>B.</ce:initials>
<ce:surname>Schrors</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>547</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>222</first-page>
<last-page>226</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.P., Simon, P., Lower, M., Bukur, V., Tadmor, A.D., Luxemburger, U., Schrors, B., et al.: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 547, 222–226 (2017)</ref-fulltext>
<ce:source-text>Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.P., Simon, P., Lower, M., Bukur, V., Tadmor, A.D., Luxemburger, U., Schrors, B., et al.: Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 547, 222–226 (2017)</ce:source-text>
</reference>
<reference seq="35">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>T.N.</ce:initials>
<ce:surname>Schumacher</ce:surname>
</author>
<author seq="2">
<ce:initials>R.D.</ce:initials>
<ce:surname>Schreiber</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Neoantigens in Cancer Immunotherapy</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>348</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>69</first-page>
<last-page>74</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>Science</ref-text>
</ref-info>
<ref-fulltext>Schumacher, T.N., Schreiber, R.D.: Neoantigens in cancer immunotherapy, vol. 348, pp. 69–74. Science (2015)</ref-fulltext>
<ce:source-text>Schumacher, T.N., Schreiber, R.D.: Neoantigens in cancer immunotherapy, vol. 348, pp. 69–74. Science (2015)</ce:source-text>
</reference>
<reference seq="36">
<ref-info>
<ref-title>
<ref-titletext-english>Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.K.</ce:initials>
<ce:surname>Hong</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Macintyre</ce:surname>
</author>
<author seq="3">
<ce:initials>D.C.</ce:initials>
<ce:surname>Wedge</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>van Loo</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Patel</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Lunke</ce:surname>
</author>
<author seq="7">
<ce:initials>L.B.</ce:initials>
<ce:surname>Alexandrov</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Sloggett</ce:surname>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Cmero</ce:surname>
</author>
<author seq="10">
<ce:initials>F.</ce:initials>
<ce:surname>Marass</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6605</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hong, M.K., Macintyre, G., Wedge, D.C., Van Loo, P., Patel, K., Lunke, S., Alexandrov, L.B., Sloggett, C., Cmero, M., Marass, F., et al.: Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 6, 6605 (2015)</ref-fulltext>
<ce:source-text>Hong, M.K., Macintyre, G., Wedge, D.C., Van Loo, P., Patel, K., Lunke, S., Alexandrov, L.B., Sloggett, C., Cmero, M., Marass, F., et al.: Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun. 6, 6605 (2015)</ce:source-text>
</reference>
<reference seq="37">
<ref-info>
<ref-title>
<ref-titletext-english>Primary colorectal cancers and their subsequent hepatic metastases are genetically different: Implications for selection of patients for targeted treatment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.S.</ce:initials>
<ce:surname>Vermaat</ce:surname>
</author>
<author seq="2">
<ce:initials>I.J.</ce:initials>
<ce:surname>Nijman</ce:surname>
</author>
<author seq="3">
<ce:initials>M.J.</ce:initials>
<ce:surname>Koudijs</ce:surname>
</author>
<author seq="4">
<ce:initials>F.L.</ce:initials>
<ce:surname>Gerritse</ce:surname>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Scherer</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Mokry</ce:surname>
</author>
<author seq="7">
<ce:initials>W.M.</ce:initials>
<ce:surname>Roessingh</ce:surname>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Lansu</ce:surname>
</author>
<author seq="9">
<ce:initials>E.</ce:initials>
<ce:surname>de Bruijn</ce:surname>
</author>
<author seq="10">
<ce:initials>R.</ce:initials>
<ce:surname>van Hillegersberg</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Clin Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>688</first-page>
<last-page>699</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vermaat, J.S., Nijman, I.J., Koudijs, M.J., Gerritse, F.L., Scherer, S.J., Mokry, M., Roessingh, W.M., Lansu, N., de Bruijn, E., van Hillegersberg, R., et al.: Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res. 18, 688–699 (2012)</ref-fulltext>
<ce:source-text>Vermaat, J.S., Nijman, I.J., Koudijs, M.J., Gerritse, F.L., Scherer, S.J., Mokry, M., Roessingh, W.M., Lansu, N., de Bruijn, E., van Hillegersberg, R., et al.: Primary colorectal cancers and their subsequent hepatic metastases are genetically different: implications for selection of patients for targeted treatment. Clin Cancer Res. 18, 688–699 (2012)</ce:source-text>
</reference>
<reference seq="38">
<ref-info>
<ref-title>
<ref-titletext-english>Activating ESR1 mutations in hormone-resistant metastatic breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.R.</ce:initials>
<ce:surname>Robinson</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.M.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Vats</ce:surname>
</author>
<author seq="4">
<ce:initials>F.</ce:initials>
<ce:surname>Su</ce:surname>
</author>
<author seq="5">
<ce:initials>R.J.</ce:initials>
<ce:surname>Lonigro</ce:surname>
</author>
<author seq="6">
<ce:initials>X.</ce:initials>
<ce:surname>Cao</ce:surname>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Kalyana-Sundaram</ce:surname>
</author>
<author seq="8">
<ce:initials>R.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="9">
<ce:initials>Y.</ce:initials>
<ce:surname>Ning</ce:surname>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Hodges</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat Genet</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1446</first-page>
<last-page>1451</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Robinson, D.R., Wu, Y.M., Vats, P., Su, F., Lonigro, R.J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al.: Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 45, 1446–1451 (2013)</ref-fulltext>
<ce:source-text>Robinson, D.R., Wu, Y.M., Vats, P., Su, F., Lonigro, R.J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al.: Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 45, 1446–1451 (2013)</ce:source-text>
</reference>
<reference seq="39">
<ref-info>
<ref-title>
<ref-titletext-english>ESR1 ligand-binding domain mutations in hormone-resistant breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>W.</ce:initials>
<ce:surname>Toy</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Shen</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Won</ce:surname>
</author>
<author seq="4">
<ce:initials>B.</ce:initials>
<ce:surname>Green</ce:surname>
</author>
<author seq="5">
<ce:initials>R.A.</ce:initials>
<ce:surname>Sakr</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Will</ce:surname>
</author>
<author seq="7">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="8">
<ce:initials>K.</ce:initials>
<ce:surname>Gala</ce:surname>
</author>
<author seq="9">
<ce:initials>S.</ce:initials>
<ce:surname>Fanning</ce:surname>
</author>
<author seq="10">
<ce:initials>T.A.</ce:initials>
<ce:surname>King</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat Genet</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>45</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1439</first-page>
<last-page>1445</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Toy, W., Shen, Y., Won, H., Green, B., Sakr, R.A., Will, M., Li, Z., Gala, K., Fanning, S., King, T.A., et al.: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 45, 1439–1445 (2013)</ref-fulltext>
<ce:source-text>Toy, W., Shen, Y., Won, H., Green, B., Sakr, R.A., Will, M., Li, Z., Gala, K., Fanning, S., King, T.A., et al.: ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 45, 1439–1445 (2013)</ce:source-text>
</reference>
<reference seq="40">
<ref-info>
<ref-title>
<ref-titletext-english>Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.L.</ce:initials>
<ce:surname>Gonzalez</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Hancock</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="4">
<ce:initials>C.L.</ce:initials>
<ce:surname>Gersch</ce:surname>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>Larios</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>David</ce:surname>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="8">
<ce:initials>D.F.</ce:initials>
<ce:surname>Hayes</ce:surname>
</author>
<author seq="9">
<ce:initials>S.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="10">
<ce:initials>J.M.</ce:initials>
<ce:surname>Rae</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res Treat</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>180</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>611</first-page>
<last-page>622</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gonzalez, T.L., Hancock, M., Sun, S., Gersch, C.L., Larios, J.M., David, W., Hu, J., Hayes, D.F., Wang, S., Rae, J.M.: Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer. Breast Cancer Res Treat. 180, 611–622 (2020)</ref-fulltext>
<ce:source-text>Gonzalez, T.L., Hancock, M., Sun, S., Gersch, C.L., Larios, J.M., David, W., Hu, J., Hayes, D.F., Wang, S., Rae, J.M.: Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer. Breast Cancer Res Treat. 180, 611–622 (2020)</ce:source-text>
</reference>
<reference seq="41">
<ref-info>
<ref-title>
<ref-titletext-english>Pan-cancer whole-genome analyses of metastatic solid tumours</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Priestley</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Baber</ce:surname>
</author>
<author seq="3">
<ce:initials>M.P.</ce:initials>
<ce:surname>Lolkema</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Steeghs</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>de Bruijn</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Shale</ce:surname>
</author>
<author seq="7">
<ce:initials>K.</ce:initials>
<ce:surname>Duyvesteyn</ce:surname>
</author>
<author seq="8">
<ce:initials>S.</ce:initials>
<ce:surname>Haidari</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>van Hoeck</ce:surname>
</author>
<author seq="10">
<ce:initials>W.</ce:initials>
<ce:surname>Onstenk</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>575</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>210</first-page>
<last-page>216</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Priestley, P., Baber, J., Lolkema, M.P., Steeghs, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al.: Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 575, 210–216 (2019)</ref-fulltext>
<ce:source-text>Priestley, P., Baber, J., Lolkema, M.P., Steeghs, N., de Bruijn, E., Shale, C., Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al.: Pan-cancer whole-genome analyses of metastatic solid tumours. Nature. 575, 210–216 (2019)</ce:source-text>
</reference>
<reference seq="42">
<ref-info>
<ref-title>
<ref-titletext-english>Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Ferrara</ce:surname>
</author>
<author seq="2">
<ce:initials>K.J.</ce:initials>
<ce:surname>Hillan</ce:surname>
</author>
<author seq="3">
<ce:initials>H.P.</ce:initials>
<ce:surname>Gerber</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Novotny</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Drug Discov</ref-sourcetitle>
<ref-publicationyear first="2004"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>391</first-page>
<last-page>400</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W.: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3, 391–400 (2004)</ref-fulltext>
<ce:source-text>Ferrara, N., Hillan, K.J., Gerber, H.P., Novotny, W.: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3, 391–400 (2004)</ce:source-text>
</reference>
<reference seq="43">
<ref-info>
<ref-title>
<ref-titletext-english>Bevacizumab: A review of its use in metastatic colorectal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.L.</ce:initials>
<ce:surname>McCormack</ce:surname>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Keam</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Drugs</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>68</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>487</first-page>
<last-page>506</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>McCormack, P.L., Keam, S.J.: Bevacizumab: A review of its use in metastatic colorectal cancer. Drugs. 68, 487–506 (2008)</ref-fulltext>
<ce:source-text>McCormack, P.L., Keam, S.J.: Bevacizumab: A review of its use in metastatic colorectal cancer. Drugs. 68, 487–506 (2008)</ce:source-text>
</reference>
<reference seq="44">
<ref-info>
<ref-title>
<ref-titletext-english>Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ebos</ce:surname>
</author>
<author seq="2">
<ce:initials>C.R.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Cruz-Munoz</ce:surname>
</author>
<author seq="4">
<ce:initials>G.A.</ce:initials>
<ce:surname>Bjarnason</ce:surname>
</author>
<author seq="5">
<ce:initials>J.G.</ce:initials>
<ce:surname>Christensen</ce:surname>
</author>
<author seq="6">
<ce:initials>R.S.</ce:initials>
<ce:surname>Kerbel</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>232</first-page>
<last-page>239</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S.: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15, 232–239 (2009)</ref-fulltext>
<ce:source-text>Ebos, J.M., Lee, C.R., Cruz-Munoz, W., Bjarnason, G.A., Christensen, J.G., Kerbel, R.S.: Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 15, 232–239 (2009)</ce:source-text>
</reference>
<reference seq="45">
<ref-info>
<ref-title>
<ref-titletext-english>Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Loges</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Mazzone</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Hohensinner</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Carmeliet</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>167</first-page>
<last-page>170</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Loges, S., Mazzone, M., Hohensinner, P., Carmeliet, P.: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell. 15, 167–170 (2009)</ref-fulltext>
<ce:source-text>Loges, S., Mazzone, M., Hohensinner, P., Carmeliet, P.: Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell. 15, 167–170 (2009)</ce:source-text>
</reference>
<reference seq="46">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis: From dissemination to organ- specific colonization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.X.</ce:initials>
<ce:surname>Nguyen</ce:surname>
</author>
<author seq="2">
<ce:initials>P.D.</ce:initials>
<ce:surname>Bos</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>274</first-page>
<last-page>284</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ- specific colonization. Nat Rev Cancer. 9, 274–284 (2009)</ref-fulltext>
<ce:source-text>Nguyen, D.X., Bos, P.D., Massague, J.: Metastasis: from dissemination to organ- specific colonization. Nat Rev Cancer. 9, 274–284 (2009)</ce:source-text>
</reference>
<reference seq="47">
<ref-info>
<ref-title>
<ref-titletext-english>Surviving at a Distance: Organ-Specific Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cancer</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>76</first-page>
<last-page>91</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Obenauf, A.C., Massague, J.: Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer. 1, 76–91 (2015)</ref-fulltext>
<ce:source-text>Obenauf, A.C., Massague, J.: Surviving at a Distance: Organ-Specific Metastasis. Trends Cancer. 1, 76–91 (2015)</ce:source-text>
</reference>
<reference seq="48">
<ref-info>
<ref-title>
<ref-titletext-english>Emerging Biological Principles of Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.W.</ce:initials>
<ce:surname>Lambert</ce:surname>
</author>
<author seq="2">
<ce:initials>D.R.</ce:initials>
<ce:surname>Pattabiraman</ce:surname>
</author>
<author seq="3">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>670</first-page>
<last-page>691</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging Biological Principles of Metastasis. Cell. 168, 670–691 (2017)</ref-fulltext>
<ce:source-text>Lambert, A.W., Pattabiraman, D.R., Weinberg, R.A.: Emerging Biological Principles of Metastasis. Cell. 168, 670–691 (2017)</ce:source-text>
</reference>
<reference seq="49">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic colonization by circulating tumour cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
<author seq="2">
<ce:initials>A.C.</ce:initials>
<ce:surname>Obenauf</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>529</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>298</first-page>
<last-page>306</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ref-fulltext>
<ce:source-text>Massague, J., Obenauf, A.C.: Metastatic colonization by circulating tumour cells. Nature. 529, 298–306 (2016)</ce:source-text>
</reference>
<reference seq="50">
<ref-info>
<ref-title>
<ref-titletext-english>Cancer treatment and survivorship statistics, 2019</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.D.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Nogueira</ce:surname>
</author>
<author seq="3">
<ce:initials>A.B.</ce:initials>
<ce:surname>Mariotto</ce:surname>
</author>
<author seq="4">
<ce:initials>J.H.</ce:initials>
<ce:surname>Rowland</ce:surname>
</author>
<author seq="5">
<ce:initials>K.R.</ce:initials>
<ce:surname>Yabroff</ce:surname>
</author>
<author seq="6">
<ce:initials>C.M.</ce:initials>
<ce:surname>Alfano</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Jemal</ce:surname>
</author>
<author seq="8">
<ce:initials>J.L.</ce:initials>
<ce:surname>Kramer</ce:surname>
</author>
<author seq="9">
<ce:initials>R.L.</ce:initials>
<ce:surname>Siegel</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>CA Cancer J Clin</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>69</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>363</first-page>
<last-page>385</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Miller, K.D., Nogueira, L., Mariotto, A.B., Rowland, J.H., Yabroff, K.R., Alfano, C.M., Jemal, A., Kramer, J.L., Siegel, R.L.: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69, 363–385 (2019)</ref-fulltext>
<ce:source-text>Miller, K.D., Nogueira, L., Mariotto, A.B., Rowland, J.H., Yabroff, K.R., Alfano, C.M., Jemal, A., Kramer, J.L., Siegel, R.L.: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69, 363–385 (2019)</ce:source-text>
</reference>
<reference seq="51">
<ref-info>
<ref-title>
<ref-titletext-english>Early dissemination seeds metastasis in breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Hosseini</ce:surname>
</author>
<author seq="2">
<ce:initials>M.M.S.</ce:initials>
<ce:surname>Obradovic</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Hoffmann</ce:surname>
</author>
<author seq="4">
<ce:initials>K.L.</ce:initials>
<ce:surname>Harper</ce:surname>
</author>
<author seq="5">
<ce:initials>M.S.</ce:initials>
<ce:surname>Sosa</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Werner-Klein</ce:surname>
</author>
<author seq="7">
<ce:initials>L.K.</ce:initials>
<ce:surname>Nanduri</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Werno</ce:surname>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Ehrl</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Maneck</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>540</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>552</first-page>
<last-page>558</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hosseini, H., Obradovic, M.M.S., Hoffmann, M., Harper, K.L., Sosa, M.S., Werner-Klein, M., Nanduri, L.K., Werno, C., Ehrl, C., Maneck, M., et al.: Early dissemination seeds metastasis in breast cancer. Nature. 540, 552–558 (2016)</ref-fulltext>
<ce:source-text>Hosseini, H., Obradovic, M.M.S., Hoffmann, M., Harper, K.L., Sosa, M.S., Werner-Klein, M., Nanduri, L.K., Werno, C., Ehrl, C., Maneck, M., et al.: Early dissemination seeds metastasis in breast cancer. Nature. 540, 552–558 (2016)</ce:source-text>
</reference>
<reference seq="52">
<ref-info>
<ref-title>
<ref-titletext-english>Quantitative evidence for early metastatic seeding in colorectal cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Ding</ce:surname>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Sun</ce:surname>
</author>
<author seq="5">
<ce:initials>J.A.</ce:initials>
<ce:surname>Seoane</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Scott Shaffer</ce:surname>
</author>
<author seq="7">
<ce:initials>C.J.</ce:initials>
<ce:surname>Suarez</ce:surname>
</author>
<author seq="8">
<ce:initials>A.S.</ce:initials>
<ce:surname>Berghoff</ce:surname>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Cremolini</ce:surname>
</author>
<author seq="10">
<ce:initials>A.</ce:initials>
<ce:surname>Falcone</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat Genet</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1113</first-page>
<last-page>1122</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J.A., Scott Shaffer, J., Suarez, C.J., Berghoff, A.S., Cremolini, C., Falcone, A., et al.: Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 51, 1113–1122 (2019)</ref-fulltext>
<ce:source-text>Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J.A., Scott Shaffer, J., Suarez, C.J., Berghoff, A.S., Cremolini, C., Falcone, A., et al.: Quantitative evidence for early metastatic seeding in colorectal cancer. Nat Genet. 51, 1113–1122 (2019)</ce:source-text>
</reference>
<reference seq="53">
<ref-info>
<ref-title>
<ref-titletext-english>The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Alix-Panabieres</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Discov</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>2</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>974</first-page>
<last-page>975</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pantel, K., Alix-Panabieres, C.: The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov. 2, 974–975 (2012)</ref-fulltext>
<ce:source-text>Pantel, K., Alix-Panabieres, C.: The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer. Cancer Discov. 2, 974–975 (2012)</ce:source-text>
</reference>
<reference seq="54">
<ref-info>
<ref-title>
<ref-titletext-english>Circulating epithelial cells in patients with benign colon diseases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Deneve</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Nocca</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Coffy</ce:surname>
</author>
<author seq="5">
<ce:initials>J.P.</ce:initials>
<ce:surname>Vendrell</ce:surname>
</author>
<author seq="6">
<ce:initials>T.</ce:initials>
<ce:surname>Maudelonde</ce:surname>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Alix-Panabieres</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin Chem</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>58</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>936</first-page>
<last-page>940</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pantel, K., Deneve, E., Nocca, D., Coffy, A., Vendrell, J.P., Maudelonde, T., Riethdorf, S., Alix-Panabieres, C.: Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 58, 936–940 (2012)</ref-fulltext>
<ce:source-text>Pantel, K., Deneve, E., Nocca, D., Coffy, A., Vendrell, J.P., Maudelonde, T., Riethdorf, S., Alix-Panabieres, C.: Circulating epithelial cells in patients with benign colon diseases. Clin Chem. 58, 936–940 (2012)</ce:source-text>
</reference>
<reference seq="55">
<ref-info>
<ref-title>
<ref-titletext-english>EMT and dissemination precede pancreatic tumor formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.D.</ce:initials>
<ce:surname>Rhim</ce:surname>
</author>
<author seq="2">
<ce:initials>E.T.</ce:initials>
<ce:surname>Mirek</ce:surname>
</author>
<author seq="3">
<ce:initials>N.M.</ce:initials>
<ce:surname>Aiello</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Maitra</ce:surname>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>Bailey</ce:surname>
</author>
<author seq="6">
<ce:initials>F.</ce:initials>
<ce:surname>McAllister</ce:surname>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Reichert</ce:surname>
</author>
<author seq="8">
<ce:initials>G.L.</ce:initials>
<ce:surname>Beatty</ce:surname>
</author>
<author seq="9">
<ce:initials>A.K.</ce:initials>
<ce:surname>Rustgi</ce:surname>
</author>
<author seq="10">
<ce:initials>R.H.</ce:initials>
<ce:surname>Vonderheide</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>148</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>349</first-page>
<last-page>361</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al.: EMT and dissemination precede pancreatic tumor formation. Cell. 148, 349–361 (2012)</ref-fulltext>
<ce:source-text>Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al.: EMT and dissemination precede pancreatic tumor formation. Cell. 148, 349–361 (2012)</ce:source-text>
</reference>
<reference seq="56">
<ref-info>
<ref-title>
<ref-titletext-english>New insights into the mechanisms of epithelial- mesenchymal transition and implications for cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Dongre</ce:surname>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Mol Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>69</first-page>
<last-page>84</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Dongre, A., Weinberg, R.A.: New insights into the mechanisms of epithelial- mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20, 69–84 (2019)</ref-fulltext>
<ce:source-text>Dongre, A., Weinberg, R.A.: New insights into the mechanisms of epithelial- mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 20, 69–84 (2019)</ce:source-text>
</reference>
<reference seq="57">
<ref-info>
<ref-title>
<ref-titletext-english>Classifying collective cancer cell invasion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Friedl</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Locker</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Sahai</ce:surname>
</author>
<author seq="4">
<ce:initials>J.E.</ce:initials>
<ce:surname>Segall</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>777</first-page>
<last-page>783</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Friedl, P., Locker, J., Sahai, E., Segall, J.E.: Classifying collective cancer cell invasion. Nat Cell Biol. 14, 777–783 (2012)</ref-fulltext>
<ce:source-text>Friedl, P., Locker, J., Sahai, E., Segall, J.E.: Classifying collective cancer cell invasion. Nat Cell Biol. 14, 777–783 (2012)</ce:source-text>
</reference>
<reference seq="58">
<ref-info>
<ref-title>
<ref-titletext-english>Adjuvant CMF chemotherapy in operable breast cancer: Ten years later</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Bonadonna</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Rossi</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Valagussa</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Lancet</ref-sourcetitle>
<ref-publicationyear first="1985"/>
<volisspag>
<volume-issue-number>
<vol-first>1</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>976</first-page>
<last-page>977</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bonadonna, G., Rossi, A., Valagussa, P.: Adjuvant CMF chemotherapy in operable breast cancer: Ten years later. Lancet. 1, 976–977 (1985)</ref-fulltext>
<ce:source-text>Bonadonna, G., Rossi, A., Valagussa, P.: Adjuvant CMF chemotherapy in operable breast cancer: Ten years later. Lancet. 1, 976–977 (1985)</ce:source-text>
</reference>
<reference seq="59">
<ref-info>
<ref-title>
<ref-titletext-english>The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Foss</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Munoz-Sagredo</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Sleeman</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Thiele</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin Exp Metastasis</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>37</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>47</first-page>
<last-page>67</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Foss, A., Munoz-Sagredo, L., Sleeman, J., Thiele, W.: The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells. Clin Exp Metastasis. 37, 47–67 (2020)</ref-fulltext>
<ce:source-text>Foss, A., Munoz-Sagredo, L., Sleeman, J., Thiele, W.: The contribution of platelets to intravascular arrest, extravasation, and outgrowth of disseminated tumor cells. Clin Exp Metastasis. 37, 47–67 (2020)</ce:source-text>
</reference>
<reference seq="60">
<ref-info>
<ref-title>
<ref-titletext-english>TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Padua</ce:surname>
</author>
<author seq="2">
<ce:initials>X.H.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="3">
<ce:initials>Q.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Nadal</ce:surname>
</author>
<author seq="5">
<ce:initials>W.L.</ce:initials>
<ce:surname>Gerald</ce:surname>
</author>
<author seq="6">
<ce:initials>R.R.</ce:initials>
<ce:surname>Gomis</ce:surname>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2008"/>
<volisspag>
<volume-issue-number>
<vol-first>133</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>66</first-page>
<last-page>77</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Padua, D., Zhang, X.H., Wang, Q., Nadal, C., Gerald, W.L., Gomis, R.R., Massague, J.: TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 133, 66–77 (2008)</ref-fulltext>
<ce:source-text>Padua, D., Zhang, X.H., Wang, Q., Nadal, C., Gerald, W.L., Gomis, R.R., Massague, J.: TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell. 133, 66–77 (2008)</ce:source-text>
</reference>
<reference seq="61">
<ref-info>
<ref-title>
<ref-titletext-english>Dormant tumour cells, their niches and the influence of immunity</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.T.</ce:initials>
<ce:surname>Goddard</ce:surname>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Bozic</ce:surname>
</author>
<author seq="3">
<ce:initials>S.R.</ce:initials>
<ce:surname>Riddell</ce:surname>
</author>
<author seq="4">
<ce:initials>C.M.</ce:initials>
<ce:surname>Ghajar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1240</first-page>
<last-page>1249</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Goddard, E.T., Bozic, I., Riddell, S.R., Ghajar, C.M.: Dormant tumour cells, their niches and the influence of immunity. Nat Cell Biol. 20, 1240–1249 (2018)</ref-fulltext>
<ce:source-text>Goddard, E.T., Bozic, I., Riddell, S.R., Ghajar, C.M.: Dormant tumour cells, their niches and the influence of immunity. Nat Cell Biol. 20, 1240–1249 (2018)</ce:source-text>
</reference>
<reference seq="62">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosome integrins determine organotropic metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
</author>
<author seq="3">
<ce:initials>T.L.</ce:initials>
<ce:surname>Shen</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Hashimoto</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Tesic Mark</ce:surname>
</author>
<author seq="7">
<ce:initials>H.</ce:initials>
<ce:surname>Molina</ce:surname>
</author>
<author seq="8">
<ce:initials>S.</ce:initials>
<ce:surname>Kohsaka</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Di Giannatale</ce:surname>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:surname>Ceder</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>329</first-page>
<last-page>335</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hoshino, A., Costa-Silva, B., Shen, T.L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ref-fulltext>
<ce:source-text>Hoshino, A., Costa-Silva, B., Shen, T.L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al.: Tumour exosome integrins determine organotropic metastasis. Nature. 527, 329–335 (2015)</ce:source-text>
</reference>
<reference seq="63">
<ref-info>
<ref-title>
<ref-titletext-english>KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Murgai</ce:surname>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Ju</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Eason</ce:surname>
</author>
<author seq="4">
<ce:initials>J.</ce:initials>
<ce:surname>Kline</ce:surname>
</author>
<author seq="5">
<ce:initials>D.W.</ce:initials>
<ce:surname>Beury</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Kaczanowska</ce:surname>
</author>
<author seq="7">
<ce:initials>M.M.</ce:initials>
<ce:surname>Miettinen</ce:surname>
</author>
<author seq="8">
<ce:initials>M.</ce:initials>
<ce:surname>Kruhlak</ce:surname>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Lei</ce:surname>
</author>
<author seq="10">
<ce:initials>J.F.</ce:initials>
<ce:surname>Shern</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat Med</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>23</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1176</first-page>
<last-page>1190</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Murgai, M., Ju, W., Eason, M., Kline, J., Beury, D.W., Kaczanowska, S., Miettinen, M.M., Kruhlak, M., Lei, H., Shern, J.F., et al.: KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat Med. 23, 1176–1190 (2017)</ref-fulltext>
<ce:source-text>Murgai, M., Ju, W., Eason, M., Kline, J., Beury, D.W., Kaczanowska, S., Miettinen, M.M., Kruhlak, M., Lei, H., Shern, J.F., et al.: KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat Med. 23, 1176–1190 (2017)</ce:source-text>
</reference>
<reference seq="64">
<ref-info>
<ref-title>
<ref-titletext-english>Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Peinado</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Aleckovic</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Lavotshkin</ce:surname>
</author>
<author seq="4">
<ce:initials>I.</ce:initials>
<ce:surname>Matei</ce:surname>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Costa-Silva</ce:surname>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Moreno-Bueno</ce:surname>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Hergueta-Redondo</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Williams</ce:surname>
</author>
<author seq="9">
<ce:initials>G.</ce:initials>
<ce:surname>Garcia-Santos</ce:surname>
</author>
<author seq="10">
<ce:initials>C.</ce:initials>
<ce:surname>Ghajar</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat Med</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>883</first-page>
<last-page>891</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., Garcia-Santos, G., Ghajar, C., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 18, 883–891 (2012)</ref-fulltext>
<ce:source-text>Peinado, H., Aleckovic, M., Lavotshkin, S., Matei, I., Costa-Silva, B., Moreno-Bueno, G., Hergueta-Redondo, M., Williams, C., Garcia-Santos, G., Ghajar, C., et al.: Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 18, 883–891 (2012)</ce:source-text>
</reference>
<reference seq="65">
<ref-info>
<ref-title>
<ref-titletext-english>Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Rodrigues</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Hoshino</ce:surname>
</author>
<author seq="3">
<ce:initials>C.M.</ce:initials>
<ce:surname>Kenific</ce:surname>
</author>
<author seq="4">
<ce:initials>I.R.</ce:initials>
<ce:surname>Matei</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Steiner</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Freitas</ce:surname>
</author>
<author seq="7">
<ce:initials>H.S.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="8">
<ce:initials>P.R.</ce:initials>
<ce:surname>Oxley</ce:surname>
</author>
<author seq="9">
<ce:initials>I.</ce:initials>
<ce:surname>Scandariato</ce:surname>
</author>
<author seq="10">
<ce:initials>I.</ce:initials>
<ce:surname>Casanova-Salas</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>21</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1403</first-page>
<last-page>1412</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Rodrigues, G., Hoshino, A., Kenific, C.M., Matei, I.R., Steiner, L., Freitas, D., Kim, H.S., Oxley, P.R., Scandariato, I., Casanova-Salas, I., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 21, 1403–1412 (2019)</ref-fulltext>
<ce:source-text>Rodrigues, G., Hoshino, A., Kenific, C.M., Matei, I.R., Steiner, L., Freitas, D., Kim, H.S., Oxley, P.R., Scandariato, I., Casanova-Salas, I., et al.: Tumour exosomal CEMIP protein promotes cancer cell colonization in brain metastasis. Nat Cell Biol. 21, 1403–1412 (2019)</ce:source-text>
</reference>
<reference seq="66">
<ref-info>
<ref-title>
<ref-titletext-english>Dormancy in solid tumors: Implications for prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.S.</ce:initials>
<ce:surname>Ruppender</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Morrissey</ce:surname>
</author>
<author seq="3">
<ce:initials>P.H.</ce:initials>
<ce:surname>Lange</ce:surname>
</author>
<author seq="4">
<ce:initials>R.L.</ce:initials>
<ce:surname>Vessella</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Metastasis Rev</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>501</first-page>
<last-page>509</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ruppender, N.S., Morrissey, C., Lange, P.H., Vessella, R.L.: Dormancy in solid tumors: implications for prostate cancer. Cancer Metastasis Rev. 32, 501–509 (2013)</ref-fulltext>
<ce:source-text>Ruppender, N.S., Morrissey, C., Lange, P.H., Vessella, R.L.: Dormancy in solid tumors: implications for prostate cancer. Cancer Metastasis Rev. 32, 501–509 (2013)</ce:source-text>
</reference>
<reference seq="67">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis dormancy in estrogen receptor-positive breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.H.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Giuliano</ce:surname>
</author>
<author seq="3">
<ce:initials>M.V.</ce:initials>
<ce:surname>Trivedi</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Schiff</ce:surname>
</author>
<author seq="5">
<ce:initials>C.K.</ce:initials>
<ce:surname>Osborne</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Clin Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>19</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6389</first-page>
<last-page>6397</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, X.H., Giuliano, M., Trivedi, M.V., Schiff, R., Osborne, C.K.: Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 19, 6389–6397 (2013)</ref-fulltext>
<ce:source-text>Zhang, X.H., Giuliano, M., Trivedi, M.V., Schiff, R., Osborne, C.K.: Metastasis dormancy in estrogen receptor-positive breast cancer. Clin Cancer Res. 19, 6389–6397 (2013)</ce:source-text>
</reference>
<reference seq="68">
<ref-info>
<ref-title>
<ref-titletext-english>Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.J.</ce:initials>
<ce:surname>Aslakson</ce:surname>
</author>
<author seq="2">
<ce:initials>F.R.</ce:initials>
<ce:surname>Miller</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1992"/>
<volisspag>
<volume-issue-number>
<vol-first>52</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1399</first-page>
<last-page>1405</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aslakson, C.J., Miller, F.R.: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399–1405 (1992)</ref-fulltext>
<ce:source-text>Aslakson, C.J., Miller, F.R.: Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52, 1399–1405 (1992)</ce:source-text>
</reference>
<reference seq="69">
<ref-info>
<ref-title>
<ref-titletext-english>A multigenic program mediating breast cancer metastasis to bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
<author seq="2">
<ce:initials>P.M.</ce:initials>
<ce:surname>Siegel</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Shu</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Drobnjak</ce:surname>
</author>
<author seq="5">
<ce:initials>S.M.</ce:initials>
<ce:surname>Kakonen</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Cordon-Cardo</ce:surname>
</author>
<author seq="7">
<ce:initials>T.A.</ce:initials>
<ce:surname>Guise</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2003"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>537</first-page>
<last-page>549</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., Guise, T.A., Massague, J.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3, 537–549 (2003)</ref-fulltext>
<ce:source-text>Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., Guise, T.A., Massague, J.: A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3, 537–549 (2003)</ce:source-text>
</reference>
<reference seq="70">
<ref-info>
<ref-title>
<ref-titletext-english>VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Mu</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Riethdorf</ce:surname>
</author>
<author seq="5">
<ce:initials>Q.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Yuan</ce:surname>
</author>
<author seq="7">
<ce:initials>J.</ce:initials>
<ce:surname>Yan</ce:surname>
</author>
<author seq="8">
<ce:initials>Y.</ce:initials>
<ce:surname>Hua</ce:surname>
</author>
<author seq="9">
<ce:initials>B.J.</ce:initials>
<ce:surname>Tiede</ce:surname>
</author>
<author seq="10">
<ce:initials>X.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>701</first-page>
<last-page>714</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., Yan, J., Hua, Y., Tiede, B.J., Lu, X., et al.: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 20, 701–714 (2011)</ref-fulltext>
<ce:source-text>Lu, X., Mu, E., Wei, Y., Riethdorf, S., Yang, Q., Yuan, M., Yan, J., Hua, Y., Tiede, B.J., Lu, X., et al.: VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors. Cancer Cell. 20, 701–714 (2011)</ce:source-text>
</reference>
<reference seq="71">
<ref-info>
<ref-title>
<ref-titletext-english>The Relationship Between Dormant Cancer Cells and Their Microenvironment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>N.</ce:initials>
<ce:surname>Linde</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Fluegen</ce:surname>
</author>
<author seq="3">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Adv Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>132</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>45</first-page>
<last-page>71</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Linde, N., Fluegen, G., Aguirre-Ghiso, J.A.: The Relationship Between Dormant Cancer Cells and Their Microenvironment. Adv Cancer Res. 132, 45–71 (2016)</ref-fulltext>
<ce:source-text>Linde, N., Fluegen, G., Aguirre-Ghiso, J.A.: The Relationship Between Dormant Cancer Cells and Their Microenvironment. Adv Cancer Res. 132, 45–71 (2016)</ce:source-text>
</reference>
<reference seq="72">
<ref-info>
<ref-title>
<ref-titletext-english>Models, mechanisms and clinical evidence for cancer dormancy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>834</first-page>
<last-page>846</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aguirre-Ghiso, J.A.: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7, 834–846 (2007)</ref-fulltext>
<ce:source-text>Aguirre-Ghiso, J.A.: Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 7, 834–846 (2007)</ce:source-text>
</reference>
<reference seq="73">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanism of early dissemination and metastasis in Her2(+) mammary cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.L.</ce:initials>
<ce:surname>Harper</ce:surname>
</author>
<author seq="2">
<ce:initials>M.S.</ce:initials>
<ce:surname>Sosa</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Entenberg</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Hosseini</ce:surname>
</author>
<author seq="5">
<ce:initials>J.F.</ce:initials>
<ce:surname>Cheung</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Nobre</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Avivar-Valderas</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Nagi</ce:surname>
</author>
<author seq="9">
<ce:initials>N.</ce:initials>
<ce:surname>Girnius</ce:surname>
</author>
<author seq="10">
<ce:initials>R.J.</ce:initials>
<ce:surname>Davis</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>540</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>588</first-page>
<last-page>592</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Harper, K.L., Sosa, M.S., Entenberg, D., Hosseini, H., Cheung, J.F., Nobre, R., Avivar-Valderas, A., Nagi, C., Girnius, N., Davis, R.J., et al.: Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature. 540, 588–592 (2016)</ref-fulltext>
<ce:source-text>Harper, K.L., Sosa, M.S., Entenberg, D., Hosseini, H., Cheung, J.F., Nobre, R., Avivar-Valderas, A., Nagi, C., Girnius, N., Davis, R.J., et al.: Mechanism of early dissemination and metastasis in Her2(+) mammary cancer. Nature. 540, 588–592 (2016)</ce:source-text>
</reference>
<reference seq="74">
<ref-info>
<ref-title>
<ref-titletext-english>Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Schlimok</ce:surname>
</author>
<author seq="2">
<ce:initials>I.</ce:initials>
<ce:surname>Funke</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Holzmann</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Gottlinger</ce:surname>
</author>
<author seq="5">
<ce:initials>G.</ce:initials>
<ce:surname>Schmidt</ce:surname>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Hauser</ce:surname>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Swierkot</ce:surname>
</author>
<author seq="8">
<ce:initials>H.H.</ce:initials>
<ce:surname>Warnecke</ce:surname>
</author>
<author seq="9">
<ce:initials>B.</ce:initials>
<ce:surname>Schneider</ce:surname>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Koprowski</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Proc Natl Acad Sci U S A</ref-sourcetitle>
<ref-publicationyear first="1987"/>
<volisspag>
<volume-issue-number>
<vol-first>84</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8672</first-page>
<last-page>8676</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Schlimok, G., Funke, I., Holzmann, B., Gottlinger, G., Schmidt, G., Hauser, H., Swierkot, S., Warnecke, H.H., Schneider, B., Koprowski, H., et al.: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A. 84, 8672–8676 (1987)</ref-fulltext>
<ce:source-text>Schlimok, G., Funke, I., Holzmann, B., Gottlinger, G., Schmidt, G., Hauser, H., Swierkot, S., Warnecke, H.H., Schneider, B., Koprowski, H., et al.: Micrometastatic cancer cells in bone marrow: in vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies. Proc Natl Acad Sci U S A. 84, 8672–8676 (1987)</ce:source-text>
</reference>
<reference seq="75">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic niche functions and therapeutic opportunities</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Celia-Terrassa</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Kang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>868</first-page>
<last-page>877</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Celia-Terrassa, T., Kang, Y.: Metastatic niche functions and therapeutic opportunities. Nat Cell Biol. 20, 868–877 (2018)</ref-fulltext>
<ce:source-text>Celia-Terrassa, T., Kang, Y.: Metastatic niche functions and therapeutic opportunities. Nat Cell Biol. 20, 868–877 (2018)</ce:source-text>
</reference>
<reference seq="76">
<ref-info>
<ref-title>
<ref-titletext-english>Metastasis prevention by targeting the dormant niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Ghajar</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>238</first-page>
<last-page>247</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ghajar, C.M.: Metastasis prevention by targeting the dormant niche. Nat Rev Cancer. 15, 238–247 (2015)</ref-fulltext>
<ce:source-text>Ghajar, C.M.: Metastasis prevention by targeting the dormant niche. Nat Rev Cancer. 15, 238–247 (2015)</ce:source-text>
</reference>
<reference seq="77">
<ref-info>
<ref-title>
<ref-titletext-english>Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.</ce:initials>
<ce:surname>Shiozawa</ce:surname>
</author>
<author seq="2">
<ce:initials>E.A.</ce:initials>
<ce:surname>Pedersen</ce:surname>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Havens</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Jung</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Mishra</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Joseph</ce:surname>
</author>
<author seq="7">
<ce:initials>J.K.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="8">
<ce:initials>L.R.</ce:initials>
<ce:surname>Patel</ce:surname>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Ying</ce:surname>
</author>
<author seq="10">
<ce:initials>A.M.</ce:initials>
<ce:surname>Ziegler</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J Clin Invest</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>121</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1298</first-page>
<last-page>1312</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Shiozawa, Y., Pedersen, E.A., Havens, A.M., Jung, Y., Mishra, A., Joseph, J., Kim, J.K., Patel, L.R., Ying, C., Ziegler, A.M., et al.: Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 121, 1298–1312 (2011)</ref-fulltext>
<ce:source-text>Shiozawa, Y., Pedersen, E.A., Havens, A.M., Jung, Y., Mishra, A., Joseph, J., Kim, J.K., Patel, L.R., Ying, C., Ziegler, A.M., et al.: Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 121, 1298–1312 (2011)</ce:source-text>
</reference>
<reference seq="78">
<ref-info>
<ref-title>
<ref-titletext-english>Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.A.</ce:initials>
<ce:surname>Lawson</ce:surname>
</author>
<author seq="2">
<ce:initials>M.M.</ce:initials>
<ce:surname>McDonald</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Kovacic</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Hua Khoo</ce:surname>
</author>
<author seq="5">
<ce:initials>R.L.</ce:initials>
<ce:surname>Terry</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Down</ce:surname>
</author>
<author seq="7">
<ce:initials>W.</ce:initials>
<ce:surname>Kaplan</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Paton-Hough</ce:surname>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Fellows</ce:surname>
</author>
<author seq="10">
<ce:initials>J.A.</ce:initials>
<ce:surname>Pettitt</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>6</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>8983</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lawson, M.A., McDonald, M.M., Kovacic, N., Hua Khoo, W., Terry, R.L., Down, J., Kaplan, W., Paton-Hough, J., Fellows, C., Pettitt, J.A., et al.: Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 6, 8983 (2015)</ref-fulltext>
<ce:source-text>Lawson, M.A., McDonald, M.M., Kovacic, N., Hua Khoo, W., Terry, R.L., Down, J., Kaplan, W., Paton-Hough, J., Fellows, C., Pettitt, J.A., et al.: Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 6, 8983 (2015)</ce:source-text>
</reference>
<reference seq="79">
<ref-info>
<ref-title>
<ref-titletext-english>The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Tian</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Goldstein</ce:surname>
</author>
<author seq="5">
<ce:initials>I.</ce:initials>
<ce:surname>Bado</ce:surname>
</author>
<author seq="6">
<ce:initials>W.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="7">
<ce:initials>B.R.</ce:initials>
<ce:surname>Arenkiel</ce:surname>
</author>
<author seq="8">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="10">
<ce:initials>S.</ce:initials>
<ce:surname>Du</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
<iss-first>823</iss-first>
<iss-last>839</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Tian, L., Liu, J., Goldstein, A., Bado, I., Zhang, W., Arenkiel, B.R., Li, Z., Yang, M., Du, S., et al.: The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability. Cancer Cell. 34(823-839), e827 (2018)</ref-fulltext>
<ce:source-text>Wang, H., Tian, L., Liu, J., Goldstein, A., Bado, I., Zhang, W., Arenkiel, B.R., Li, Z., Yang, M., Du, S., et al.: The Osteogenic Niche Is a Calcium Reservoir of Bone Micrometastases and Confers Unexpected Therapeutic Vulnerability. Cancer Cell. 34(823-839), e827 (2018)</ce:source-text>
</reference>
<reference seq="80">
<ref-info>
<ref-title>
<ref-titletext-english>The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>C.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="4">
<ce:initials>T.</ce:initials>
<ce:surname>Welte</ce:surname>
</author>
<author seq="5">
<ce:initials>A.M.</ce:initials>
<ce:surname>Muscarella</ce:surname>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Tian</ce:surname>
</author>
<author seq="7">
<ce:initials>H.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<author seq="8">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<author seq="9">
<ce:initials>S.</ce:initials>
<ce:surname>Du</ce:surname>
</author>
<author seq="10">
<ce:initials>J.</ce:initials>
<ce:surname>Tao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>193</first-page>
<last-page>210</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Yu, C., Gao, X., Welte, T., Muscarella, A.M., Tian, L., Zhao, H., Zhao, Z., Du, S., Tao, J., et al.: The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 27, 193–210 (2015)</ref-fulltext>
<ce:source-text>Wang, H., Yu, C., Gao, X., Welte, T., Muscarella, A.M., Tian, L., Zhao, H., Zhao, Z., Du, S., Tao, J., et al.: The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 27, 193–210 (2015)</ce:source-text>
</reference>
<reference seq="81">
<ref-info>
<ref-title>
<ref-titletext-english>Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Zheng</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Bae</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kasimir-Bauer</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Tang</ce:surname>
</author>
<author seq="5">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Ren</ce:surname>
</author>
<author seq="7">
<ce:initials>M.</ce:initials>
<ce:surname>Yuan</ce:surname>
</author>
<author seq="8">
<ce:initials>M.</ce:initials>
<ce:surname>Esposito</ce:surname>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="10">
<ce:initials>Y.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Cell</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>32</vol-first>
<iss-first>731</iss-first>
<iss-last>747</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zheng, H., Bae, Y., Kasimir-Bauer, S., Tang, R., Chen, J., Ren, G., Yuan, M., Esposito, M., Li, W., Wei, Y., et al.: Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. Cancer Cell. 32(731-747), e736 (2017)</ref-fulltext>
<ce:source-text>Zheng, H., Bae, Y., Kasimir-Bauer, S., Tang, R., Chen, J., Ren, G., Yuan, M., Esposito, M., Li, W., Wei, Y., et al.: Therapeutic Antibody Targeting Tumor- and Osteoblastic Niche-Derived Jagged1 Sensitizes Bone Metastasis to Chemotherapy. Cancer Cell. 32(731-747), e736 (2017)</ce:source-text>
</reference>
<reference seq="82">
<ref-info>
<ref-title>
<ref-titletext-english>Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Ding</ce:surname>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>495</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>231</first-page>
<last-page>235</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ding, L., Morrison, S.J.: Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature. 495, 231–235 (2013)</ref-fulltext>
<ce:source-text>Ding, L., Morrison, S.J.: Haematopoietic stem cells and early lymphoid progenitors occupy distinct bone marrow niches. Nature. 495, 231–235 (2013)</ce:source-text>
</reference>
<reference seq="83">
<ref-info>
<ref-title>
<ref-titletext-english>The bone marrow niche for haematopoietic stem cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
<author seq="2">
<ce:initials>D.T.</ce:initials>
<ce:surname>Scadden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>505</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>327</first-page>
<last-page>334</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Morrison, S.J., Scadden, D.T.: The bone marrow niche for haematopoietic stem cells. Nature. 505, 327–334 (2014)</ref-fulltext>
<ce:source-text>Morrison, S.J., Scadden, D.T.: The bone marrow niche for haematopoietic stem cells. Nature. 505, 327–334 (2014)</ce:source-text>
</reference>
<reference seq="84">
<ref-info>
<ref-title>
<ref-titletext-english>Involvement of chemokine receptors in breast cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Muller</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Homey</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Soto</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Ge</ce:surname>
</author>
<author seq="5">
<ce:initials>D.</ce:initials>
<ce:surname>Catron</ce:surname>
</author>
<author seq="6">
<ce:initials>M.E.</ce:initials>
<ce:surname>Buchanan</ce:surname>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>McClanahan</ce:surname>
</author>
<author seq="8">
<ce:initials>E.</ce:initials>
<ce:surname>Murphy</ce:surname>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Yuan</ce:surname>
</author>
<author seq="10">
<ce:initials>S.N.</ce:initials>
<ce:surname>Wagner</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>410</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>50</first-page>
<last-page>56</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410, 50–56 (2001)</ref-fulltext>
<ce:source-text>Muller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M.E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S.N., et al.: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410, 50–56 (2001)</ce:source-text>
</reference>
<reference seq="85">
<ref-info>
<ref-title>
<ref-titletext-english>Homeostatic chemokine receptors and organ-specific metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Zlotnik</ce:surname>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Burkhardt</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Homey</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Immunol</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>597</first-page>
<last-page>606</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Zlotnik, A., Burkhardt, A.M., Homey, B.: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11, 597–606 (2011)</ref-fulltext>
<ce:source-text>Zlotnik, A., Burkhardt, A.M., Homey, B.: Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol. 11, 597–606 (2011)</ce:source-text>
</reference>
<reference seq="86">
<ref-info>
<ref-title>
<ref-titletext-english>The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Chakraborty</ce:surname>
</author>
<author seq="3">
<ce:initials>A.P.</ce:initials>
<ce:surname>Lee-Lim</ce:surname>
</author>
<author seq="4">
<ce:initials>Q.</ce:initials>
<ce:surname>Mo</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Decker</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Vonica</ce:surname>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Shen</ce:surname>
</author>
<author seq="8">
<ce:initials>E.</ce:initials>
<ce:surname>Brogi</ce:surname>
</author>
<author seq="9">
<ce:initials>A.H.</ce:initials>
<ce:surname>Brivanlou</ce:surname>
</author>
<author seq="10">
<ce:initials>F.G.</ce:initials>
<ce:surname>Giancotti</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2012"/>
<volisspag>
<volume-issue-number>
<vol-first>150</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>764</first-page>
<last-page>779</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, H., Chakraborty, G., Lee-Lim, A.P., Mo, Q., Decker, M., Vonica, A., Shen, R., Brogi, E., Brivanlou, A.H., Giancotti, F.G.: The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 150, 764–779 (2012)</ref-fulltext>
<ce:source-text>Gao, H., Chakraborty, G., Lee-Lim, A.P., Mo, Q., Decker, M., Vonica, A., Shen, R., Brogi, E., Brivanlou, A.H., Giancotti, F.G.: The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell. 150, 764–779 (2012)</ce:source-text>
</reference>
<reference seq="87">
<ref-info>
<ref-title>
<ref-titletext-english>Niches for Hematopoietic Stem Cells and Their Progeny</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Q.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<author seq="2">
<ce:initials>P.S.</ce:initials>
<ce:surname>Frenette</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Immunity</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>48</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>632</first-page>
<last-page>648</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Wei, Q., Frenette, P.S.: Niches for Hematopoietic Stem Cells and Their Progeny. Immunity. 48, 632–648 (2018)</ref-fulltext>
<ce:source-text>Wei, Q., Frenette, P.S.: Niches for Hematopoietic Stem Cells and Their Progeny. Immunity. 48, 632–648 (2018)</ce:source-text>
</reference>
<reference seq="88">
<ref-info>
<ref-title>
<ref-titletext-english>Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Mignatti</ce:surname>
</author>
<author seq="4">
<ce:initials>K.</ce:initials>
<ce:surname>Kovalski</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Ossowski</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Mol Biol Cell</ref-sourcetitle>
<ref-publicationyear first="2001"/>
<volisspag>
<volume-issue-number>
<vol-first>12</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>863</first-page>
<last-page>879</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Aguirre-Ghiso, J.A., Liu, D., Mignatti, A., Kovalski, K., Ossowski, L.: Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 12, 863–879 (2001)</ref-fulltext>
<ce:source-text>Aguirre-Ghiso, J.A., Liu, D., Mignatti, A., Kovalski, K., Ossowski, L.: Urokinase receptor and fibronectin regulate the ERK (MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell. 12, 863–879 (2001)</ce:source-text>
</reference>
<reference seq="89">
<ref-info>
<ref-title>
<ref-titletext-english>Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Kobayashi</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Okuda</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Xing</ce:surname>
</author>
<author seq="4">
<ce:initials>P.R.</ce:initials>
<ce:surname>Pandey</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Watabe</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Hirota</ce:surname>
</author>
<author seq="7">
<ce:initials>S.K.</ce:initials>
<ce:surname>Pai</ce:surname>
</author>
<author seq="8">
<ce:initials>W.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="9">
<ce:initials>K.</ce:initials>
<ce:surname>Fukuda</ce:surname>
</author>
<author seq="10">
<ce:initials>C.</ce:initials>
<ce:surname>Chambers</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>J Exp Med</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>208</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2641</first-page>
<last-page>2655</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kobayashi, A., Okuda, H., Xing, F., Pandey, P.R., Watabe, M., Hirota, S., Pai, S.K., Liu, W., Fukuda, K., Chambers, C., et al.: Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 208, 2641–2655 (2011)</ref-fulltext>
<ce:source-text>Kobayashi, A., Okuda, H., Xing, F., Pandey, P.R., Watabe, M., Hirota, S., Pai, S.K., Liu, W., Fukuda, K., Chambers, C., et al.: Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J Exp Med. 208, 2641–2655 (2011)</ce:source-text>
</reference>
<reference seq="90">
<ref-info>
<ref-title>
<ref-titletext-english>TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Bragado</ce:surname>
</author>
<author seq="2">
<ce:initials>Y.</ce:initials>
<ce:surname>Estrada</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Parikh</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Krause</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Capobianco</ce:surname>
</author>
<author seq="6">
<ce:initials>H.G.</ce:initials>
<ce:surname>Farina</ce:surname>
</author>
<author seq="7">
<ce:initials>D.M.</ce:initials>
<ce:surname>Schewe</ce:surname>
</author>
<author seq="8">
<ce:initials>J.A.</ce:initials>
<ce:surname>Aguirre-Ghiso</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>15</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1351</first-page>
<last-page>1361</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Bragado, P., Estrada, Y., Parikh, F., Krause, S., Capobianco, C., Farina, H.G., Schewe, D.M., Aguirre-Ghiso, J.A.: TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nat Cell Biol. 15, 1351–1361 (2013)</ref-fulltext>
<ce:source-text>Bragado, P., Estrada, Y., Parikh, F., Krause, S., Capobianco, C., Farina, H.G., Schewe, D.M., Aguirre-Ghiso, J.A.: TGF-beta2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38alpha/beta signalling. Nat Cell Biol. 15, 1351–1361 (2013)</ce:source-text>
</reference>
<reference seq="91">
<ref-info>
<ref-title>
<ref-titletext-english>Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.</ce:initials>
<ce:surname>Catena</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Bhattacharya</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>El Rayes</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Choi</ce:surname>
</author>
<author seq="6">
<ce:initials>D.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Ryu</ce:surname>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Joshi</ce:surname>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Bielenberg</ce:surname>
</author>
<author seq="10">
<ce:initials>S.B.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Discov</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>578</first-page>
<last-page>589</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Catena, R., Bhattacharya, N., El Rayes, T., Wang, S., Choi, H., Gao, D., Ryu, S., Joshi, N., Bielenberg, D., Lee, S.B., et al.: Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578–589 (2013)</ref-fulltext>
<ce:source-text>Catena, R., Bhattacharya, N., El Rayes, T., Wang, S., Choi, H., Gao, D., Ryu, S., Joshi, N., Bielenberg, D., Lee, S.B., et al.: Bone marrow-derived Gr1+ cells can generate a metastasis-resistant microenvironment via induced secretion of thrombospondin-1. Cancer Discov. 3, 578–589 (2013)</ce:source-text>
</reference>
<reference seq="92">
<ref-info>
<ref-title>
<ref-titletext-english>Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.W.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="2">
<ce:initials>E.C.</ce:initials>
<ce:surname>Finger</ce:surname>
</author>
<author seq="3">
<ce:initials>M.M.</ce:initials>
<ce:surname>Olcina</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Vilalta</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Aguilera</ce:surname>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Miao</ce:surname>
</author>
<author seq="7">
<ce:initials>A.R.</ce:initials>
<ce:surname>Merkel</ce:surname>
</author>
<author seq="8">
<ce:initials>J.R.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="9">
<ce:initials>J.A.</ce:initials>
<ce:surname>Sterling</ce:surname>
</author>
<author seq="10">
<ce:initials>J.Y.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>18</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1078</first-page>
<last-page>1089</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Johnson, R.W., Finger, E.C., Olcina, M.M., Vilalta, M., Aguilera, T., Miao, Y., Merkel, A.R., Johnson, J.R., Sterling, J.A., Wu, J.Y., et al.: Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol. 18, 1078–1089 (2016)</ref-fulltext>
<ce:source-text>Johnson, R.W., Finger, E.C., Olcina, M.M., Vilalta, M., Aguilera, T., Miao, Y., Merkel, A.R., Johnson, J.R., Sterling, J.A., Wu, J.Y., et al.: Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol. 18, 1078–1089 (2016)</ce:source-text>
</reference>
<reference seq="93">
<ref-info>
<ref-title>
<ref-titletext-english>Metastases in immune-mediated dormancy: A new opportunity for targeting cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Romero</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Garrido</ce:surname>
</author>
<author seq="3">
<ce:initials>A.M.</ce:initials>
<ce:surname>Garcia-Lora</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>74</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>6750</first-page>
<last-page>6757</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Romero, I., Garrido, F., Garcia-Lora, A.M.: Metastases in immune-mediated dormancy: A new opportunity for targeting cancer. Cancer Res. 74, 6750–6757 (2014)</ref-fulltext>
<ce:source-text>Romero, I., Garrido, F., Garcia-Lora, A.M.: Metastases in immune-mediated dormancy: A new opportunity for targeting cancer. Cancer Res. 74, 6750–6757 (2014)</ce:source-text>
</reference>
<reference seq="94">
<ref-info>
<ref-title>
<ref-titletext-english>Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Malladi</ce:surname>
</author>
<author seq="2">
<ce:initials>D.G.</ce:initials>
<ce:surname>Macalinao</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Jin</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>He</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Basnet</ce:surname>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Zou</ce:surname>
</author>
<author seq="7">
<ce:initials>E.</ce:initials>
<ce:surname>de Stanchina</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Massague</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>165</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>45</first-page>
<last-page>60</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Malladi, S., Macalinao, D.G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., Massague, J.: Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell. 165, 45–60 (2016)</ref-fulltext>
<ce:source-text>Malladi, S., Macalinao, D.G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., Massague, J.: Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell. 165, 45–60 (2016)</ce:source-text>
</reference>
<reference seq="95">
<ref-info>
<ref-title>
<ref-titletext-english>Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Schlimok</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Kutter</ce:surname>
</author>
<author seq="4">
<ce:initials>G.</ce:initials>
<ce:surname>Schaller</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Genz</ce:surname>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Wiebecke</ce:surname>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Backmann</ce:surname>
</author>
<author seq="8">
<ce:initials>I.</ce:initials>
<ce:surname>Funke</ce:surname>
</author>
<author seq="9">
<ce:initials>G.</ce:initials>
<ce:surname>Riethmuller</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="1991"/>
<volisspag>
<volume-issue-number>
<vol-first>51</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>4712</first-page>
<last-page>4715</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pantel, K., Schlimok, G., Kutter, D., Schaller, G., Genz, T., Wiebecke, B., Backmann, R., Funke, I., Riethmuller, G.: Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 51, 4712–4715 (1991)</ref-fulltext>
<ce:source-text>Pantel, K., Schlimok, G., Kutter, D., Schaller, G., Genz, T., Wiebecke, B., Backmann, R., Funke, I., Riethmuller, G.: Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells. Cancer Res. 51, 4712–4715 (1991)</ce:source-text>
</reference>
<reference seq="96">
<ref-info>
<ref-title>
<ref-titletext-english>Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Pommier</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Anaparthy</ce:surname>
</author>
<author seq="3">
<ce:initials>N.</ce:initials>
<ce:surname>Memos</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.L.</ce:initials>
<ce:surname>Kelley</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Gouronnec</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Yan</ce:surname>
</author>
<author seq="7">
<ce:initials>C.</ce:initials>
<ce:surname>Auffray</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>Albrengues</ce:surname>
</author>
<author seq="9">
<ce:initials>M.</ce:initials>
<ce:surname>Egeblad</ce:surname>
</author>
<author seq="10">
<ce:initials>C.A.</ce:initials>
<ce:surname>Iacobuzio-Donahue</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Science</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<page-information>
<pages>
<first-page>360</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pommier, A., Anaparthy, N., Memos, N., Kelley, Z.L., Gouronnec, A., Yan, R., Auffray, C., Albrengues, J., Egeblad, M., Iacobuzio-Donahue, C.A., et al.: Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 360 (2018)</ref-fulltext>
<ce:source-text>Pommier, A., Anaparthy, N., Memos, N., Kelley, Z.L., Gouronnec, A., Yan, R., Auffray, C., Albrengues, J., Egeblad, M., Iacobuzio-Donahue, C.A., et al.: Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 360 (2018)</ce:source-text>
</reference>
<reference seq="97">
<ref-info>
<ref-title>
<ref-titletext-english>A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.F.</ce:initials>
<ce:surname>Sanmamed</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>175</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>313</first-page>
<last-page>326</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Sanmamed, M.F., Chen, L.: A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 175, 313–326 (2018)</ref-fulltext>
<ce:source-text>Sanmamed, M.F., Chen, L.: A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization. Cell. 175, 313–326 (2018)</ce:source-text>
</reference>
<reference seq="98">
<ref-info>
<ref-title>
<ref-titletext-english>Adaptive immunity maintains occult cancer in an equilibrium state</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.M.</ce:initials>
<ce:surname>Koebel</ce:surname>
</author>
<author seq="2">
<ce:initials>W.</ce:initials>
<ce:surname>Vermi</ce:surname>
</author>
<author seq="3">
<ce:initials>J.B.</ce:initials>
<ce:surname>Swann</ce:surname>
</author>
<author seq="4">
<ce:initials>N.</ce:initials>
<ce:surname>Zerafa</ce:surname>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Rodig</ce:surname>
</author>
<author seq="6">
<ce:initials>L.J.</ce:initials>
<ce:surname>Old</ce:surname>
</author>
<author seq="7">
<ce:initials>M.J.</ce:initials>
<ce:surname>Smyth</ce:surname>
</author>
<author seq="8">
<ce:initials>R.D.</ce:initials>
<ce:surname>Schreiber</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2007"/>
<volisspag>
<volume-issue-number>
<vol-first>450</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>903</first-page>
<last-page>907</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J., Schreiber, R.D.: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450, 903–907 (2007)</ref-fulltext>
<ce:source-text>Koebel, C.M., Vermi, W., Swann, J.B., Zerafa, N., Rodig, S.J., Old, L.J., Smyth, M.J., Schreiber, R.D.: Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 450, 903–907 (2007)</ce:source-text>
</reference>
<reference seq="99">
<ref-info>
<ref-title>
<ref-titletext-english>Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>F.E.</ce:initials>
<ce:surname>Buroni</ce:surname>
</author>
<author seq="2">
<ce:initials>M.G.</ce:initials>
<ce:surname>Persico</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Pasi</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Lodola</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Nano</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Aprile</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Anticancer Res</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>5719</first-page>
<last-page>5730</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Buroni, F.E., Persico, M.G., Pasi, F., Lodola, L., Nano, R., Aprile, C.: Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. Anticancer Res. 36, 5719–5730 (2016)</ref-fulltext>
<ce:source-text>Buroni, F.E., Persico, M.G., Pasi, F., Lodola, L., Nano, R., Aprile, C.: Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. Anticancer Res. 36, 5719–5730 (2016)</ce:source-text>
</reference>
<reference seq="100">
<ref-info>
<ref-title>
<ref-titletext-english>Alpha emitter radium-223 and survival in metastatic prostate cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Parker</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Nilsson</ce:surname>
</author>
<author seq="3">
<ce:initials>D.</ce:initials>
<ce:surname>Heinrich</ce:surname>
</author>
<author seq="4">
<ce:initials>S.I.</ce:initials>
<ce:surname>Helle</ce:surname>
</author>
<author seq="5">
<ce:initials>J.M.</ce:initials>
<ce:surname>O'sullivan</ce:surname>
</author>
<author seq="6">
<ce:initials>S.D.</ce:initials>
<ce:surname>Fossa</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Chodacki</ce:surname>
</author>
<author seq="8">
<ce:initials>P.</ce:initials>
<ce:surname>Wiechno</ce:surname>
</author>
<author seq="9">
<ce:initials>J.</ce:initials>
<ce:surname>Logue</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Seke</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2013"/>
<volisspag>
<volume-issue-number>
<vol-first>369</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>213</first-page>
<last-page>223</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fossa, S.D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al.: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369, 213–223 (2013)</ref-fulltext>
<ce:source-text>Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O'Sullivan, J.M., Fossa, S.D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al.: Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 369, 213–223 (2013)</ce:source-text>
</reference>
<reference seq="101">
<ref-info>
<ref-title>
<ref-titletext-english>The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.I.</ce:initials>
<ce:surname>Suominen</ce:surname>
</author>
<author seq="2">
<ce:initials>T.</ce:initials>
<ce:surname>Wilson</ce:surname>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Kakonen</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Scholz</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Int J Mol Sci</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<page-information>
<pages>
<first-page>20</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Suominen, M.I., Wilson, T., Kakonen, S.M., Scholz, A.: The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. Int J Mol Sci. 20 (2019)</ref-fulltext>
<ce:source-text>Suominen, M.I., Wilson, T., Kakonen, S.M., Scholz, A.: The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis. Int J Mol Sci. 20 (2019)</ce:source-text>
</reference>
<reference seq="102">
<ref-info>
<ref-title>
<ref-titletext-english>Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>von Minckwitz</ce:surname>
</author>
<author seq="2">
<ce:initials>C.S.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="3">
<ce:initials>M.S.</ce:initials>
<ce:surname>Mano</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Loibl</ce:surname>
</author>
<author seq="5">
<ce:initials>E.P.</ce:initials>
<ce:surname>Mamounas</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Untch</ce:surname>
</author>
<author seq="7">
<ce:initials>N.</ce:initials>
<ce:surname>Wolmark</ce:surname>
</author>
<author seq="8">
<ce:initials>P.</ce:initials>
<ce:surname>Rastogi</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Schneeweiss</ce:surname>
</author>
<author seq="10">
<ce:initials>A.</ce:initials>
<ce:surname>Redondo</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>N Engl J Med</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>380</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>617</first-page>
<last-page>628</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>von Minckwitz, G., Huang, C.S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al.: Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 380, 617–628 (2019)</ref-fulltext>
<ce:source-text>von Minckwitz, G., Huang, C.S., Mano, M.S., Loibl, S., Mamounas, E.P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al.: Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 380, 617–628 (2019)</ce:source-text>
</reference>
<reference seq="103">
<ref-info>
<ref-title>
<ref-titletext-english>Trastuzumab emtansine: Mechanisms of action and drug resistance</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Barok</ce:surname>
</author>
<author seq="2">
<ce:initials>H.</ce:initials>
<ce:surname>Joensuu</ce:surname>
</author>
<author seq="3">
<ce:initials>J.</ce:initials>
<ce:surname>Isola</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Breast Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>209</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Barok, M., Joensuu, H., Isola, J.: Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 16, 209 (2014)</ref-fulltext>
<ce:source-text>Barok, M., Joensuu, H., Isola, J.: Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 16, 209 (2014)</ce:source-text>
</reference>
<reference seq="104">
<ref-info>
<ref-title>
<ref-titletext-english>Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.C.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="2">
<ce:initials>B.R.</ce:initials>
<ce:surname>Lin</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.C.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.L.</ce:initials>
<ce:surname>Lin</ce:surname>
</author>
<author seq="5">
<ce:initials>H.S.</ce:initials>
<ce:surname>Lai</ce:surname>
</author>
<author seq="6">
<ce:initials>K.W.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="7">
<ce:initials>J.T.</ce:initials>
<ce:surname>Liang</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Medicine (Baltimore)</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>95</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Yang, P.C., Lin, B.R., Chen, Y.C., Lin, Y.L., Lai, H.S., Huang, K.W., Liang, J.T.: Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer. Medicine (Baltimore). 95, e3338 (2016)</ref-fulltext>
<ce:source-text>Yang, P.C., Lin, B.R., Chen, Y.C., Lin, Y.L., Lai, H.S., Huang, K.W., Liang, J.T.: Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer. Medicine (Baltimore). 95, e3338 (2016)</ce:source-text>
</reference>
<reference seq="105">
<ref-info>
<ref-title>
<ref-titletext-english>Thermal Ablation of Metastatic Colon Cancer to the Liver</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.C.</ce:initials>
<ce:surname>Camacho</ce:surname>
</author>
<author seq="2">
<ce:initials>E.N.</ce:initials>
<ce:surname>Petre</ce:surname>
</author>
<author seq="3">
<ce:initials>C.T.</ce:initials>
<ce:surname>Sofocleous</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Semin Intervent Radiol</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>36</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>310</first-page>
<last-page>318</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Camacho, J.C., Petre, E.N., Sofocleous, C.T.: Thermal Ablation of Metastatic Colon Cancer to the Liver. Semin Intervent Radiol. 36, 310–318 (2019)</ref-fulltext>
<ce:source-text>Camacho, J.C., Petre, E.N., Sofocleous, C.T.: Thermal Ablation of Metastatic Colon Cancer to the Liver. Semin Intervent Radiol. 36, 310–318 (2019)</ce:source-text>
</reference>
<reference seq="106">
<ref-info>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Faubert</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Solmonson</ce:surname>
</author>
<author seq="3">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Metabolic Reprogramming and Cancer Progression</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<page-information>
<pages>
<first-page>368</first-page>
</pages>
</page-information>
</volisspag>
<ref-text>Science (New York, NY</ref-text>
</ref-info>
<ref-fulltext>Faubert, B., Solmonson, A., DeBerardinis, R.J.: Metabolic reprogramming and cancer progression, p. 368. Science New York, NY (2020)</ref-fulltext>
<ce:source-text>Faubert, B., Solmonson, A., DeBerardinis, R.J.: Metabolic reprogramming and cancer progression, p. 368. Science New York, NY (2020)</ce:source-text>
</reference>
<reference seq="107">
<ref-info>
<ref-title>
<ref-titletext-english>Hallmarks of cancer: The next generation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.</ce:initials>
<ce:surname>Hanahan</ce:surname>
</author>
<author seq="2">
<ce:initials>R.A.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>144</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>646</first-page>
<last-page>674</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. 144, 646–674 (2011)</ref-fulltext>
<ce:source-text>Hanahan, D., Weinberg, R.A.: Hallmarks of cancer: The next generation. Cell. 144, 646–674 (2011)</ce:source-text>
</reference>
<reference seq="108">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the Warburg effect: The metabolic requirements of cell proliferation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
</author>
<author seq="2">
<ce:initials>L.C.</ce:initials>
<ce:surname>Cantley</ce:surname>
</author>
<author seq="3">
<ce:initials>C.B.</ce:initials>
<ce:surname>Thompson</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science (New York, NY)</ref-sourcetitle>
<ref-publicationyear first="2009"/>
<volisspag>
<volume-issue-number>
<vol-first>324</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1029</first-page>
<last-page>1033</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science (New York, NY). 324, 1029–1033 (2009)</ref-fulltext>
<ce:source-text>Vander Heiden, M.G., Cantley, L.C., Thompson, C.B.: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science (New York, NY). 324, 1029–1033 (2009)</ce:source-text>
</reference>
<reference seq="109">
<ref-info>
<ref-title>
<ref-titletext-english>The Metabolism of Tumors in the Body</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.</ce:initials>
<ce:surname>Warburg</ce:surname>
</author>
<author seq="2">
<ce:initials>F.</ce:initials>
<ce:surname>Wind</ce:surname>
</author>
<author seq="3">
<ce:initials>E.</ce:initials>
<ce:surname>Negelein</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Gen Physiol</ref-sourcetitle>
<ref-publicationyear first="1927"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>519</first-page>
<last-page>530</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Warburg, O., Wind, F., Negelein, E.: The Metabolism of Tumors in the Body. J Gen Physiol. 8, 519–530 (1927)</ref-fulltext>
<ce:source-text>Warburg, O., Wind, F., Negelein, E.: The Metabolism of Tumors in the Body. J Gen Physiol. 8, 519–530 (1927)</ce:source-text>
</reference>
<reference seq="110">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolomics and Isotope Tracing</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Jang</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="3">
<ce:initials>J.D.</ce:initials>
<ce:surname>Rabinowitz</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>173</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>822</first-page>
<last-page>837</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jang, C., Chen, L., Rabinowitz, J.D.: Metabolomics and Isotope Tracing. Cell. 173, 822–837 (2018)</ref-fulltext>
<ce:source-text>Jang, C., Chen, L., Rabinowitz, J.D.: Metabolomics and Isotope Tracing. Cell. 173, 822–837 (2018)</ce:source-text>
</reference>
<reference seq="111">
<ref-info>
<ref-title>
<ref-titletext-english>Applications of metabolomics to study cancer metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.K.</ce:initials>
<ce:surname>Kaushik</ce:surname>
</author>
<author seq="2">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Biochim Biophys Acta Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>1870</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2</first-page>
<last-page>14</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kaushik, A.K., DeBerardinis, R.J.: Applications of metabolomics to study cancer metabolism. Biochim Biophys Acta Rev Cancer. 1870, 2–14 (2018)</ref-fulltext>
<ce:source-text>Kaushik, A.K., DeBerardinis, R.J.: Applications of metabolomics to study cancer metabolism. Biochim Biophys Acta Rev Cancer. 1870, 2–14 (2018)</ce:source-text>
</reference>
<reference seq="112">
<ref-info>
<ref-title>
<ref-titletext-english>Regulation of cancer cell metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.A.</ce:initials>
<ce:surname>Cairns</ce:surname>
</author>
<author seq="2">
<ce:initials>I.S.</ce:initials>
<ce:surname>Harris</ce:surname>
</author>
<author seq="3">
<ce:initials>T.W.</ce:initials>
<ce:surname>Mak</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2011"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>85</first-page>
<last-page>95</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Cairns, R.A., Harris, I.S., Mak, T.W.: Regulation of cancer cell metabolism. Nat Rev Cancer. 11, 85–95 (2011)</ref-fulltext>
<ce:source-text>Cairns, R.A., Harris, I.S., Mak, T.W.: Regulation of cancer cell metabolism. Nat Rev Cancer. 11, 85–95 (2011)</ce:source-text>
</reference>
<reference seq="113">
<ref-info>
<ref-title>
<ref-titletext-english>The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Shi</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Tasdogan</ce:surname>
</author>
<author seq="3">
<ce:initials>F.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
<author seq="6">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Sci Adv</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
</volisspag>
<ref-text>eaao5268</ref-text>
</ref-info>
<ref-fulltext>Shi, X., Tasdogan, A., Huang, F., Hu, Z., Morrison, S.J., DeBerardinis, R.J.: The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. Sci Adv. 3, eaao5268 (2017)</ref-fulltext>
<ce:source-text>Shi, X., Tasdogan, A., Huang, F., Hu, Z., Morrison, S.J., DeBerardinis, R.J.: The abundance of metabolites related to protein methylation correlates with the metastatic capacity of human melanoma xenografts. Sci Adv. 3, eaao5268 (2017)</ce:source-text>
</reference>
<reference seq="114">
<ref-info>
<ref-title>
<ref-titletext-english>Understanding the Intersections between Metabolism and Cancer Biology</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
</author>
<author seq="2">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>168</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>657</first-page>
<last-page>669</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Vander Heiden, M.G., DeBerardinis, R.J.: Understanding the Intersections between Metabolism and Cancer Biology. Cell. 168, 657–669 (2017)</ref-fulltext>
<ce:source-text>Vander Heiden, M.G., DeBerardinis, R.J.: Understanding the Intersections between Metabolism and Cancer Biology. Cell. 168, 657–669 (2017)</ce:source-text>
</reference>
<reference seq="115">
<ref-info>
<ref-title>
<ref-titletext-english>Modelling glandular epithelial cancers in three-dimensional cultures</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Debnath</ce:surname>
</author>
<author seq="2">
<ce:initials>J.S.</ce:initials>
<ce:surname>Brugge</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Rev Cancer</ref-sourcetitle>
<ref-publicationyear first="2005"/>
<volisspag>
<volume-issue-number>
<vol-first>5</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>675</first-page>
<last-page>688</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Debnath, J., Brugge, J.S.: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 5, 675–688 (2005)</ref-fulltext>
<ce:source-text>Debnath, J., Brugge, J.S.: Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer. 5, 675–688 (2005)</ce:source-text>
</reference>
<reference seq="116">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>R.J.</ce:initials>
<ce:surname>Kishton</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Sukumar</ce:surname>
</author>
<author seq="3">
<ce:initials>N.P.</ce:initials>
<ce:surname>Restifo</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>94</first-page>
<last-page>109</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Kishton, R.J., Sukumar, M., Restifo, N.P.: Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab. 26, 94–109 (2017)</ref-fulltext>
<ce:source-text>Kishton, R.J., Sukumar, M., Restifo, N.P.: Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metab. 26, 94–109 (2017)</ce:source-text>
</reference>
<reference seq="117">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Hallmarks of Metastasis Formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Doglioni</ce:surname>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Trends in Cell Biology</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>673</first-page>
<last-page>684</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>(a)</ref-text>
</ref-info>
<ref-fulltext>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends in cell biology. 28, 673–684 (2018a)</ref-fulltext>
<ce:source-text>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends in cell biology. 28, 673–684 (2018a)</ce:source-text>
</reference>
<reference seq="118">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Adaptation Fuels Lymph Node Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ubellacker</ce:surname>
</author>
<author seq="2">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>29</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>785</first-page>
<last-page>786</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ubellacker, J.M., Morrison, S.J.: Metabolic Adaptation Fuels Lymph Node Metastasis. Cell Metab. 29, 785–786 (2019)</ref-fulltext>
<ce:source-text>Ubellacker, J.M., Morrison, S.J.: Metabolic Adaptation Fuels Lymph Node Metastasis. Cell Metab. 29, 785–786 (2019)</ce:source-text>
</reference>
<reference seq="119">
<ref-info>
<ref-title>
<ref-titletext-english>Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.D.</ce:initials>
<ce:surname>Dinardo</ce:surname>
</author>
<author seq="2">
<ce:initials>E.M.</ce:initials>
<ce:surname>Stein</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>de Botton</ce:surname>
</author>
<author seq="4">
<ce:initials>G.J.</ce:initials>
<ce:surname>Roboz</ce:surname>
</author>
<author seq="5">
<ce:initials>J.K.</ce:initials>
<ce:surname>Altman</ce:surname>
</author>
<author seq="6">
<ce:initials>A.S.</ce:initials>
<ce:surname>Mims</ce:surname>
</author>
<author seq="7">
<ce:initials>R.</ce:initials>
<ce:surname>Swords</ce:surname>
</author>
<author seq="8">
<ce:initials>R.H.</ce:initials>
<ce:surname>Collins</ce:surname>
</author>
<author seq="9">
<ce:initials>G.N.</ce:initials>
<ce:surname>Mannis</ce:surname>
</author>
<author seq="10">
<ce:initials>D.A.</ce:initials>
<ce:surname>Pollyea</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>The New England Journal of Medicine</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>378</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2386</first-page>
<last-page>2398</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Swords, R., Collins, R.H., Mannis, G.N., Pollyea, D.A., et al.: Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine. 378, 2386–2398 (2018)</ref-fulltext>
<ce:source-text>DiNardo, C.D., Stein, E.M., de Botton, S., Roboz, G.J., Altman, J.K., Mims, A.S., Swords, R., Collins, R.H., Mannis, G.N., Pollyea, D.A., et al.: Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML. The New England journal of medicine. 378, 2386–2398 (2018)</ce:source-text>
</reference>
<reference seq="120">
<ref-info>
<ref-title>
<ref-titletext-english>Acetate is a bioenergetic substrate for human glioblastoma and brain metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>T.</ce:initials>
<ce:surname>Mashimo</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Pichumani</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Vemireddy</ce:surname>
</author>
<author seq="4">
<ce:initials>K.J.</ce:initials>
<ce:surname>Hatanpaa</ce:surname>
</author>
<author seq="5">
<ce:initials>D.K.</ce:initials>
<ce:surname>Singh</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>Sirasanagandla</ce:surname>
</author>
<author seq="7">
<ce:initials>S.</ce:initials>
<ce:surname>Nannepaga</ce:surname>
</author>
<author seq="8">
<ce:initials>S.G.</ce:initials>
<ce:surname>Piccirillo</ce:surname>
</author>
<author seq="9">
<ce:initials>Z.</ce:initials>
<ce:surname>Kovacs</ce:surname>
</author>
<author seq="10">
<ce:initials>C.</ce:initials>
<ce:surname>Foong</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>159</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1603</first-page>
<last-page>1614</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Mashimo, T., Pichumani, K., Vemireddy, V., Hatanpaa, K.J., Singh, D.K., Sirasanagandla, S., Nannepaga, S., Piccirillo, S.G., Kovacs, Z., Foong, C., et al.: Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 159, 1603–1614 (2014)</ref-fulltext>
<ce:source-text>Mashimo, T., Pichumani, K., Vemireddy, V., Hatanpaa, K.J., Singh, D.K., Sirasanagandla, S., Nannepaga, S., Piccirillo, S.G., Kovacs, Z., Foong, C., et al.: Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell. 159, 1603–1614 (2014)</ce:source-text>
</reference>
<reference seq="121">
<ref-info>
<ref-title>
<ref-titletext-english>Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.M.</ce:initials>
<ce:surname>Palmieri</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Menga</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Martin-Perez</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Quinto</ce:surname>
</author>
<author seq="5">
<ce:initials>C.</ce:initials>
<ce:surname>Riera-Domingo</ce:surname>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>de Tullio</ce:surname>
</author>
<author seq="7">
<ce:initials>D.C.</ce:initials>
<ce:surname>Hooper</ce:surname>
</author>
<author seq="8">
<ce:initials>W.H.</ce:initials>
<ce:surname>Lamers</ce:surname>
</author>
<author seq="9">
<ce:initials>B.</ce:initials>
<ce:surname>Ghesquiere</ce:surname>
</author>
<author seq="10">
<ce:initials>D.W.</ce:initials>
<ce:surname>McVicar</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>20</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1654</first-page>
<last-page>1666</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Palmieri, E.M., Menga, A., Martin-Perez, R., Quinto, A., Riera-Domingo, C., De Tullio, G., Hooper, D.C., Lamers, W.H., Ghesquiere, B., McVicar, D.W., et al.: Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis. Cell Rep. 20, 1654–1666 (2017)</ref-fulltext>
<ce:source-text>Palmieri, E.M., Menga, A., Martin-Perez, R., Quinto, A., Riera-Domingo, C., De Tullio, G., Hooper, D.C., Lamers, W.H., Ghesquiere, B., McVicar, D.W., et al.: Pharmacologic or Genetic Targeting of Glutamine Synthetase Skews Macrophages toward an M1-like Phenotype and Inhibits Tumor Metastasis. Cell Rep. 20, 1654–1666 (2017)</ce:source-text>
</reference>
<reference seq="122">
<ref-info>
<ref-title>
<ref-titletext-english>HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>Y.H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>C.L.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>W.C.</ce:initials>
<ce:surname>Chiu</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.C.</ce:initials>
<ce:surname>Twu</ce:surname>
</author>
<author seq="5">
<ce:initials>Y.J.</ce:initials>
<ce:surname>Liao</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cancers</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<page-information>
<pages>
<first-page>11</first-page>
</pages>
</page-information>
</volisspag>
<ref-text>(b)</ref-text>
</ref-info>
<ref-fulltext>Wang, Y.H., Liu, C.L., Chiu, W.C., Twu, Y.C., Liao, Y.J.: HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma. Cancers, 11 (2019b)</ref-fulltext>
<ce:source-text>Wang, Y.H., Liu, C.L., Chiu, W.C., Twu, Y.C., Liao, Y.J.: HMGCS2 Mediates Ketone Production and Regulates the Proliferation and Metastasis of Hepatocellular Carcinoma. Cancers, 11 (2019b)</ce:source-text>
</reference>
<reference seq="123">
<ref-info>
<ref-title>
<ref-titletext-english>Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="2">
<ce:initials>H.J.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="3">
<ce:initials>X.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="4">
<ce:initials>L.</ce:initials>
<ce:surname>Huo</ce:surname>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="6">
<ce:initials>L.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="8">
<ce:initials>J.</ce:initials>
<ce:surname>He</ce:surname>
</author>
<author seq="9">
<ce:initials>L.R.</ce:initials>
<ce:surname>Bollu</ce:surname>
</author>
<author seq="10">
<ce:initials>G.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Res</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>75</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>554</first-page>
<last-page>565</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Chen, J., Lee, H.J., Wu, X., Huo, L., Kim, S.J., Xu, L., Wang, Y., He, J., Bollu, L.R., Gao, G., et al.: Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 75, 554–565 (2015)</ref-fulltext>
<ce:source-text>Chen, J., Lee, H.J., Wu, X., Huo, L., Kim, S.J., Xu, L., Wang, Y., He, J., Bollu, L.R., Gao, G., et al.: Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 75, 554–565 (2015)</ce:source-text>
</reference>
<reference seq="124">
<ref-info>
<ref-title>
<ref-titletext-english>Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Broekaert</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Christen</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Boon</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Radaelli</ce:surname>
</author>
<author seq="6">
<ce:initials>M.F.</ce:initials>
<ce:surname>Orth</ce:surname>
</author>
<author seq="7">
<ce:initials>C.</ce:initials>
<ce:surname>Verfaillie</ce:surname>
</author>
<author seq="8">
<ce:initials>T.G.P.</ce:initials>
<ce:surname>Grunewald</ce:surname>
</author>
<author seq="9">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15267</first-page>
</pages>
</page-information>
</volisspag>
<ref-text>(a)</ref-text>
</ref-info>
<ref-fulltext>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017a)</ref-fulltext>
<ce:source-text>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017a)</ce:source-text>
</reference>
<reference seq="125">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1alpha Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Andrzejewski</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Klimcakova</ce:surname>
</author>
<author seq="3">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Tabaries</ce:surname>
</author>
<author seq="5">
<ce:initials>M.G.</ce:initials>
<ce:surname>Annis</ce:surname>
</author>
<author seq="6">
<ce:initials>S.</ce:initials>
<ce:surname>McGuirk</ce:surname>
</author>
<author seq="7">
<ce:initials>J.J.</ce:initials>
<ce:surname>Northey</ce:surname>
</author>
<author seq="8">
<ce:initials>V.</ce:initials>
<ce:surname>Chenard</ce:surname>
</author>
<author seq="9">
<ce:initials>U.</ce:initials>
<ce:surname>Sriram</ce:surname>
</author>
<author seq="10">
<ce:initials>D.J.</ce:initials>
<ce:surname>Papadopoli</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>26</vol-first>
<iss-first>778</iss-first>
<iss-last>787</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Andrzejewski, S., Klimcakova, E., Johnson, R.M., Tabaries, S., Annis, M.G., McGuirk, S., Northey, J.J., Chenard, V., Sriram, U., Papadopoli, D.J., et al.: PGC-1alpha Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. Cell Metab. 26(778-787), e775 (2017)</ref-fulltext>
<ce:source-text>Andrzejewski, S., Klimcakova, E., Johnson, R.M., Tabaries, S., Annis, M.G., McGuirk, S., Northey, J.J., Chenard, V., Sriram, U., Papadopoli, D.J., et al.: PGC-1alpha Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs. Cell Metab. 26(778-787), e775 (2017)</ce:source-text>
</reference>
<reference seq="126">
<ref-info>
<ref-title>
<ref-titletext-english>Extracellular Metabolic Energetics Can Promote Cancer Progression</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.M.</ce:initials>
<ce:surname>Loo</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Scherl</ce:surname>
</author>
<author seq="3">
<ce:initials>A.</ce:initials>
<ce:surname>Nguyen</ce:surname>
</author>
<author seq="4">
<ce:initials>F.Y.</ce:initials>
<ce:surname>Man</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Weinberg</ce:surname>
</author>
<author seq="6">
<ce:initials>Z.S.</ce:initials>
<ce:surname>Zeng</ce:surname>
</author>
<author seq="7">
<ce:initials>L.</ce:initials>
<ce:surname>Saltz</ce:surname>
</author>
<author seq="8">
<ce:initials>P.B.</ce:initials>
<ce:surname>Paty</ce:surname>
</author>
<author seq="9">
<ce:initials>S.F.</ce:initials>
<ce:surname>Tavazoie</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>160</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>393</first-page>
<last-page>406</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Loo, J.M., Scherl, A., Nguyen, A., Man, F.Y., Weinberg, E., Zeng, Z.S., Saltz, L., Paty, P.B., Tavazoie, S.F.: Extracellular Metabolic Energetics Can Promote Cancer Progression. Cell. 160, 393–406 (2015)</ref-fulltext>
<ce:source-text>Loo, J.M., Scherl, A., Nguyen, A., Man, F.Y., Weinberg, E., Zeng, Z.S., Saltz, L., Paty, P.B., Tavazoie, S.F.: Extracellular Metabolic Energetics Can Promote Cancer Progression. Cell. 160, 393–406 (2015)</ce:source-text>
</reference>
<reference seq="127">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic reprogramming during TGFbeta1-induced epithelial-to- mesenchymal transition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Jiang</ce:surname>
</author>
<author seq="2">
<ce:initials>L.</ce:initials>
<ce:surname>Xiao</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Sugiura</ce:surname>
</author>
<author seq="4">
<ce:initials>X.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Ali</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Kuro-O</ce:surname>
</author>
<author seq="7">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
<author seq="8">
<ce:initials>D.A.</ce:initials>
<ce:surname>Boothman</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Oncogene</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>34</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>3908</first-page>
<last-page>3916</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jiang, L., Xiao, L., Sugiura, H., Huang, X., Ali, A., Kuro-o, M., Deberardinis, R.J., Boothman, D.A.: Metabolic reprogramming during TGFbeta1-induced epithelial-to- mesenchymal transition. Oncogene. 34, 3908–3916 (2015)</ref-fulltext>
<ce:source-text>Jiang, L., Xiao, L., Sugiura, H., Huang, X., Ali, A., Kuro-o, M., Deberardinis, R.J., Boothman, D.A.: Metabolic reprogramming during TGFbeta1-induced epithelial-to- mesenchymal transition. Oncogene. 34, 3908–3916 (2015)</ce:source-text>
</reference>
<reference seq="128">
<ref-info>
<ref-title>
<ref-titletext-english>Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.</ce:initials>
<ce:surname>Curtis</ce:surname>
</author>
<author seq="2">
<ce:initials>H.A.</ce:initials>
<ce:surname>Kenny</ce:surname>
</author>
<author seq="3">
<ce:initials>B.</ce:initials>
<ce:surname>Ashcroft</ce:surname>
</author>
<author seq="4">
<ce:initials>A.</ce:initials>
<ce:surname>Mukherjee</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="6">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Helou</ce:surname>
</author>
<author seq="8">
<ce:initials>R.</ce:initials>
<ce:surname>Batlle</ce:surname>
</author>
<author seq="9">
<ce:initials>X.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="10">
<ce:initials>N.</ce:initials>
<ce:surname>Gutierrez</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2018"/>
</ref-info>
<ref-fulltext>Curtis, M., Kenny, H.A., Ashcroft, B., Mukherjee, A., Johnson, A., Zhang, Y., Helou, Y., Batlle, R., Liu, X., Gutierrez, N., et al.: Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. (2018)</ref-fulltext>
<ce:source-text>Curtis, M., Kenny, H.A., Ashcroft, B., Mukherjee, A., Johnson, A., Zhang, Y., Helou, Y., Batlle, R., Liu, X., Gutierrez, N., et al.: Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. (2018)</ce:source-text>
</reference>
<reference seq="129">
<ref-info>
<ref-title>
<ref-titletext-english>Asparagine bioavailability governs metastasis in a model of breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.R.V.</ce:initials>
<ce:surname>Knott</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Wagenblast</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Khan</ce:surname>
</author>
<author seq="4">
<ce:initials>S.Y.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Soto</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Wagner</ce:surname>
</author>
<author seq="7">
<ce:initials>M.O.</ce:initials>
<ce:surname>Turgeon</ce:surname>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Fish</ce:surname>
</author>
<author seq="9">
<ce:initials>N.</ce:initials>
<ce:surname>Erard</ce:surname>
</author>
<author seq="10">
<ce:initials>A.L.</ce:initials>
<ce:surname>Gable</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>554</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>378</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>(a)</ref-text>
</ref-info>
<ref-fulltext>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018a)</ref-fulltext>
<ce:source-text>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018a)</ce:source-text>
</reference>
<reference seq="130">
<ref-info>
<ref-title>
<ref-titletext-english>UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>R.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>W.</ce:initials>
<ce:surname>Zhu</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Chu</ce:surname>
</author>
<author seq="5">
<ce:initials>H.</ce:initials>
<ce:surname>Yu</ce:surname>
</author>
<author seq="6">
<ce:initials>P.</ce:initials>
<ce:surname>Wei</ce:surname>
</author>
<author seq="7">
<ce:initials>X.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="8">
<ce:initials>H.</ce:initials>
<ce:surname>Zhu</ce:surname>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="10">
<ce:initials>J.</ce:initials>
<ce:surname>Liang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>571</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>127</first-page>
<last-page>131</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>(a)</ref-text>
</ref-info>
<ref-fulltext>Wang, X., Liu, R., Zhu, W., Chu, H., Yu, H., Wei, P., Wu, X., Zhu, H., Gao, H., Liang, J., et al.: UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. Nature. 571, 127–131 (2019a)</ref-fulltext>
<ce:source-text>Wang, X., Liu, R., Zhu, W., Chu, H., Yu, H., Wei, P., Wu, X., Zhu, H., Gao, H., Liang, J., et al.: UDP-glucose accelerates SNAI1 mRNA decay and impairs lung cancer metastasis. Nature. 571, 127–131 (2019a)</ce:source-text>
</reference>
<reference seq="131">
<ref-info>
<ref-title>
<ref-titletext-english>A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="2">
<ce:initials>Q.</ce:initials>
<ce:surname>Liang</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="4">
<ce:initials>L.L.</ce:initials>
<ce:surname>Jiang</ce:surname>
</author>
<author seq="5">
<ce:initials>W.M.</ce:initials>
<ce:surname>Gu</ce:surname>
</author>
<author seq="6">
<ce:initials>M.Y.</ce:initials>
<ce:surname>Luo</ce:surname>
</author>
<author seq="7">
<ce:initials>Y.B.</ce:initials>
<ce:surname>Tang</ce:surname>
</author>
<author seq="8">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>30</vol-first>
<iss-first>1107</iss-first>
<iss-last>1119</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Huang, K., Liang, Q., Zhou, Y., Jiang, L.L., Gu, W.M., Luo, M.Y., Tang, Y.B., Wang, Y., Lu, W., Huang, M., et al.: A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metab. 30(1107-1119), e1108 (2019)</ref-fulltext>
<ce:source-text>Huang, K., Liang, Q., Zhou, Y., Jiang, L.L., Gu, W.M., Luo, M.Y., Tang, Y.B., Wang, Y., Lu, W., Huang, M., et al.: A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer. Cell Metab. 30(1107-1119), e1108 (2019)</ce:source-text>
</reference>
<reference seq="132">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>van Weverwijk</ce:surname>
</author>
<author seq="2">
<ce:initials>N.</ce:initials>
<ce:surname>Koundouros</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Iravani</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Ashenden</ce:surname>
</author>
<author seq="5">
<ce:initials>Q.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="6">
<ce:initials>G.</ce:initials>
<ce:surname>Poulogiannis</ce:surname>
</author>
<author seq="7">
<ce:initials>U.</ce:initials>
<ce:surname>Jungwirth</ce:surname>
</author>
<author seq="8">
<ce:initials>C.M.</ce:initials>
<ce:surname>Isacke</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2698</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>van Weverwijk, A., Koundouros, N., Iravani, M., Ashenden, M., Gao, Q., Poulogiannis, G., Jungwirth, U., Isacke, C.M.: Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. Nat Commun. 10, 2698 (2019)</ref-fulltext>
<ce:source-text>van Weverwijk, A., Koundouros, N., Iravani, M., Ashenden, M., Gao, Q., Poulogiannis, G., Jungwirth, U., Isacke, C.M.: Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. Nat Commun. 10, 2698 (2019)</ce:source-text>
</reference>
<reference seq="133">
<ref-info>
<ref-title>
<ref-titletext-english>Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>P.</ce:initials>
<ce:surname>Bu</ce:surname>
</author>
<author seq="2">
<ce:initials>K.Y.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="3">
<ce:initials>K.</ce:initials>
<ce:surname>Xiang</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="5">
<ce:initials>S.B.</ce:initials>
<ce:surname>Crown</ce:surname>
</author>
<author seq="6">
<ce:initials>N.</ce:initials>
<ce:surname>Rakhilin</ce:surname>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Ai</ce:surname>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="9">
<ce:initials>R.</ce:initials>
<ce:surname>Xi</ce:surname>
</author>
<author seq="10">
<ce:initials>I.</ce:initials>
<ce:surname>Astapova</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>27</vol-first>
<iss-first>1249</iss-first>
<iss-last>1262</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Bu, P., Chen, K.Y., Xiang, K., Johnson, C., Crown, S.B., Rakhilin, N., Ai, Y., Wang, L., Xi, R., Astapova, I., et al.: Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis. Cell Metab. 27(1249-1262), e1244 (2018)</ref-fulltext>
<ce:source-text>Bu, P., Chen, K.Y., Xiang, K., Johnson, C., Crown, S.B., Rakhilin, N., Ai, Y., Wang, L., Xi, R., Astapova, I., et al.: Aldolase B-Mediated Fructose Metabolism Drives Metabolic Reprogramming of Colon Cancer Liver Metastasis. Cell Metab. 27(1249-1262), e1244 (2018)</ce:source-text>
</reference>
<reference seq="134">
<ref-info>
<ref-title>
<ref-titletext-english>TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Corbet</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Bastien</ce:surname>
</author>
<author seq="3">
<ce:initials>J.P.</ce:initials>
<ce:surname>Santiago de Jesus</ce:surname>
</author>
<author seq="4">
<ce:initials>E.</ce:initials>
<ce:surname>Dierge</ce:surname>
</author>
<author seq="5">
<ce:initials>R.</ce:initials>
<ce:surname>Martherus</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Vander Linden</ce:surname>
</author>
<author seq="7">
<ce:initials>B.</ce:initials>
<ce:surname>Doix</ce:surname>
</author>
<author seq="8">
<ce:initials>C.</ce:initials>
<ce:surname>Degavre</ce:surname>
</author>
<author seq="9">
<ce:initials>C.</ce:initials>
<ce:surname>Guilbaud</ce:surname>
</author>
<author seq="10">
<ce:initials>L.</ce:initials>
<ce:surname>Petit</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>11</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>454</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Corbet, C., Bastien, E., Santiago de Jesus, J.P., Dierge, E., Martherus, R., Vander Linden, C., Doix, B., Degavre, C., Guilbaud, C., Petit, L., et al.: TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 11, 454 (2020)</ref-fulltext>
<ce:source-text>Corbet, C., Bastien, E., Santiago de Jesus, J.P., Dierge, E., Martherus, R., Vander Linden, C., Doix, B., Degavre, C., Guilbaud, C., Petit, L., et al.: TGFbeta2-induced formation of lipid droplets supports acidosis-driven EMT and the metastatic spreading of cancer cells. Nat Commun. 11, 454 (2020)</ce:source-text>
</reference>
<reference seq="135">
<ref-info>
<ref-title>
<ref-titletext-english>Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>J.H.</ce:initials>
<ce:surname>Park</ce:surname>
</author>
<author seq="2">
<ce:initials>S.</ce:initials>
<ce:surname>Vithayathil</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Kumar</ce:surname>
</author>
<author seq="4">
<ce:initials>P.L.</ce:initials>
<ce:surname>Sung</ce:surname>
</author>
<author seq="5">
<ce:initials>L.E.</ce:initials>
<ce:surname>Dobrolecki</ce:surname>
</author>
<author seq="6">
<ce:initials>V.</ce:initials>
<ce:surname>Putluri</ce:surname>
</author>
<author seq="7">
<ce:initials>V.B.</ce:initials>
<ce:surname>Bhat</ce:surname>
</author>
<author seq="8">
<ce:initials>S.K.</ce:initials>
<ce:surname>Bhowmik</ce:surname>
</author>
<author seq="9">
<ce:initials>V.</ce:initials>
<ce:surname>Gupta</ce:surname>
</author>
<author seq="10">
<ce:initials>K.</ce:initials>
<ce:surname>Arora</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Rep</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>14</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>2154</first-page>
<last-page>2165</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Park, J.H., Vithayathil, S., Kumar, S., Sung, P.L., Dobrolecki, L.E., Putluri, V., Bhat, V.B., Bhowmik, S.K., Gupta, V., Arora, K., et al.: Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep. 14, 2154–2165 (2016)</ref-fulltext>
<ce:source-text>Park, J.H., Vithayathil, S., Kumar, S., Sung, P.L., Dobrolecki, L.E., Putluri, V., Bhat, V.B., Bhowmik, S.K., Gupta, V., Arora, K., et al.: Fatty Acid Oxidation-Driven Src Links Mitochondrial Energy Reprogramming and Oncogenic Properties in Triple-Negative Breast Cancer. Cell Rep. 14, 2154–2165 (2016)</ce:source-text>
</reference>
<reference seq="136">
<ref-info>
<ref-title>
<ref-titletext-english>Targeting metastasis-initiating cells through the fatty acid receptor CD36</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.</ce:initials>
<ce:surname>Pascual</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Avgustinova</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Mejetta</ce:surname>
</author>
<author seq="4">
<ce:initials>M.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<author seq="5">
<ce:initials>A.</ce:initials>
<ce:surname>Castellanos</ce:surname>
</author>
<author seq="6">
<ce:initials>C.S.</ce:initials>
<ce:surname>Attolini</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Berenguer</ce:surname>
</author>
<author seq="8">
<ce:initials>N.</ce:initials>
<ce:surname>Prats</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Toll</ce:surname>
</author>
<author seq="10">
<ce:initials>J.A.</ce:initials>
<ce:surname>Hueto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>541</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>41</first-page>
<last-page>45</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Pascual, G., Avgustinova, A., Mejetta, S., Martin, M., Castellanos, A., Attolini, C.S., Berenguer, A., Prats, N., Toll, A., Hueto, J.A., et al.: Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 541, 41–45 (2017)</ref-fulltext>
<ce:source-text>Pascual, G., Avgustinova, A., Mejetta, S., Martin, M., Castellanos, A., Attolini, C.S., Berenguer, A., Prats, N., Toll, A., Hueto, J.A., et al.: Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 541, 41–45 (2017)</ce:source-text>
</reference>
<reference seq="137">
<ref-info>
<ref-title>
<ref-titletext-english>Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.K.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="2">
<ce:initials>S.H.</ce:initials>
<ce:surname>Jeong</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Jang</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Bae</ce:surname>
</author>
<author seq="5">
<ce:initials>Y.H.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="6">
<ce:initials>I.</ce:initials>
<ce:surname>Park</ce:surname>
</author>
<author seq="7">
<ce:initials>S.K.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="8">
<ce:initials>G.Y.</ce:initials>
<ce:surname>Koh</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Science (New York, NY)</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>363</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>644</first-page>
<last-page>649</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lee, C.K., Jeong, S.H., Jang, C., Bae, H., Kim, Y.H., Park, I., Kim, S.K., Koh, G.Y.: Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science (New York, NY). 363, 644–649 (2019)</ref-fulltext>
<ce:source-text>Lee, C.K., Jeong, S.H., Jang, C., Bae, H., Kim, Y.H., Park, I., Kim, S.K., Koh, G.Y.: Tumor metastasis to lymph nodes requires YAP-dependent metabolic adaptation. Science (New York, NY). 363, 644–649 (2019)</ce:source-text>
</reference>
<reference seq="138">
<ref-info>
<ref-title>
<ref-titletext-english>Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.A.</ce:initials>
<ce:surname>Hawk</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.T.</ce:initials>
<ce:surname>Schafer</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>J Biol Chem</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>293</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>7531</first-page>
<last-page>7537</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Hawk, M.A., Schafer, Z.T.: Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. J Biol Chem. 293, 7531–7537 (2018)</ref-fulltext>
<ce:source-text>Hawk, M.A., Schafer, Z.T.: Mechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment. J Biol Chem. 293, 7531–7537 (2018)</ce:source-text>
</reference>
<reference seq="139">
<ref-info>
<ref-title>
<ref-titletext-english>Reductive carboxylation supports redox homeostasis during anchorage-independent growth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Jiang</ce:surname>
</author>
<author seq="2">
<ce:initials>A.A.</ce:initials>
<ce:surname>Shestov</ce:surname>
</author>
<author seq="3">
<ce:initials>P.</ce:initials>
<ce:surname>Swain</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Yang</ce:surname>
</author>
<author seq="5">
<ce:initials>S.J.</ce:initials>
<ce:surname>Parker</ce:surname>
</author>
<author seq="6">
<ce:initials>Q.A.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="7">
<ce:initials>L.S.</ce:initials>
<ce:surname>Terada</ce:surname>
</author>
<author seq="8">
<ce:initials>N.D.</ce:initials>
<ce:surname>Adams</ce:surname>
</author>
<author seq="9">
<ce:initials>M.T.</ce:initials>
<ce:surname>McCabe</ce:surname>
</author>
<author seq="10">
<ce:initials>B.</ce:initials>
<ce:surname>Pietrak</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>532</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>255</first-page>
<last-page>258</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Jiang, L., Shestov, A.A., Swain, P., Yang, C., Parker, S.J., Wang, Q.A., Terada, L.S., Adams, N.D., McCabe, M.T., Pietrak, B., et al.: Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 532, 255–258 (2016)</ref-fulltext>
<ce:source-text>Jiang, L., Shestov, A.A., Swain, P., Yang, C., Parker, S.J., Wang, Q.A., Terada, L.S., Adams, N.D., McCabe, M.T., Pietrak, B., et al.: Reductive carboxylation supports redox homeostasis during anchorage-independent growth. Nature. 532, 255–258 (2016)</ce:source-text>
</reference>
<reference seq="140">
<ref-info>
<ref-title>
<ref-titletext-english>Oxidative stress inhibits distant metastasis by human melanoma cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.</ce:initials>
<ce:surname>Piskounova</ce:surname>
</author>
<author seq="2">
<ce:initials>M.</ce:initials>
<ce:surname>Agathocleous</ce:surname>
</author>
<author seq="3">
<ce:initials>M.M.</ce:initials>
<ce:surname>Murphy</ce:surname>
</author>
<author seq="4">
<ce:initials>Z.</ce:initials>
<ce:surname>Hu</ce:surname>
</author>
<author seq="5">
<ce:initials>S.E.</ce:initials>
<ce:surname>Huddlestun</ce:surname>
</author>
<author seq="6">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhao</ce:surname>
</author>
<author seq="7">
<ce:initials>A.M.</ce:initials>
<ce:surname>Leitch</ce:surname>
</author>
<author seq="8">
<ce:initials>T.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="9">
<ce:initials>R.J.</ce:initials>
<ce:surname>Deberardinis</ce:surname>
</author>
<author seq="10">
<ce:initials>S.J.</ce:initials>
<ce:surname>Morrison</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>527</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>186</first-page>
<last-page>191</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Piskounova, E., Agathocleous, M., Murphy, M.M., Hu, Z., Huddlestun, S.E., Zhao, Z., Leitch, A.M., Johnson, T.M., DeBerardinis, R.J., Morrison, S.J.: Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 527, 186–191 (2015)</ref-fulltext>
<ce:source-text>Piskounova, E., Agathocleous, M., Murphy, M.M., Hu, Z., Huddlestun, S.E., Zhao, Z., Leitch, A.M., Johnson, T.M., DeBerardinis, R.J., Morrison, S.J.: Oxidative stress inhibits distant metastasis by human melanoma cells. Nature. 527, 186–191 (2015)</ce:source-text>
</reference>
<reference seq="141">
<ref-info>
<ref-title>
<ref-titletext-english>Antioxidants can increase melanoma metastasis in mice</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>K.</ce:initials>
<ce:surname>Le Gal</ce:surname>
</author>
<author seq="2">
<ce:initials>M.X.</ce:initials>
<ce:surname>Ibrahim</ce:surname>
</author>
<author seq="3">
<ce:initials>C.</ce:initials>
<ce:surname>Wiel</ce:surname>
</author>
<author seq="4">
<ce:initials>V.I.</ce:initials>
<ce:surname>Sayin</ce:surname>
</author>
<author seq="5">
<ce:initials>M.K.</ce:initials>
<ce:surname>Akula</ce:surname>
</author>
<author seq="6">
<ce:initials>C.</ce:initials>
<ce:surname>Karlsson</ce:surname>
</author>
<author seq="7">
<ce:initials>M.G.</ce:initials>
<ce:surname>Dalin</ce:surname>
</author>
<author seq="8">
<ce:initials>L.M.</ce:initials>
<ce:surname>Akyurek</ce:surname>
</author>
<author seq="9">
<ce:initials>P.</ce:initials>
<ce:surname>Lindahl</ce:surname>
</author>
<author seq="10">
<ce:initials>J.</ce:initials>
<ce:surname>Nilsson</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Science Translational Medicine</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>7</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Le Gal, K., Ibrahim, M.X., Wiel, C., Sayin, V.I., Akula, M.K., Karlsson, C., Dalin, M.G., Akyurek, L.M., Lindahl, P., Nilsson, J., et al.: Antioxidants can increase melanoma metastasis in mice. Science translational medicine. 7, 308re308 (2015)</ref-fulltext>
<ce:source-text>Le Gal, K., Ibrahim, M.X., Wiel, C., Sayin, V.I., Akula, M.K., Karlsson, C., Dalin, M.G., Akyurek, L.M., Lindahl, P., Nilsson, J., et al.: Antioxidants can increase melanoma metastasis in mice. Science translational medicine. 7, 308re308 (2015)</ce:source-text>
</reference>
<reference seq="142">
<ref-info>
<ref-title>
<ref-titletext-english>PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>V.S.</ce:initials>
<ce:surname>Lebleu</ce:surname>
</author>
<author seq="2">
<ce:initials>J.T.</ce:initials>
<ce:surname>O'connell</ce:surname>
</author>
<author seq="3">
<ce:initials>K.N.</ce:initials>
<ce:surname>Gonzalez Herrera</ce:surname>
</author>
<author seq="4">
<ce:initials>H.</ce:initials>
<ce:surname>Wikman</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Pantel</ce:surname>
</author>
<author seq="6">
<ce:initials>M.C.</ce:initials>
<ce:surname>Haigis</ce:surname>
</author>
<author seq="7">
<ce:initials>F.M.</ce:initials>
<ce:surname>de Carvalho</ce:surname>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Damascena</ce:surname>
</author>
<author seq="9">
<ce:initials>L.T.</ce:initials>
<ce:surname>Domingos Chinen</ce:surname>
</author>
<author seq="10">
<ce:initials>R.M.</ce:initials>
<ce:surname>Rocha</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nat Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2014"/>
<volisspag>
<volume-issue-number>
<vol-first>16</vol-first>
<iss-first>992</iss-first>
<iss-text>1003</iss-text>
</volume-issue-number>
<page-information>
<pages>
<first-page>1001</first-page>
<last-page>1015</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>LeBleu, V.S., O'Connell, J.T., Gonzalez Herrera, K.N., Wikman, H., Pantel, K., Haigis, M.C., de Carvalho, F.M., Damascena, A., Domingos Chinen, L.T., Rocha, R.M., et al.: PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 16(992-1003), 1001–1015 (2014)</ref-fulltext>
<ce:source-text>LeBleu, V.S., O'Connell, J.T., Gonzalez Herrera, K.N., Wikman, H., Pantel, K., Haigis, M.C., de Carvalho, F.M., Damascena, A., Domingos Chinen, L.T., Rocha, R.M., et al.: PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 16(992-1003), 1001–1015 (2014)</ce:source-text>
</reference>
<reference seq="143">
<ref-info>
<ref-title>
<ref-titletext-english>NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>H.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="2">
<ce:initials>X.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="3">
<ce:initials>M.</ce:initials>
<ce:surname>Long</ce:surname>
</author>
<author seq="4">
<ce:initials>Y.</ce:initials>
<ce:surname>Huang</ce:surname>
</author>
<author seq="5">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="6">
<ce:initials>R.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="7">
<ce:initials>Y.</ce:initials>
<ce:surname>Zheng</ce:surname>
</author>
<author seq="8">
<ce:initials>X.</ce:initials>
<ce:surname>Liao</ce:surname>
</author>
<author seq="9">
<ce:initials>Y.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="10">
<ce:initials>Q.</ce:initials>
<ce:surname>Liao</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Science Translational Medicine</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al.: NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science translational medicine. 8, 334ra351 (2016)</ref-fulltext>
<ce:source-text>Wang, H., Liu, X., Long, M., Huang, Y., Zhang, L., Zhang, R., Zheng, Y., Liao, X., Wang, Y., Liao, Q., et al.: NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis. Science translational medicine. 8, 334ra351 (2016)</ce:source-text>
</reference>
<reference seq="144">
<ref-info>
<ref-title>
<ref-titletext-english>BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>C.</ce:initials>
<ce:surname>Wiel</ce:surname>
</author>
<author seq="2">
<ce:initials>K.</ce:initials>
<ce:surname>Le Gal</ce:surname>
</author>
<author seq="3">
<ce:initials>M.X.</ce:initials>
<ce:surname>Ibrahim</ce:surname>
</author>
<author seq="4">
<ce:initials>C.A.</ce:initials>
<ce:surname>Jahangir</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Kashif</ce:surname>
</author>
<author seq="6">
<ce:initials>H.</ce:initials>
<ce:surname>Yao</ce:surname>
</author>
<author seq="7">
<ce:initials>D.V.</ce:initials>
<ce:surname>Ziegler</ce:surname>
</author>
<author seq="8">
<ce:initials>X.</ce:initials>
<ce:surname>Xu</ce:surname>
</author>
<author seq="9">
<ce:initials>T.</ce:initials>
<ce:surname>Ghosh</ce:surname>
</author>
<author seq="10">
<ce:initials>T.</ce:initials>
<ce:surname>Mondal</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>178</vol-first>
<iss-first>330</iss-first>
<iss-last>345</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Wiel, C., Le Gal, K., Ibrahim, M.X., Jahangir, C.A., Kashif, M., Yao, H., Ziegler, D.V., Xu, X., Ghosh, T., Mondal, T., et al.: BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis. Cell. 178(330-345), e322 (2019)</ref-fulltext>
<ce:source-text>Wiel, C., Le Gal, K., Ibrahim, M.X., Jahangir, C.A., Kashif, M., Yao, H., Ziegler, D.V., Xu, X., Ghosh, T., Mondal, T., et al.: BACH1 Stabilization by Antioxidants Stimulates Lung Cancer Metastasis. Cell. 178(330-345), e322 (2019)</ce:source-text>
</reference>
<reference seq="145">
<ref-info>
<ref-title>
<ref-titletext-english>Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>G.M.</ce:initials>
<ce:surname>Fischer</ce:surname>
</author>
<author seq="2">
<ce:initials>A.</ce:initials>
<ce:surname>Jalali</ce:surname>
</author>
<author seq="3">
<ce:initials>D.A.</ce:initials>
<ce:surname>Kircher</ce:surname>
</author>
<author seq="4">
<ce:initials>W.C.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="5">
<ce:initials>J.L.</ce:initials>
<ce:surname>McQuade</ce:surname>
</author>
<author seq="6">
<ce:initials>L.E.</ce:initials>
<ce:surname>Haydu</ce:surname>
</author>
<author seq="7">
<ce:initials>A.Y.</ce:initials>
<ce:surname>Joon</ce:surname>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Reuben</ce:surname>
</author>
<author seq="9">
<ce:initials>M.P.</ce:initials>
<ce:surname>de Macedo</ce:surname>
</author>
<author seq="10">
<ce:initials>F.C.L.</ce:initials>
<ce:surname>Carapeto</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Discovery</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>9</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>628</first-page>
<last-page>645</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fischer, G.M., Jalali, A., Kircher, D.A., Lee, W.C., McQuade, J.L., Haydu, L.E., Joon, A.Y., Reuben, A., de Macedo, M.P., Carapeto, F.C.L., et al.: Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer discovery. 9, 628–645 (2019)</ref-fulltext>
<ce:source-text>Fischer, G.M., Jalali, A., Kircher, D.A., Lee, W.C., McQuade, J.L., Haydu, L.E., Joon, A.Y., Reuben, A., de Macedo, M.P., Carapeto, F.C.L., et al.: Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer discovery. 9, 628–645 (2019)</ce:source-text>
</reference>
<reference seq="146">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic heterogeneity confers differences in melanoma metastatic potential</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>A.</ce:initials>
<ce:surname>Tasdogan</ce:surname>
</author>
<author seq="2">
<ce:initials>B.</ce:initials>
<ce:surname>Faubert</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Ramesh</ce:surname>
</author>
<author seq="4">
<ce:initials>J.M.</ce:initials>
<ce:surname>Ubellacker</ce:surname>
</author>
<author seq="5">
<ce:initials>B.</ce:initials>
<ce:surname>Shen</ce:surname>
</author>
<author seq="6">
<ce:initials>A.</ce:initials>
<ce:surname>Solmonson</ce:surname>
</author>
<author seq="7">
<ce:initials>M.M.</ce:initials>
<ce:surname>Murphy</ce:surname>
</author>
<author seq="8">
<ce:initials>Z.</ce:initials>
<ce:surname>Gu</ce:surname>
</author>
<author seq="9">
<ce:initials>W.</ce:initials>
<ce:surname>Gu</ce:surname>
</author>
<author seq="10">
<ce:initials>M.</ce:initials>
<ce:surname>Martin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>577</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>115</first-page>
<last-page>120</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Tasdogan, A., Faubert, B., Ramesh, V., Ubellacker, J.M., Shen, B., Solmonson, A., Murphy, M.M., Gu, Z., Gu, W., Martin, M., et al.: Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature. 577, 115–120 (2020)</ref-fulltext>
<ce:source-text>Tasdogan, A., Faubert, B., Ramesh, V., Ubellacker, J.M., Shen, B., Solmonson, A., Murphy, M.M., Gu, Z., Gu, W., Martin, M., et al.: Metabolic heterogeneity confers differences in melanoma metastatic potential. Nature. 577, 115–120 (2020)</ce:source-text>
</reference>
<reference seq="147">
<ref-info>
<ref-title>
<ref-titletext-english>Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.</ce:initials>
<ce:surname>Christen</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Lorendeau</ce:surname>
</author>
<author seq="3">
<ce:initials>R.</ce:initials>
<ce:surname>Schmieder</ce:surname>
</author>
<author seq="4">
<ce:initials>D.</ce:initials>
<ce:surname>Broekaert</ce:surname>
</author>
<author seq="5">
<ce:initials>K.</ce:initials>
<ce:surname>Metzger</ce:surname>
</author>
<author seq="6">
<ce:initials>K.</ce:initials>
<ce:surname>Veys</ce:surname>
</author>
<author seq="7">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="8">
<ce:initials>J.M.</ce:initials>
<ce:surname>Buescher</ce:surname>
</author>
<author seq="9">
<ce:initials>M.F.</ce:initials>
<ce:surname>Orth</ce:surname>
</author>
<author seq="10">
<ce:initials>S.M.</ce:initials>
<ce:surname>Davidson</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Reports</ref-sourcetitle>
<ref-publicationyear first="2016"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>837</first-page>
<last-page>848</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Christen, S., Lorendeau, D., Schmieder, R., Broekaert, D., Metzger, K., Veys, K., Elia, I., Buescher, J.M., Orth, M.F., Davidson, S.M., et al.: Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis. Cell Reports. 17, 837–848 (2016)</ref-fulltext>
<ce:source-text>Christen, S., Lorendeau, D., Schmieder, R., Broekaert, D., Metzger, K., Veys, K., Elia, I., Buescher, J.M., Orth, M.F., Davidson, S.M., et al.: Breast Cancer-Derived Lung Metastases Show Increased Pyruvate Carboxylase-Dependent Anaplerosis. Cell Reports. 17, 837–848 (2016)</ce:source-text>
</reference>
<reference seq="148">
<ref-info>
<ref-title>
<ref-titletext-english>Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>B.</ce:initials>
<ce:surname>Ngo</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Osorio-Vasquez</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Doll</ce:surname>
</author>
<author seq="5">
<ce:initials>S.</ce:initials>
<ce:surname>Bustraan</ce:surname>
</author>
<author seq="6">
<ce:initials>R.J.</ce:initials>
<ce:surname>Liang</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Luengo</ce:surname>
</author>
<author seq="8">
<ce:initials>S.M.</ce:initials>
<ce:surname>Davidson</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Ali</ce:surname>
</author>
<author seq="10">
<ce:initials>G.B.</ce:initials>
<ce:surname>Ferraro</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cancer Discov</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>10</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>1352</first-page>
<last-page>1373</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ngo, B., Kim, E., Osorio-Vasquez, V., Doll, S., Bustraan, S., Liang, R.J., Luengo, A., Davidson, S.M., Ali, A., Ferraro, G.B., et al.: Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discov. 10, 1352–1373 (2020)</ref-fulltext>
<ce:source-text>Ngo, B., Kim, E., Osorio-Vasquez, V., Doll, S., Bustraan, S., Liang, R.J., Luengo, A., Davidson, S.M., Ali, A., Ferraro, G.B., et al.: Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discov. 10, 1352–1373 (2020)</ce:source-text>
</reference>
<reference seq="149">
<ref-info>
<ref-title>
<ref-titletext-english>Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>M.Y.</ce:initials>
<ce:surname>Fong</ce:surname>
</author>
<author seq="2">
<ce:initials>W.Y.</ce:initials>
<ce:surname>Zhou</ce:surname>
</author>
<author seq="3">
<ce:initials>L.</ce:initials>
<ce:surname>Liu</ce:surname>
</author>
<author seq="4">
<ce:initials>A.Y.</ce:initials>
<ce:surname>Alontaga</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Chandra</ce:surname>
</author>
<author seq="6">
<ce:initials>J.</ce:initials>
<ce:surname>Ashby</ce:surname>
</author>
<author seq="7">
<ce:initials>A.</ce:initials>
<ce:surname>Chow</ce:surname>
</author>
<author seq="8">
<ce:initials>S.T.F.</ce:initials>
<ce:surname>O'connor</ce:surname>
</author>
<author seq="9">
<ce:initials>S.S.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="10">
<ce:initials>A.R.</ce:initials>
<ce:surname>Chin</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature Cell Biology</ref-sourcetitle>
<ref-publicationyear first="2015"/>
<volisspag>
<volume-issue-number>
<vol-first>17</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>183</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Fong, M.Y., Zhou, W.Y., Liu, L., Alontaga, A.Y., Chandra, M., Ashby, J., Chow, A., O'Connor, S.T.F., Li, S.S., Chin, A.R., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nature Cell Biology. 17, 183-+ (2015)</ref-fulltext>
<ce:source-text>Fong, M.Y., Zhou, W.Y., Liu, L., Alontaga, A.Y., Chandra, M., Ashby, J., Chow, A., O'Connor, S.T.F., Li, S.S., Chin, A.R., et al.: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nature Cell Biology. 17, 183-+ (2015)</ce:source-text>
</reference>
<reference seq="150">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolites and the tumour microenvironment: From cellular mechanisms to systemic metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="2">
<ce:initials>M.C.</ce:initials>
<ce:surname>Haigis</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Metab</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<volume-issue-number>
<vol-first>3</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>21</first-page>
<last-page>32</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Elia, I., Haigis, M.C.: Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 3, 21–32 (2021)</ref-fulltext>
<ce:source-text>Elia, I., Haigis, M.C.: Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism. Nat Metab. 3, 21–32 (2021)</ce:source-text>
</reference>
<reference seq="151">
<ref-info>
<ref-title>
<ref-titletext-english>Modulating the therapeutic response of tumours to dietary serine and glycine starvation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>O.D.K.</ce:initials>
<ce:surname>Maddocks</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Athineos</ce:surname>
</author>
<author seq="3">
<ce:initials>E.C.</ce:initials>
<ce:surname>Cheung</ce:surname>
</author>
<author seq="4">
<ce:initials>P.</ce:initials>
<ce:surname>Lee</ce:surname>
</author>
<author seq="5">
<ce:initials>T.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="6">
<ce:initials>N.J.F.</ce:initials>
<ce:surname>Van den Broek</ce:surname>
</author>
<author seq="7">
<ce:initials>G.M.</ce:initials>
<ce:surname>Mackay</ce:surname>
</author>
<author seq="8">
<ce:initials>C.F.</ce:initials>
<ce:surname>Labuschagne</ce:surname>
</author>
<author seq="9">
<ce:initials>D.</ce:initials>
<ce:surname>Gay</ce:surname>
</author>
<author seq="10">
<ce:initials>F.</ce:initials>
<ce:surname>Kruiswijk</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>544</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>372</first-page>
<last-page>376</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Maddocks, O.D.K., Athineos, D., Cheung, E.C., Lee, P., Zhang, T., van den Broek, N.J.F., Mackay, G.M., Labuschagne, C.F., Gay, D., Kruiswijk, F., et al.: Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 544, 372–376 (2017)</ref-fulltext>
<ce:source-text>Maddocks, O.D.K., Athineos, D., Cheung, E.C., Lee, P., Zhang, T., van den Broek, N.J.F., Mackay, G.M., Labuschagne, C.F., Gay, D., Kruiswijk, F., et al.: Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature. 544, 372–376 (2017)</ce:source-text>
</reference>
<reference seq="152">
<ref-info>
<ref-title>
<ref-titletext-english>Serine Is an Essential Metabolite for Effector T Cell Expansion</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.H.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Bantug</ce:surname>
</author>
<author seq="3">
<ce:initials>T.</ce:initials>
<ce:surname>Griss</ce:surname>
</author>
<author seq="4">
<ce:initials>S.</ce:initials>
<ce:surname>Condotta</ce:surname>
</author>
<author seq="5">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="6">
<ce:initials>B.</ce:initials>
<ce:surname>Samborska</ce:surname>
</author>
<author seq="7">
<ce:initials>N.</ce:initials>
<ce:surname>Mainolfi</ce:surname>
</author>
<author seq="8">
<ce:initials>V.</ce:initials>
<ce:surname>Suri</ce:surname>
</author>
<author seq="9">
<ce:initials>H.</ce:initials>
<ce:surname>Guak</ce:surname>
</author>
<author seq="10">
<ce:initials>M.L.</ce:initials>
<ce:surname>Balmer</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>25</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>482</first-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Ma, E.H., Bantug, G., Griss, T., Condotta, S., Johnson, R.M., Samborska, B., Mainolfi, N., Suri, V., Guak, H., Balmer, M.L., et al.: Serine Is an Essential Metabolite for Effector T Cell Expansion. Cell Metab. 25, 482 (2017)</ref-fulltext>
<ce:source-text>Ma, E.H., Bantug, G., Griss, T., Condotta, S., Johnson, R.M., Samborska, B., Mainolfi, N., Suri, V., Guak, H., Balmer, M.L., et al.: Serine Is an Essential Metabolite for Effector T Cell Expansion. Cell Metab. 25, 482 (2017)</ce:source-text>
</reference>
<reference seq="153">
<ref-info>
<ref-title>
<ref-titletext-english>Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>D.G.</ce:initials>
<ce:surname>Roy</ce:surname>
</author>
<author seq="2">
<ce:initials>J.</ce:initials>
<ce:surname>Chen</ce:surname>
</author>
<author seq="3">
<ce:initials>V.</ce:initials>
<ce:surname>Mamane</ce:surname>
</author>
<author seq="4">
<ce:initials>E.H.</ce:initials>
<ce:surname>Ma</ce:surname>
</author>
<author seq="5">
<ce:initials>B.M.</ce:initials>
<ce:surname>Muhire</ce:surname>
</author>
<author seq="6">
<ce:initials>R.D.</ce:initials>
<ce:surname>Sheldon</ce:surname>
</author>
<author seq="7">
<ce:initials>T.</ce:initials>
<ce:surname>Shorstova</ce:surname>
</author>
<author seq="8">
<ce:initials>R.</ce:initials>
<ce:surname>Koning</ce:surname>
</author>
<author seq="9">
<ce:initials>R.M.</ce:initials>
<ce:surname>Johnson</ce:surname>
</author>
<author seq="10">
<ce:initials>E.</ce:initials>
<ce:surname>Esaulova</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2020"/>
<volisspag>
<volume-issue-number>
<vol-first>31</vol-first>
<iss-first>250</iss-first>
<iss-last>266</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Roy, D.G., Chen, J., Mamane, V., Ma, E.H., Muhire, B.M., Sheldon, R.D., Shorstova, T., Koning, R., Johnson, R.M., Esaulova, E., et al.: Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming. Cell Metab. 31(250-266), e259 (2020)</ref-fulltext>
<ce:source-text>Roy, D.G., Chen, J., Mamane, V., Ma, E.H., Muhire, B.M., Sheldon, R.D., Shorstova, T., Koning, R., Johnson, R.M., Esaulova, E., et al.: Methionine Metabolism Shapes T Helper Cell Responses through Regulation of Epigenetic Reprogramming. Cell Metab. 31(250-266), e259 (2020)</ce:source-text>
</reference>
<reference seq="154">
<ref-info>
<ref-title>
<ref-titletext-english>Dietary methionine influences therapy in mouse cancer models and alters human metabolism</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>X.</ce:initials>
<ce:surname>Gao</ce:surname>
</author>
<author seq="2">
<ce:initials>S.M.</ce:initials>
<ce:surname>Sanderson</ce:surname>
</author>
<author seq="3">
<ce:initials>Z.</ce:initials>
<ce:surname>Dai</ce:surname>
</author>
<author seq="4">
<ce:initials>M.A.</ce:initials>
<ce:surname>Reid</ce:surname>
</author>
<author seq="5">
<ce:initials>D.E.</ce:initials>
<ce:surname>Cooper</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Lu</ce:surname>
</author>
<author seq="7">
<ce:initials>J.P.</ce:initials>
<ce:surname>Richie</ce:surname>
</author>
<author seq="8">
<ce:initials>A.</ce:initials>
<ce:surname>Ciccarella</ce:surname>
</author>
<author seq="9">
<ce:initials>A.</ce:initials>
<ce:surname>Calcagnotto</ce:surname>
</author>
<author seq="10">
<ce:initials>P.G.</ce:initials>
<ce:surname>Mikhael</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2019"/>
<volisspag>
<volume-issue-number>
<vol-first>572</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>397</first-page>
<last-page>401</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Gao, X., Sanderson, S.M., Dai, Z., Reid, M.A., Cooper, D.E., Lu, M., Richie Jr., J.P., Ciccarella, A., Calcagnotto, A., Mikhael, P.G., et al.: Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature. 572, 397–401 (2019)</ref-fulltext>
<ce:source-text>Gao, X., Sanderson, S.M., Dai, Z., Reid, M.A., Cooper, D.E., Lu, M., Richie Jr., J.P., Ciccarella, A., Calcagnotto, A., Mikhael, P.G., et al.: Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature. 572, 397–401 (2019)</ce:source-text>
</reference>
<reference seq="155">
<ref-info>
<ref-title>
<ref-titletext-english>Creatine promotes cancer metastasis through activation of Smad2/3</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>L.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="2">
<ce:initials>Z.</ce:initials>
<ce:surname>Zhu</ce:surname>
</author>
<author seq="3">
<ce:initials>H.</ce:initials>
<ce:surname>Yan</ce:surname>
</author>
<author seq="4">
<ce:initials>W.</ce:initials>
<ce:surname>Wang</ce:surname>
</author>
<author seq="5">
<ce:initials>Z.</ce:initials>
<ce:surname>Wu</ce:surname>
</author>
<author seq="6">
<ce:initials>F.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="7">
<ce:initials>Q.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="8">
<ce:initials>G.</ce:initials>
<ce:surname>Shi</ce:surname>
</author>
<author seq="9">
<ce:initials>J.</ce:initials>
<ce:surname>Du</ce:surname>
</author>
<author seq="10">
<ce:initials>H.</ce:initials>
<ce:surname>Cai</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Cell Metab</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<volume-issue-number>
<vol-first>33</vol-first>
<iss-first>1111</iss-first>
<iss-last>1123</iss-last>
</volume-issue-number>
</volisspag>
</ref-info>
<ref-fulltext>Zhang, L., Zhu, Z., Yan, H., Wang, W., Wu, Z., Zhang, F., Zhang, Q., Shi, G., Du, J., Cai, H., et al.: Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metab. 33(1111-1123), e1114 (2021)</ref-fulltext>
<ce:source-text>Zhang, L., Zhu, Z., Yan, H., Wang, W., Wu, Z., Zhang, F., Zhang, Q., Shi, G., Du, J., Cai, H., et al.: Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metab. 33(1111-1123), e1114 (2021)</ce:source-text>
</reference>
<reference seq="156">
<ref-info>
<ref-title>
<ref-titletext-english>Low glycaemic diets alter lipid metabolism to influence tumour growth</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>E.C.</ce:initials>
<ce:surname>Lien</ce:surname>
</author>
<author seq="2">
<ce:initials>A.M.</ce:initials>
<ce:surname>Westermark</ce:surname>
</author>
<author seq="3">
<ce:initials>Y.</ce:initials>
<ce:surname>Zhang</ce:surname>
</author>
<author seq="4">
<ce:initials>C.</ce:initials>
<ce:surname>Yuan</ce:surname>
</author>
<author seq="5">
<ce:initials>Z.</ce:initials>
<ce:surname>Li</ce:surname>
</author>
<author seq="6">
<ce:initials>A.N.</ce:initials>
<ce:surname>Lau</ce:surname>
</author>
<author seq="7">
<ce:initials>K.M.</ce:initials>
<ce:surname>Sapp</ce:surname>
</author>
<author seq="8">
<ce:initials>B.M.</ce:initials>
<ce:surname>Wolpin</ce:surname>
</author>
<author seq="9">
<ce:initials>M.G.</ce:initials>
<ce:surname>Vander Heiden</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2021"/>
<volisspag>
<volume-issue-number>
<vol-first>599</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>302</first-page>
<last-page>307</last-page>
</pages>
</page-information>
</volisspag>
</ref-info>
<ref-fulltext>Lien, E.C., Westermark, A.M., Zhang, Y., Yuan, C., Li, Z., Lau, A.N., Sapp, K.M., Wolpin, B.M., Vander Heiden, M.G.: Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 599, 302–307 (2021)</ref-fulltext>
<ce:source-text>Lien, E.C., Westermark, A.M., Zhang, Y., Yuan, C., Li, Z., Lau, A.N., Sapp, K.M., Wolpin, B.M., Vander Heiden, M.G.: Low glycaemic diets alter lipid metabolism to influence tumour growth. Nature. 599, 302–307 (2021)</ce:source-text>
</reference>
<reference seq="157">
<ref-info>
<ref-title>
<ref-titletext-english>Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="2">
<ce:initials>D.</ce:initials>
<ce:surname>Broekaert</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Christen</ce:surname>
</author>
<author seq="4">
<ce:initials>R.</ce:initials>
<ce:surname>Boon</ce:surname>
</author>
<author seq="5">
<ce:initials>E.</ce:initials>
<ce:surname>Radaelli</ce:surname>
</author>
<author seq="6">
<ce:initials>M.F.</ce:initials>
<ce:surname>Orth</ce:surname>
</author>
<author seq="7">
<ce:initials>C.</ce:initials>
<ce:surname>Verfaillie</ce:surname>
</author>
<author seq="8">
<ce:initials>T.G.P.</ce:initials>
<ce:surname>Grunewald</ce:surname>
</author>
<author seq="9">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Nat Commun</ref-sourcetitle>
<ref-publicationyear first="2017"/>
<volisspag>
<volume-issue-number>
<vol-first>8</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>15267</first-page>
</pages>
</page-information>
</volisspag>
<ref-text>(b)</ref-text>
</ref-info>
<ref-fulltext>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017b)</ref-fulltext>
<ce:source-text>Elia, I., Broekaert, D., Christen, S., Boon, R., Radaelli, E., Orth, M.F., Verfaillie, C., Grunewald, T.G.P., Fendt, S.M.: Proline metabolism supports metastasis formation and could be inhibited to selectively target metastasizing cancer cells. Nat Commun. 8, 15267 (2017b)</ce:source-text>
</reference>
<reference seq="158">
<ref-info>
<ref-title>
<ref-titletext-english>Metabolic Hallmarks of Metastasis Formation</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>I.</ce:initials>
<ce:surname>Elia</ce:surname>
</author>
<author seq="2">
<ce:initials>G.</ce:initials>
<ce:surname>Doglioni</ce:surname>
</author>
<author seq="3">
<ce:initials>S.M.</ce:initials>
<ce:surname>Fendt</ce:surname>
</author>
</ref-authors>
<ref-sourcetitle>Trends Cell Biol</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>28</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>673</first-page>
<last-page>684</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>(b)</ref-text>
</ref-info>
<ref-fulltext>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends Cell Biol. 28, 673–684 (2018b)</ref-fulltext>
<ce:source-text>Elia, I., Doglioni, G., Fendt, S.M.: Metabolic Hallmarks of Metastasis Formation. Trends Cell Biol. 28, 673–684 (2018b)</ce:source-text>
</reference>
<reference seq="159">
<ref-info>
<ref-title>
<ref-titletext-english>Asparagine bioavailability governs metastasis in a model of breast cancer</ref-titletext-english>
</ref-title>
<ref-authors>
<author seq="1">
<ce:initials>S.R.V.</ce:initials>
<ce:surname>Knott</ce:surname>
</author>
<author seq="2">
<ce:initials>E.</ce:initials>
<ce:surname>Wagenblast</ce:surname>
</author>
<author seq="3">
<ce:initials>S.</ce:initials>
<ce:surname>Khan</ce:surname>
</author>
<author seq="4">
<ce:initials>S.Y.</ce:initials>
<ce:surname>Kim</ce:surname>
</author>
<author seq="5">
<ce:initials>M.</ce:initials>
<ce:surname>Soto</ce:surname>
</author>
<author seq="6">
<ce:initials>M.</ce:initials>
<ce:surname>Wagner</ce:surname>
</author>
<author seq="7">
<ce:initials>M.O.</ce:initials>
<ce:surname>Turgeon</ce:surname>
</author>
<author seq="8">
<ce:initials>L.</ce:initials>
<ce:surname>Fish</ce:surname>
</author>
<author seq="9">
<ce:initials>N.</ce:initials>
<ce:surname>Erard</ce:surname>
</author>
<author seq="10">
<ce:initials>A.L.</ce:initials>
<ce:surname>Gable</ce:surname>
</author>
<et-al/>
</ref-authors>
<ref-sourcetitle>Nature</ref-sourcetitle>
<ref-publicationyear first="2018"/>
<volisspag>
<volume-issue-number>
<vol-first>554</vol-first>
</volume-issue-number>
<page-information>
<pages>
<first-page>378</first-page>
<last-page>381</last-page>
</pages>
</page-information>
</volisspag>
<ref-text>(b)</ref-text>
</ref-info>
<ref-fulltext>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018b)</ref-fulltext>
<ce:source-text>Knott, S.R.V., Wagenblast, E., Khan, S., Kim, S.Y., Soto, M., Wagner, M., Turgeon, M.O., Fish, L., Erard, N., Gable, A.L., et al.: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 554, 378–381 (2018b)</ce:source-text>
</reference>
</bibliography>
</tail>
</bibrecord>
</unit-content>
</unit-info>
</unit>
</units>
